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Abstract 
By repeating and optimizing procedure from earlier work in this group, three N-substituted 
meso-anthracene-maleimides have been prepared in excellent yields 88 – 94%. These 
compounds were successfully desymmetrised to the corresponding 3-methoxy -lactams, 
using B-OMe oxazaborolidine catalyst derived from cis-1-amino-indan-2-ol. Under the 
optimized conditions, improved yields and excellent enantioselectivities of 95 – >99% of the 
methoxy-lactams were obtained. Desymmetrisation of the N-PMP substrate gave one 
enantiomer of the product but proceeded by rapid conversion of the hydroxy-lactam 
intermediate to the over-reduced pyrrolidine compound. Investigation in to the correlation 
between this high selectivity and the formation of the over reduced product revealed that an 
in-situ stereoablative process by the (1R, 2S) version of the B-OMe catalyst serves to upgrade 
the enantioselectivity.   
This desymmetrisation methodology has been employed for the total synthesis of natural 
product, pyrrolam A which was obtained in six steps from the desymmetrised material in 
48% overall yield and 94% ee. 
By adapting literature methodology, N-PMP glutarimide and a number of N-benzyl 
glutarimides have been successfully synthesised via the corresponding glutaric anhydrides in 
moderate yields (52 – 87%). Desymmetrisation of N-PMP-3-phenyl glutarimide to the 
corresponding δ-lactam using B-OMe and B-Me oxazaborolidine catalysts derived from cis-
1-amino-indan-2-ol gave excellent selectivity but low yields of the products with both 
catalysts due to the formation of over reduced piperidine product. Further investigation 
revealed an in-situ stereoablative process causes an upgrade of ee in both (1R, 2S) and (1S, 
2R) versions of B-Me oxazaborolidine catalyst, with matched and mismatched 
enantioselectivity with the two enantiomers of the catalyst. The N-Bn substrates were 
successfully desymmetrised, using B-Me oxazaborolidine catalyst, to the corresponding δ-
lactams in moderate yields (20 – 61%) and high enantioselectivities (54 – 92%). 
Desymmetrisation of a representative N-Bn substrate with the prolinol oxazaborolidine 
catalyst under the same conditions gave poor yield and enantioselectivity of the product (13% 
yield, 13% ee). 
Functionalisation of a representative N-Bn desymmetrised product gave various (3S, 4R)-
disubstituted 2-piperidinones in good yields and excellent diastereoselectivity. Subsequent 
reduction of the 2-piperidinones gave (3S, 4R)-disubstituted piperidines which are important 
structural motifs in many biologically active natural products and pharmaceuticals. 
Chapter 1 
   Introduction 
 
1.1 Chirality 
The importance of chirality is well recognised. Many natural products are chiral and their 
physiological or pharmacological properties depend upon their recognition by chiral 
receptors, which may interact only with molecules of the proper absolute configuration. In 
pharmaceuticals, as well as related industries, asymmetry plays an important role, since both 
enantiomers of a specific drug do not necessarily have the same activity.
1
 Duloxetine (Figure 
1), for example, is an antidepressant drug targeting the presynaptic cell.
2
 It is a dual inhibitor 
preventing the reuptake of serotonin as well as norepinephrine and is sold in its (S)-form as a 
hydrochloride salt under the name Cymbalta.
3
 For duloxetine, the (S)-enantiomer has been 
found to be twice as potent as the (R)-enantiomer, whereas for norduloxetine (Figure 1), the 
(R)-enantiomer was found more potent than the (S)-enantiomer as a reuptake inhibitor of the 
human serotonin transporter.
4
 Due to this difference in biological activity of the two 
enantiomers, there was a requirement to have both enantiomers synthesised separately and 
therefore several different methods have been reported for the enantioselective synthesis of 
duloxetine.
5,
 
6,
 
7,
 
8,
 
9
 The evaluation of a chiral drug in enantiopure form is now a standard 
requirement for every new pharmaceutical agent and the development of new synthetic 
methods to obtain enantiopure compounds has become a key goal for pharmaceutical 
companies.
1
 The search for new and efficient methods for the synthesis of optically pure 
compounds has thus been an active area of research in organic synthesis. 
 
Figure 1. Duloxetin and norduloxetin drugs 
 
1.2 Asymmetric synthesis 
Since enantiomers have the same physical and chemical properties (except in a chiral 
environment), common laboratory reaction conditions applied in the synthesis of new chiral 
2 
 
compounds usually end up with racemic mixtures as the product. The interaction of an achiral 
reagent with a prochiral substrate leads to enantiomeric transition states, which in turn leads 
to a racemic product. However, when a chiral reagent or environment is employed, the two 
enantiomers may interact differently with the chiral environment, thereby leading to 
diastereomeric transition states with the potential to have unequal energies. This leads to the 
formation of a product consisting of an excess of one enantiomer over the other. Such a 
‘chiral environment’ may be an enantiomerically pure molecule or part of a molecule which 
may be a reagent or a catalyst, or a chiral group covalently attached to the starting material.
10
 
Chemists have been able to achieve this by a variety of techniques.  
1.2.1 Chiral reagent 
One way to prepare an enantiomerically enriched chiral molecule is to use a chiral reagent to 
install the new stereogenic centre. This method needs a stoichiometric amount of the reagent 
which once consumed may be difficult to recycle. Thus, this method is sometimes expensive.  
The enantioselective allylation of aldehydes by the use of allyl diisopinocampheylborane as 
chiral reagent is one such example and has been intensely studied by Brown et al.
11
 They 
postulated that the reaction proceeds via a chair-like six-membered transition state, with the 
allyl group of the chiral boron reagent oriented away from the large group of the aldehyde. 
This makes the large substituent in the aldehyde to adopt a pseudo-equatorial conformation in 
the six-membered transition state and the aldehyde facial selectivity is derived from 
minimisation of steric interactions between the axial Ipc ligand and the allyl group (Scheme 
1).
11,
 
12
   
 
Scheme 1. Brown’s postulation of enantioselective allylation of aldehydes 
3 
 
The reaction was found to be general with a range of aldehydes examined, giving the same 
stereochemical outcome in all cases (Table 1).
13,
 
12
 
 
Table 1. Brown’s allylation of prochiral aldehydes 
       ___________________________________________________________ 
  Entry   R  Yield (%)        ee (%) Configuration 
 _________________________________________________________________  
    1  CH3      74           93       R 
    2  n-C3H7      71           86       R 
    3  n-C4H9      72           87       R 
    4  i-C3H7      86           90       S 
    5  t-C4H9      88           83       S 
    6  C6H5      81           96       S 
 ________________________________________________________________ 
 
1.2.2 Chiral auxiliary 
Another method used to induce chirality in a molecule is by the use of a chiral auxiliary. This 
method has three key processes. Firstly, an enantiomerically pure compound (the chiral 
auxiliary) is attached to the starting material. A chemical reaction is then performed, which 
due to the presence of the auxiliary favours the formation of one diastereomer. Finally, the 
auxiliary is removed to give an enantioenriched product (Figure 2). The advantage of this 
method is that the chiral auxiliary can in most cases be recycled after cleavage, and a single 
auxiliary can be compatible with different reactions. However, since a stoichiometric amount 
of the auxiliary is needed, the method can be expensive if the auxiliary cannot be recycled or 
is difficult to prepare.  
 
Figure 2. Chiral auxiliary strategy 
Perhaps the commonest chiral auxiliaries in asymmetric synthesis are the chiral 2- 
oxazolidinones 1 and 2 developed by Evans and co-workers (Figure 3).
14 
Introduction of the 
4 
 
auxiliary by deprotonation of the oxazolidinone with n-BuLi and coupling with a suitable 
electrophile gives the enantiomerically pure N-acyl derivatives such as 3 and 6 (Scheme 2). 
 
Figure 3. Evans chiral auxiliaries 
Evans and co-workers have demonstrated the utility of these auxiliaries to prepare chiral 
compounds in excellent selectivity. Enantioselective aldol condensation reaction of the n-
propanoyl derivative 3 with various aldehydes gave the corresponding syn methyl alcohols 4 
in high yields and excellent diastereoselectivities. The chiral auxiliaries were then removed 
without racemisation to give the corresponding chiral syn-α-methyl-β-hydroxy carboxylic 
acids 5 in good yields.
15
 In a different work, Evans et al. employed the chiral auxiliary for the 
asymmetric alkylation of esters.
14
 Reaction of the chiral N-propanoyl derivative 6 with 1.1 
equivalent of the lithium base, LiN(i-Pr)2, at – 78 
o
C generated an in situ chelated (Z)-lithium 
enolate intermediate 7, which upon treatment with benzylbromide at 0 
o
C gave the alkylated 
amide 8 in good yield and excellent diastereoselectivity. The chelated intermediate gave the 
sense of asymmetric induction where the diastereoface selection was dictated by the 
isopropyl substituent on the C-4 of the oxazolidone ring. Again, the chiral auxiliary was 
safely removed without racemisation by treating the amide with lithium benzyloxide to obtain 
the chiral α-benzyl ester 9 in excellent enantioselectivity (Scheme 2).14 
 
 
Scheme 2. Evans’ chiral auxiliary strategy for asymmetric reactions 
5 
 
 
 
1.2.3 Chiral catalyst 
The most elegant and economically attractive way to introduce chirality into a molecule is by 
using a small amount of a chiral controller to induce the asymmetric transformation. In this 
type of enantioselective transformation, a relatively small amount of enantiopure molecule is 
introduced into a reaction where it interacts with the prochiral substrate, thereby activating 
and directing a stereoselective transformation. Once the reaction is complete, the catalyst 
dissociates from the substrate allowing initiation of another cycle. This method is less 
expensive than both the chiral reagent and chiral auxiliary methods since a small amount of 
catalyst is needed. Hence, it is becoming more popular than any other method in the field of 
asymmetric synthesis.  
Organic molecules can catalyse reactions by four different mechanisms:
16 
i. Activation of the reaction based on the nucleophilic / electrophilic properties of 
the catalyst. The chiral catalyst is not consumed in the reaction and does not 
require parallel regeneration. 
ii. Organic molecules that form reactive intermediates. The chiral catalyst is 
consumed in the reaction and requires regeneration in a parallel catalytic cycle. 
iii. Phase-transfer reactions. The chiral catalyst forms a host-guest complex with the 
substrate and shuttles between the standard organic solvent and a second phase 
(i.e. the solid or aqueous phase in which the reaction takes place). 
iv. Molecular-cavity-accelerated asymmetric transformations, in which the catalyst 
may select between the competing substrates, depending on size and structure 
criteria.     
The popularity of the use of a chiral catalyst has led to the emergence of a great variety of 
chiral catalysts that enable the preparation of the required products in the highest possible 
enantiomeric excess (ee). Some of the most important reactions include asymmetric 
homogeneous and heterogeneous metal catalytic reactions, asymmetric organocatalytic and 
enzyme-catalysed procedures.
17
  
Asymmetric metal catalysis is an attractive field of organic synthesis. Products with excellent 
enantioselectivities have been obtained using catalysts with well-defined chiral ligands. 
Chiral diphosphines and chelating compounds with nitrogen as donor atoms have been given 
significant attention.
18
 With the advent of a very important ligand 2,3-O-isopropylidene-2,3-
6 
 
dihydroxy-1,4-bis(diphenylphosphino)butane, DIOP introduced by Kagan and Dang,
19
 
rhodium complexes became popular in enantioselective catalytic hydrogenation reactions.
 
Studies on the stereochemistry of homogeneous asymmetric reactions have taken their 
models from the hydrogenation and transfer hydrogenation of prochiral compounds with C=C 
bonds and prochiral ketones in the presence of Rh and Ru complexes.
17
 One of these studies 
reveals that (R,R)-(S,S)-i-Bu-TRAP-Rh catalyst 10 provides 97% ee for hydrogenation of a 
tetrahydropyrazine carboxamide derivative 12 to (S)-13 under mild reaction conditions with a 
2 % catalyst loading (Scheme 3, Table 2, entry 1).
18
 The same work revealed that phosphorus 
substituents of TRAP ligand remarkably affected not only the enantioselectivity but also 
catalytic activity. The rhodium complex coordinated with Ph- and i-PrTRAP converted 12 to 
13 in only 7 and 5 % yields, respectively, with no ee in both cases (Table 2, entries 3 & 4). It 
was thought that the bulky phenyl and isopropyl groups on the phosphorus atoms on the 
chiral ligand might block coordination of the ligand to the rhodium metal centre. 
Interestingly, a related (R,R)-(S,S)-Me-TRAP-Rh catalyst provides the hydrogenation product 
13 with an opposite configuration (Table 2, entry 2).
20 
 
 
 
Scheme 3. Asymmetric hydrogenation of tetrahydropyrazine carboxamide derivative  
 
Table 2. Asymmetric hydrogenation of tetrahydropyrazine carboxamide 
Entry      Ligand         Conversion (%)            ee of 13 (%)   Configuration of 13   
1.            i-Bu-TRAP                  100                              97                                S 
2.            Me-TRAP              34                               61                                R 
3.            Ph-TRAP                   7                                 -                                   - 
4.            i-PrTRAP                   5                                 -                                   - 
 
The catalytic asymmetric epoxidation of allylic alcohols discovered by Sharpless and Katsuki 
in 1980 is another breakthrough in modern asymmetric synthesis.
21
 They reported that a 
7 
 
combination of commercially available and inexpensive (+) or (‒)-diethyl tartrate, titanium 
tetraisopropoxide and tert-butyl hydroperoxide was found to epoxidise a wide variety of 
allylic alcohols in high yield and excellent enantiomeric excess (Scheme 4).
21 
This 
methodology has two important features. Firstly, it gives uniformly high asymmetric 
inductions throughout a range of substitution patterns in the allylic substrates. Secondly, for a 
given tartrate enantiomer, the epoxide oxygen is delivered from the same enantiotopic face of 
the olefin regardless of the substitution pattern. Thus, the stereochemistry of the product is 
completely predictable depending on which enantiomer of the tartrate is used. When the 
olefinic unit is in the plane of the drawing with the hydroxymethyl substituent at the lower 
right (Figure 4), the use of (natural) (+)-diethyl tartrate leads to addition of the epoxide 
oxygen from the bottom. However, when the unnatural isomer (‒)-diethyl tartrate is used, the 
epoxide oxygen is added from the top.
21
  
 
Scheme 4. Sharpless epoxidation of allylic alcohols  
 
Figure 4. Mnemonic for the Sharpless asymmetric dihydroxylation 
In other work, Sharpless and co-workers demonstrated the use of chiral diamine ligands 14 
and 15 derived from Cinchona alkaloids (Figure 5) as chiral catalysts in the osmium-
catalysed asymmetric dihydroxylation of alkenes giving excellent yield and enantiomeric 
excess (Scheme 5).
22, 23
 When alkenes with other functional groups were used, only the 
8 
 
alkene unit was hydroxylated while the other functional groups remained unaffected. They 
also discovered that the more electron-rich the alkene is, the faster it will react. However, to 
achieve the highest level of enantioselectivity there must be some difference in size between 
the substituents attached to the alkene otherwise selectivities are affected.
24
  
     
Scheme 5. Sharpless asymmetric dihydroxylation  
This great work was fully developed by Sharpless in collaboration with many chemists into 
what is now popularly known as the Sharpless catalytic asymmetric dihydroxylation of 
olefins and is one of the most selective and reliable of known organic transformations to date. 
They developed a general procedure for a stereochemical addition of K3FeCN6 and OsO4 to 
olefins in 
t
BuOH-H2O to yield chiral diols and is applicable to a wide range of olefinic 
substrates.
22–25
 Because of the expense and toxicity of osmium, the reagents are available as 
stable, commercially available solids as pre-formulated mixtures containing K2OsO2(OH)4 as 
the source of OsO4 and K3FeCN6 which is the re-oxidant in the catalytic cycle. The solids are 
purchased in two variations as ‘AD-mix α’ or ‘AD-mix β’ containing the necessary bidentate 
chiral ligand (Figure 5), stoichiometric oxidant (K3FeCN6), and the osmium tetroxide in the 
form of dipotassium osmate dihydrate [(K2OsO2(OH)4)] each giving the absolute 
stereochemistry of the desired diol to a remarkable accuracy.
23
 
 
 
Figure 5. Ligands used in AD-mix α and AD-mix β 
 
 
9 
 
1.3 Oxazaborolidines 
1.3.1  History 
The first effective asymmetric borane reduction of aromatic ketones utilising stoichiometric 
amounts of optically active 1,3,2-oxazaborolidine 17 prepared in situ from the β-amino 
alcohol 16 and BH3.THF was reported in 1981 by Itsuno et al. (Scheme 6).
26
 
In that work and the subsequent ones, a number of prochiral ketones were reduced to the 
corresponding secondary alcohols with different levels of enantioselectivity using chiral 
amino alcohols and BH3.THF in 1:2 ratio. The best results were obtained with (S)-valine 
derivatives. Stereoselectivities of up to 73% ee were reached in the presence of (S)-valinol 16 
and aromatic ketones such as n-BuCOPh (Scheme 6).
 
However reduction of aliphatic ketones 
proceeded with low ee’s. Reduction of n-HexCOMe for example gave only 10% ee using the 
same conditions.
27
 
 
Scheme 6. Itsuno's enantioselective reduction of prochiral ketone 
In 1983 Itsuno et al. reported a bulkier version of (S)-valinol (S)-18. The asymmetric borane 
reduction of prochiral aromatic ketones with oxazaborolidine (S)-19, prepared from (S)-18 
and borane in situ gave the corresponding aromatic secondary alcohols in 94 ‒ 100% ee and 
100% chemical yield.
28
  In all cases the (R)-enantiomer of the secondary alcohol was formed 
preferentially (Scheme 7). Although Itsuno and co-workers studied intensively the steric 
influence of various catalyst substituents and reaction conditions on enantioselectivities, no 
mechanistic detail was presented.    
 
Scheme 7. Itsuno's enantioselective reduction of prochiral ketones 
In 1987 Itsuno and co-workers isolated the resulting oxazaborolidine (S)-19 but described it 
just as a "white solid whose exact structure was not clear" and made the first attempt towards 
10 
 
its characterisation.
29
 On the basis of these observations Corey et al. fully characterised the 
"white solid" as optically active oxazaborolidine (S)-19.
30
 Corey and co-workers showed that 
oxazaborolidine 19 on its own did not reduce acetophenone after several hours at room 
temperature. However, addition of BH3.THF (0.6 eq) allowed the rapid reduction of 
acetophenone at room temperature to produce (R)-1-phenylethanol with an enantiomeric 
excess of 94%, which was quite comparable to the work by Itsuno.
31
 In the absence of the 
oxazaborolidine, BH3.THF reduced acetophenone relatively slowly at room temperature and 
the rate acceleration observed in the presence of oxazaborolidine 19 suggested that sub-
stoichiometric quantities of the oxazaborolidine 19 could be used to achieve an asymmetric 
reduction of acetophenone. Bakshi and Shibata later showed that catalytic loading of 2.5 
mol% was enough to achieve the same result presented by Itsuno et al. using a stoichiometric 
amount (Scheme ).
30
 
 
 
Scheme 8. Oxazaborolidine catalysed asymmetric reduction of acetophenone 
The investigations into the mechanism of the stereoinduction were then centred on the nature 
of the catalyst. It was envisaged that an oxazaborolidine with less conformational flexibility 
would be able to induce a greater degree of stereoinduction. Hence Corey et al. fully 
characterised and tested the catalytic behaviour of a more rigid and sterically hindered 
oxazaborolidine 21 derived from (S)-(-)-2,2-diphenylhydroxymethylpyrrolidine (α,α-diphenyl 
prolinol) 20 which was first introduced in borane reductions by Kraatz in 1986 following the 
procedure of Itsuno.
32
 Treatment of the α,α-diphenyl prolinol 20 with BH3.THF (3 eq) in 
refluxing THF led to formation of the oxazaborolidine 21 which has become popularly 
known as CBS catalyst, after Corey, Bakshi and Shibata. The result of the Corey's studies 
showed that only 1 mol% of oxazaborolidine 21 with BH3.THF (1 equiv.) was effective in 
transforming acetophenone to (R)-1-phenylethanol in quantitative yield and an impressive 
97% enantiomeric excess (Scheme 9).
33,
 
30
 
11 
 
 
Scheme 9. Preparation of CBS catalyst and its asymmetric reduction of acetophenone 
The preparation of B-H non-substituted CBS catalyst 21 required the use of excess borane 
and removal of solvent and borane in vacuo. It is also extremely air and moisture sensitive 
which is a serious setback.  The B-alkylated versions on the other hand are more stable and 
can be stored at room temperature.
34
 Thus, reaction of the corresponding α,α-diphenyl 
prolinol 20 with methylboronic acid under dehydrating conditions (4Å molecular sieves or 
Dean-Stark trap) affords (S)-22 as colourless solid (Scheme 10).
34
 However, the catalyst 
gives erratic results if water is not completely removed. Blacklock et al. reported that 
approximately 1 mg of H2O / 1 g of ketone substrate decreases the ee from 95% to 50%.
35
 
For this reason Blacklock et al. modified the preparation of the oxazaborolidines by using 
trialkylboroxine instead of alkylboronic acid followed by three successive azeotropic 
distillations with toluene to remove residual water.
36
 This method affords the catalyst in 
higher purity which is important because any trace of unreacted amino alcohol also decreases 
the enantioselectivity (Scheme 10).
36
 
 
Scheme 10. Preparation of B-Me CBS catalyst  
Apart from the stability issues, oxazaborolidine catalyst 22 was found to be a superior 
enantioselective reduction catalyst. The reduction of ketones with B-Me 22 as the catalyst 
frequently resulted in appreciably higher enantioselectivity than with B-H 21. Moreover the 
scope of its reduction is very broad. Countless successful applications of this method for the 
enantioselective synthesis of chiral secondary alcohols from ketones have been described.
33
 
The chiral alcohols are obtained in excellent enantioselectivities, near quantitative yields, 
short reaction time and the reaction leads to a product whose absolute configuration can be 
12 
 
predicted from the relative effective steric bulk of the two carbonyl appendages (Scheme 
11).
31,
 
34
 
 
  _______________________________________________ 
                                              
                                 
  __________________________________________________ 
Scheme 11. CBS reduction of ketones catalysed by B-Me catalyst 22  
1.3.2  Mechanism 
The most logical pathway for the oxazaborolidine-catalysed reduction of ketones by borane 
as proposed by Corey et al. is summarised in Scheme 12. The mechanistic model explains 1) 
the absolute stereochemistry of the reduction, 2) the outstanding enantioselectivity obtained 
for the reduction, 3) the exceptional rate enhancement of the reduction, and 4) the turnover of 
the catalyst.
31,
 
33
 
 
Scheme 12. Proposed mechanism for the catalytic enantioselective reduction of ketones by CBS 
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The first step involves the rapid coordination of BH3 to the Lewis basic nitrogen atom on the 
α face of oxazaborolidine 22 leading to a cis-fused catalyst-BH3 complex 23. The crystalline 
B-Me.BH3 complex 23 consisting of the more stable cis-fused geometry (than the 
corresponding trans arrangement) has been isolated and structurally defined by single-crystal 
X-ray diffraction analysis.
37
 The coordination of the electrophilic BH3 to the nitrogen atom of 
oxazaborolidine 22 serves to activate BH3 as a hydride donor and also to increase strongly the 
Lewis acidity of the endocyclic boron atom. The latter property leads to facile complexation 
with ketonic oxygen of the (acetophenone) substrate at the more sterically accessible electron 
lone pair (a in the case of acetophenone) leading to the more stable complex 24. This manner 
of binding minimises unfavourable steric interactions between the oxazaborolidine and the 
ketone, and aligns the electronically deficient carbonyl carbon atom and the coordinated BH3 
for face-selective hydride transfer via a six-membered transition state 24.
38,
 
39
 The size of the 
phenyl substituents on the oxazaborolidine ring restricts rotation about the B-OCR2 bond of 
22 such that intramolecular hydride transfer from boron to carbon produces complex 25 with 
high ᴨ-facial selectivity. The ketone reduction eventually produces dialkoxyborane (RO)2BH  
with regeneration of catalyst 22 possibly by addition of BH3 to complex 25 to form a six-
membered BH3-bridge species 26, which decomposes to produce the catalyst-BH3 complex 
23 and borinate 27.
40
 The catalyst may also be directly regenerated from complex 25 by 
cycloelimination forming the borinate 27 simultaneously in the process.
41
 Thus, the (S)- 
proline-derived catalyst 22 selectively promotes the formation of (R)-1-phenylethanol from 
acetophenone and BH3·THF.  
A final issue posed by the proposed mechanistic model (Scheme 12) is whether the 
complexation of the ketone by the CBS catalyst or the subsequent hydride transfer to form 
complex 25 is the rate-limiting step of the reduction.
31
 To answer this question, the rates of 
reduction of acetophenone and the p-NO2 and p-MeO derivatives catalyzed by B-Me-22 were 
measured.
42
 The relative rates of reduction were found to be 3.4 (p-NO2), 1.8 (p-MeO), and 
1.0 (p-H).
 
This implies that the coordination of the ketone to the B-Me catalyst is not strictly 
rate-limiting for these substrates. Additional information was obtained from the 
1H ‒ 2H 
kinetic isotope effect (kH/kD) for hydride transfer, which was measured with an excess of a 
1:1 mixture of B
1
H3 and B
2
H3 (6 equiv. of each) in THF with two equivalents of 
oxazaborolidine B-Me-22 and one equivalent of acetophenone. The ratio of 
1
H to 
2
H in the 
reduction product 1-phenylethanol at low conversion was determined by mass spectrometry 
to be 1.7, which is then the approximate value of kH/kD.
42
 This low value is indicative of an 
early transition state for highly exothermic transfer of hydride from the boron atom to the 
14 
 
carbonyl group.
42
 Thus, both association to the carbonyl compound and hydride transfer are 
probably fast and comparably rate-limiting.
31
 
Since their development, oxazaborolidine catalysts have been utilized for the highly effective 
asymmetric synthesis of intermediates leading to a broad range of chiral natural products and 
bioactive compounds
43,
 
44
 such as lactones and macrolides
45
, terpenoids e.g. (-)-
herbertenediol
46
, alkaloids e.g. sanjoine A
47
, and many important drugs and pharmaceuticals 
such as antitumor drugs (-)-acylfulvene and (-)-irofulven.
48, 49
   
1.4 Enantioselective desymmetrisation 
1.4.1  Background 
Desymmetrisation of an achiral or meso molecule to yield enantiomerically enriched products 
is a powerful synthetic tool. In general, an enantioselective symmetry breaking synthetic 
operation is achieved when two enantiotopic functional groups are differentiated by the use 
of a chiral reagent, enzyme or catalyst.
50
 The most common type of enantioselective 
desymmetrisation involves the formation of carbon-heteroatom bond, of which the formation 
of carbon-oxygen bonds are the most common. For this reason, compounds with oxygen-
containing functional groups such as anhydrides, epoxides, alcohols, ketones or aldehydes are 
commonly used as substrates.  There have been several reports of the addition of chiral 
alcohol nucleophiles to cyclic achiral or meso-anhydrides to achieve diastereomerically 
enriched mono-ester products.
50
 Theisan and Heathcock reported the addition of 1-(1'-
naphthyl)ethanol to 3-OTBS substituted glutaric anhydride 28 to deliver enantioenriched 
ester 29 (scheme 13).
51
 The work revealed that far higher levels of diastereoselectivity were 
obtained using 1-(1'-naphthyl)ethanol as the nucleophile in preference to 1-(1'-phenyl)ethanol 
(50:1 versus 15:1 diastereoselectivity). 
 
Scheme 13. Heathcock’s desymmetrisation of meso anhydride 
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This desymmetrisation work was later extended by the same workers to 3-phenylsubstituted 
anhydride and a variety of 3-alkylsubstituted meso-anhydrides.
52
 
 
Results from this 
investigation revealed that more sterically hindered isopropyl- and tert-butyl- substituted 
substrates resulted in lower selectivities (Scheme 14). The chiral mono-esters were esterified 
by treatment with diazomethane followed by hydrogenation to obtain the corresponding 
methyl esters which were efficiently converted to the corresponding chiral δ-lactones in three 
steps sequence (Scheme 14).
52
  
 
Scheme 14. Heathcock’s desymmetrisation of 3-substituted meso anhydrides 
Taguchi and co-workers have also developed a system for the diastereoselective opening of 
meso-succinic anhydrides 31 using 1-phenyl-3,3-bis(trifluoromethyl)propane-1,3-diol 30 as 
the chiral nucleophile (scheme 15). They reported that to achieve a good level of selectivity, 
it was necessary to use the sodium salt of the diol 30 and to conduct the reactions in a non-
polar solvent.
50
 
 
Scheme 15. Taguchi’s desymmetrisation of meso anhydrides 
Readily available stereochemically defined epoxides obtained from simple alkene precursors 
are popularly used as substrates in desymmetrisation chemistry. Nugent reported a range of 
C3-symmetric zirconium (IV) complexes 32-(L-Zr-OH)2.tBuOH that catalyse the addition of 
azide nucleophiles to meso-epoxides (scheme 16).
53
 The reaction is compatible with a range 
16 
 
of cyclic and acyclic epoxides with a particularly notable example being the use of but-2-ene 
oxide which provided the ring-opened product in an impressive 87% ee. 
 
 
Scheme 16. Nugent’s desymmetrisation of meso epoxides 
Nelson and co-workers employed a Jacobsen enantioselective epoxide hydrolysis to effect the 
desymmetrisation of centrosymmetric diepoxide 34 prepared from a simple alkenyl ketone 33 
in seven steps. Treatment of the meso diepoxide 34 with 20 mol% of (R,R)-37 in 
MeCN:CH2Cl2 (1:1) for 4 days gave selectively the diol 35 in a remarkable 98% yield and > 
95% ee (Scheme 17). The diol 35 was converted in to a known synthetic intermediate 36 in a 
total synthesis of the polyclic ether natural product hemibrevetoxin B.
54,
 
55
 
 
       
Scheme 17. Nelson’s desymmetrisation of meso centrosymmetric diepoxide 
Prochiral ketone substrates are also used extensively to achieve desymmetrisation processes. 
Interesting work reported by Masamune and Abiko used a chiral phosphonate 38 in which the 
chiral auxiliary was attached via the amide unit to desymmetrise 4-substitutedcyclohexanones 
39 in an asymmetric Horner-Emmons reaction (Scheme 18).
56
 Deprotonation of the chiral 
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phosphonate 38 using KHMDS in presence of 18-crown-6 at -20 
o
C and reacting with achiral 
4-substituted cyclohexanones 39 produced the alkenes 40 in good yields and diastereomeric 
ratios. Cleavage of the benzopyranisoxazoline unit by treatment with lithium borohydride 
provided the corresponding chiral allylic alcohols 41 in excellent yields, without racemization 
(Scheme 18). 
 
Scheme 18. Abiko’s desymmetrisation of meso cyclohexanones 
1.4.2 Enantioselective reduction of imides 
Enantioselective reduction of imides has received much attention because they form a useful 
class of starting materials in the field of asymmetric synthesis. An enantioselective reduction 
of one of the carbonyl groups leads to chiral hydroxy-lactams which have been shown to be 
versatile building blocks for the synthesis of natural products and numerous heterocyclic 
compounds, including vitamins, antibiotics, ACE inhibitors, and anticancer drugs such as (+)-
biotin, and swainsonine.
57,
 
58,
 
59
 One of the first approaches towards the asymmetric reduction 
of imides was by Chamberlin and co-workers. Their work involved the attachment of a chiral 
auxiliary derived from the commercially available D-(α)-phenylglycinol to the nitrogen atom 
of the imide 42, which they envisaged could control the diastereoselective reduction of one of 
the carbonyl groups over the other (Figure 6).
60
 Initial attempts at selective reduction of one 
of the diastereotopic carbonyl groups relied upon the intramolecular reaction of an alkoxide / 
metal species from the alcohol 43. The conformation required for such a reaction places 
either phenyl or H approximately in-plane with the other carbonyl group, and the latter 
arrangement should be more favourable (Figure 6). Initially the result was disappointing: 
LiAlH4 gave a diastereomeric excess (de) of only 22%, while the use of Red-Al resulted in a 
somewhat better 64% de. However, with tetramethylammonium triacetoxyborohydride, 
18 
 
Me4NHB(OAc)3, the stereoselectivity improved significantly to levels exceeding 90% de 
(Scheme 19).
60 
 
 
Figure 6. Chamberlin’s chiral auxiliary 
 
Scheme 19. Chamberlin’s asymmetric reduction of imides 
Meyers et al. also utilized nitrogen based-chiral auxiliaries for enantioselective reduction of 
the succinimides 44 by treatment with NaBH4 and 1.0 equivalent of HCl in absolute ethanol. 
The diastereomeric 2-ethoxy lactams 45 obtained were effectively converted to the 
corresponding chiral bicyclic lactams 46 & 47 via an acyliminium ion as single diastereomers 
and in excellent yields, by treatment with 10 equivalents of TFA at 0 
o
C (Scheme 20).
61
    
 
Scheme 20. Meyer’s asymmetric reduction of meso imides 
Enantioselective reduction methods using optically active BINAL-H complexes have been 
reported. Matsuki et al. examined the reduction of N-PMP meso imide 48 by treating with 3.5 
equivalent amount of (R)-BINAL-H(MeOH).
62
 A mixture of hydroxy-lactam 49 and 50 was 
isolated whose ratio depended on the conditions of the work-up. When the reduction was 
quenched with 10% HCl at -78 
o
C, the C3β-hydroxy-lactam isomer 49 was isolated as a sole 
product in 85% yield (Scheme 21). Quenching the reaction with 10% HCl at room 
temperature, however, led to epimerization and afforded an equimolar mixture of hydroxy-
lactams 49 and 50 (Scheme 21). Also, when the C3β-hydroxy-lactam 49 was treated with 
10% HCl in THF at room temperature for 1 hour, the C3α-hydroxy-lactam 50 was obtained in 
19 
 
95% yield. To confirm the enantioselectivity of the (R)-BINAL-H, both hydroxy-lactams 49 
and 50 were separately treated with Et3SiH / TFA to afford the corresponding lactams 
quantitatively in 88% ee and 89% ee, respectively.
62
 
 
Scheme 21. Matsuki’s asymmetric reduction of N-PMP meso imide 
The stereochemical outcome was explained using the model put forward by Noyori et al.
63
 
The attack of the BINAL-H on the carbonyl group attached to the (R)-centre of the imide 
from the convex face leads to a more favourable transition state “A” owing to the n / Π* 
attractive orbital interaction between oxygen non-bonding orbital and the LUMO of the imide 
moiety affording the C3β-hydroxy-lactam 49 (Figure 7). The transition state “B” from the 
attack of the (R)-BINAL-H on the carbonyl group attached to (S)-centre has no such 
interaction and is therefore less favoured (Figure 7).
62
 
 
Figure 7. Transition states for the reduction of succinimide 48 
Nishiyama and co-workers employed the use of a BINAL-H(EtOH) complex prepared in situ 
by mixing lithium aluminium hydride with equimolar amounts of (R)-(+)-binaphthol and 
ethanol in THF for the reduction of a meso-tartaric acid derived imide 51 in the course of the 
stereoselective synthesis of  chiral diastereomers of 3,4-dihydroxyglutamic acids 53 and 54 
(Scheme 22).
64
 The triacetate 52 was obtained as a single diastereomer suggesting attack of 
the (R)-BINAL-H reagent from the less hindered face of the carbonyl group attached to the S 
centre of the cyclic meso imide. Although they could not explain the reason for the 
20 
 
enantioselective discrimination of the enantiotopic imide carbonyl groups, they thought that 
the interaction of an acetoxy group with the (R)-BINAL-H reagent may be responsible for the 
reversal of enantioselectivity observed in Matsuki’s work.64 
 
Scheme 22. Nishiyama’s asymmetric reduction of meso imide 51 
Kang et al. reported the use of thiazazincolidine complex 58 prepared in situ from (1R,2S)-(-
)-1-phenyl-2-(1-piperidino)-1-propanethiol and diethylzinc as a good catalyst for 
enantioselective reduction of cyclic meso-imides in the presence of bis(2,6-
dimethoxyphenoxy)borane, BDMPB (Scheme 23).
65
  The catalyst was previously shown by 
Kang et al. to be an excellent catalyst for enantioselective addition of dialkylzinc to 
aldehydes
66
, and it was thus envisaged that there will be an enantiodiscriminative 
coordination of the catalyst to one of the carbonyl groups of the imide. Enantioselective 
reduction of various meso N-phenyl imides 55 to corresponding hydroxy-lactams 56 was 
carried out. The hydroxy-lactams were reduced to the corresponding hydroxy-amides with 
NaBH4 followed by acid-catalysed lactonization to give the corresponding lactones 57 in 
good yields and enantioselectivity (Scheme 23).  
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___________________________________________________________________________ 
                       
     69% yield      72% yield           61% yield           69% yield 
    84% ee      96% ee           95% ee           82% ee 
 
                      
      50% yield       56% yield          92% yield                          83% yield 
      70% ee       83% ee          82% ee               99% ee  
___________________________________________________________________________ 
Scheme 23. Kang’s asymmetric reduction of meso imides 
Two possible transition states A and B for the reduction were proposed by the authors (Figure 
8). It was envisaged that the complex B with the phenyl group pointing away from the 
catalyst should be more favourable. Moreover, it was proposed that the bulky nucleophile 
BPMPB should selectively attack the indirectly activated carbonyl carbon rather than the 
directly coordinated carbonyl group, leading to lactone 57 (Figure 8).
65 
 
 
 
Figure 8. Transition state for thiazazincolidine catalysed reduction 
While these works focused on five membered ring meso succinimides, the enantioselective 
reduction of six membered ring achiral glutarimides has not been explored much. There have 
been only two reports on the enantioselective desymmetrisation of achiral glutarimides, out 
of which only one, by Ikariya and co-workers, is an enantioselective catalytic reduction. They 
reported the use of chiral Cp
*
Ru(PN) catalysts for the enantioselective hydrogenative 
desymmetrisation of mono- and bicyclic glutarimides (and succinimides) to furnish chiral 
hydroxyamides.
67
 The chiral ruthenium catalyst 59 in presence of t-BuOK caused highly 
enantioselective hydrogenation of both monocyclic and bicyclic glutarimides to give the 
corresponding hydroxyamides in near quantitative yields and excellent ee’s (Scheme 24). 
Furthermore the authors observed that the enantioselectivity of products derived from some 
bicyclic succinimides decreased to the moderate range (52 ‒ 63% ee) with the same chiral 
22 
 
catalyst.  However, switching from catalyst 59 to 60 caused significant change in ee in the 
desymmetrisation of the five-membered ring imides (52 – 92% ee).67 
 
 
         Table 3. Enantioselective hydrogenative desymmetrisation of glutarimides 
________________________________________________________ 
Entry  Imide   ee of hydroxyamide (%)   
_________________________________________________ 
 1  R = 4FC6H4      98 
 2  R = 3,4Cl2FC6H4     91 
 3  R = C6H5      98 
 4  R = CH3      88 
_______________________________________________________ 
* Authors indicated >99% conversion 
 
 
Scheme 24. Ikariya’s enantioselective hydrogenative desymmetrisation of glutarimides 
         Table 4. Enantioselective hydrogenative desymmetrisation of bicyclic glutarimides 
________________________________________________________ 
Entry  Imide   ee of hydroxyamide (%)   
_________________________________________________ 
 1  m = 1       94 
 2  m = 2       94 
 3  m = 3       93 
_______________________________________________________ 
* Authors indicated >99% conversion 
 
In a different strategy, Simpkins and co-workers used the chiral base 64 in its bis-lithiated 
form to effect an enantioselective desymmetrisation of achiral N-Me and N-Bn glutarimides 
61 (Scheme 25).
68
 Under the optimized conditions, the desired products 62 were obtained in 
good yields, with good to excellent levels of enantioselectivity, and as single diastereomers. 
However, the formation of the doubly substituted product 63 was observed in all the 
desymmetrisation products. 
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Scheme 25. Simpkin's desymmetrisation of glutarimides using chiral base 
Table 5. Chiral base desymmetrisation of glutarimides 
___________________________________________________________________________ 
Entry  R  Electrophile            Yield of 62 (%)        ee of 62 (%)  62 / 63 
___________________________________________________________________________ 
1. Me      MeI            73              86  3.5 : 1 
2. Me      BnBr           58              74  2.5 : 1 
3. Me      4-BrC6H4CH2Br           63  77     3 : 1 
4. Me      MeO2CCN            87  75    20 : 1 
5. Bn      MeI             65              97      3 : 1 
6. Bn      AllylBr            52   90       *  
7. Bn      BnBr            61   97       2 : 1 
8. Bn      PhCHO            75               97         - 
9. Bn      MeO2CCN            71               97     6.5 : 1 
* Ratio not determined 
Results from the work showed higher levels of selectivity in N-Bn substrates than in the N-
Me series (Table 5). It was also observed that there was a correlation between high selectivity 
and the formation of the undesired di-substituted by-product 63. The authors explained that 
this observation suggested that the overall ee of the desired product was the result of an initial 
asymmetric enolisation of the glutarimide starting material, followed by an ee enhancing 
kinetic resolution (Scheme 26).
68
 
 
Scheme 26. ee enhancing kinetic resolution in desymmetrisation of glutarimides 
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1.4.3 Enantioselective reduction of imides using oxazaborolidines 
Studies of the use of a combination of oxazaborolidine catalysts and borane for the 
enantioselective reduction of meso-imides have caught the attention of many research groups. 
The first enantioselective reduction of meso-imides using an oxazaborolidine 21 / BH3 
mixture was reported by Hiemstra and co-workers.
69
 When the meso-imide 65 was treated 
with varying amounts of CBS catalyst 21 and BH3, a mixture of optically active cis- and 
trans-5-hydroxy-2-pyrrolidinones 66 was obtained. The crude mixture was immediately 
treated with EtOH/H2SO4 giving the ethoxy-lactam 67 that was isolated as a single product in 
good overall yield and with good enantioselectivity (Scheme 27).
69
 
 
Scheme 27. Hiemstra’s asymmetric reduction of meso imides 
Encouraged by the above results, the reduction was applied to various other meso N-benzyl 
imides 68 in the presence of oxazaborolidine 21 at different catalyst loadings employing 
BH3.THF as the hydride source (Scheme 28). Optimal catalyst loading was found to be 0.5 
equivalents to achieve maximum enantioselectivity. The corresponding ethoxy-lactams were 
obtained in good overall yield with complete trans-stereoselectivity and high 
enantioselectivity. The results indicated that there was a direct relationship between 
enantioselectivity obtained and the size of the bicyclic backbone. The best result was 
obtained when a cyclobutyl ring (n = 2) was present on the imide giving a maximum ee of 
89% (Table 6), while deviation from this size to a larger ring resulted in a drop in ee to 77% 
for cyclopentyl (n = 3) and 80% for cyclohexyl (Table 6, n = 4).
70
  
 
 
Scheme 28. Speckamp’s CBS catalysed reduction of meso-imides 
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Table 6. Speckamp's reduction of cyclic meso imides 
______________________________________________________________________________ 
Imide  Yield of hydroxy-  Yield of ethoxy- ee of ethoxy-lactam   
   lactam (%)    lactam (%)   (%) 
________________________________________________________________________ 
 
n = 1          74           94   88 
n = 2           -            68
*
   89 
n = 3           -            85
*
   77 
n = 4 (65)         95           87   80 
_______________________________________________________________________________ 
*
 Yield over 2 steps 
The observed stereochemical outcome was explained by adopting Corey’s transition state 
model for CBS-catalysed reduction of acetophenone (Scheme 12).
30
 In the case of cyclic 
meso-imides, however, the nitrogen moiety is the large substituent (RL) and the fused ring 
moiety is the small substituent (RS) (Figure 9). The hydride attack should therefore come 
from the least hindered face of the carbonyl carbon (attached to the R centre), producing cis 
hydroxy-lactam 69 as the kinetic product (Figure 9). It was also postulated by Hiemstra and 
co-workers that enantioselectivity is higher if the difference in size between RL and RS is 
larger, hence imides with small RS (n = 1 & n = 2) gave higher selectivity (Table 6, n = 1 & 
2).
70
 
 
Figure 9. Hiemstra’s transition state for CBS catalysed reduction of meso-imides 
Shimizu et al. employed the use of an oxazaborolidine catalyst 71 derived from L-threonine 
and borane-THF for enantioselective reduction of meso N-benzyl succinimides 70 to give the 
corresponding hydroxy-lactams in high enantiomeric purity (Scheme 29).
71
 The optimal 
oxazaborolidine loading was found to be 0.5 equivalents, otherwise leading to a lower yield 
of the hydroxy-lactam products.  
 
Scheme 29. Shimizu’s reduction of meso-imides 
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Table 7. Shimizu’s reduction of cyclic meso imides 
___________________________________________________________________________ 
   R, R            Temp. (
o
C) Yield of hydroxy-lactam (%)          ee (%) 
_____________________________________________________________________ 
AcO, AcO     0   54            98 
-(CH2)4-     0   50            92 
TBDMSO, TBDMSO    rt   76            91 
-(Bn)NCON(Bn)-    rt   73            92 
___________________________________________________________________________ 
Chen et al., in an effort to avoid the relatively expensive and less stable borane (and its 
complexes), employed enantioselective reduction of meso-imide 72 via the use of chiral 
oxazaborolidine 74 derived from (1S,2S)-(+)-threo-1-(4-nitrophenyl)-2-amino-1,3-
propanediol and in situ generated borane from LiH / BF3.Et2O. The corresponding hydroxy-
lactam 73 obtained as a single diastereomer in 85% yield and 98% ee led to a synthesis of d-
biotin (Scheme 30).
72
 
 
Scheme 30. Chen’s reduction of meso-imide 72 
In the continuation of the investigation on the mechanism and catalytic properties of the 
oxazaborolidine catalysts, the Jones research group has reported application of the catalysts 
for the reduction of meso-imides. Jones and Dixon reported desymmetrisation of meso-imide 
65 by enantioselective reduction using a chiral oxazaborolidine catalyst 76 derived from 
(1R,2S)-cis-1-amino-2-indanol followed by reduction of the hydroxy-lactam product to 
lactam 75, which proceeded with good enantiomeric excess at significantly lower catalyst 
loadings compared to reactions using the prolinol-derived (CBS) catalyst 22.
73
 At 5 mol % 
catalyst loading, 57% yield of lactam 75 was produced at an impressive 84% ee, against the 
CBS catalyst which gave an enantioselectivity of 45% ee and 44% yield. Reduction in the 
amount of catalyst to as low as 1 mol % showed no significant drop in enantioselectivity at 
around 85%, although a slight drop in the overall yield was noted. The best catalyst loading 
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was observed at 10 mol % which gave 75% yield of the lactam and enantiomeric excess of 
86% (Scheme 31).
73 
 
 
Scheme 31. Jones’ desymmetrisation of meso imide using oxazaborolidine catalyst 
In separate work, Jones and co-workers reported the crucial role of the nitrogen substituent in 
the desymmetrisation of cyclic meso-imides 65, & 78 ‒ 83 using B-Me 76 and B-OMe 77 
oxazaborolidine catalysts (Scheme 32).
74
 The research work revealed that these 
oxazaborolidine catalysts are very effective for the enantioselective reduction of a series of 
meso-imides, with the B-Me 76 catalyst providing better yield of the lactam products 75, & 
84 ‒ 89  (Table 8). More importantly, the research discovered that varying the nitrogen 
substituent on the imide greatly affects the level of enantioselectivity, with N-aryl groups 
providing very high enantioselectivity of the lactam product (Scheme 32, Table 8).
74
 
 
Scheme 32. Desymmetrisation of meso imide using oxazaborolidine catalysts 
Table 8. Reduction of cyclic meso imides using catalyst 76 and 77 
___________________________________________________________________________ 
Entry  Imide      R                                  Catalyst 76              Catalyst 77 
        _________________         __________________                                             
           Lactam    Yield (%) ee (%)          Yield (%)       ee (%) 
___________________________________________________________________________ 
 1   65      Bn           75                  57  84        53         82 
 2   78      Ph                      84                  49  99        23         99 
 3   79     (p-OMe)C6H4       85                  41  99             28         99 
 4   80    (p-NO2) C6H4        86                  24  99        9         99 
 5   81    CH2=CHCH2         87                  24  33        24         32 
 6   82     t-Bu                      88                  19   0        21           0 
 7   83      Me           89        52  75  30         70 
___________________________________________________________________________ 
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Explanations were put forward for the observed results. The reduced yields of the lactams 
observed in B-OMe catalyst were thought to be as a result of the reduced Lewis acidity of the 
boron centre in the catalyst by the additional oxygen substituent, therefore retarding the rate 
of reduction. The disappointing yield obtained with R = (p-NO2)C6H4 was attributed to the 
doubly reduced product observed in the reaction while a competitive hydroboration may be 
responsible for the poor yield obtained in the N-allyl substrate. A model was presented to 
explain the stereochemical outcome of the reductions. It was envisaged that both the borane 
and the imide bind to the least hindered convex side of the oxazaborolidine (Figure 10). Also, 
to avoid unfavourable interactions, the nitrogen substituent was placed away from the B-Me 
group of the oxazaborolidine similar to the transition state model proposed by Corey and 
hydride was supplied from the Re face of the activated carbonyl carbon (Figure 10).
74
 
 
Figure 10. Transition state for cis-1-amino-indanol-2-ol oxazaborolidine reductions 
In a different approach, the research group has reported the use of oxazaborolidines B-Me 76 
and B-OMe 77 as catalysts for the kinetic resolution of racemic C-3 substituted pyrrolidine-
2,5-diones (Scheme 33).
75
 Results obtained showed that both catalysts are effective for the 
kinetic resolution of C-3 substituted pyrrolidine-2,5-dione species at extremely low catalyst 
loadings (0.5 mol%), giving outstanding regio- and stereocontrol. In the preliminary 
experiment, reduction of the substrates to hydroxy-lactams with BH3.THF, employing B-
OMe oxazaborolidine 77 as the catalyst followed by reduction to corresponding γ-lactams 
showed full regiocontrol of the reaction in all cases, reducing only the distal carbonyl at the 
C-5 position. Applying optimised conditions, the kinetic resolution of various C-3 substituted 
pyrrolidine-2,5-diones was assessed (Table 8). 
 
 
Scheme 33. Kinetic resolution of C-3 succinimides using oxazaborolidine catalysts 
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Table 9. Kinetic resolution of N-Bn C-3 succinimides using oxazaborolidine catalysts 
___________________________________________________________________________ 
Entry             R                      Catalyst
a
       Conversion (%)
b
   ee (%)     s factor                               
             (of starting material)
c
          
___________________________________________________________________________ 
1  Me                   76     46         16      1.8 
2  Me                   77     32         11      1.8 
3  Ph                   76     52         45      3.7 
4  Ph                   77     36         28      3.9 
5  3,5-Me2C6H3       76     48         41      3.8 
6  3,5-Me2C6H3       77                39         32      4.1 
7  o-Tolyl                  76                23         24      11.6 
8  o-Tolyl                  77     43         57      12.7 
9  1-Naphthyl       76                21         23      17.3 
10  1-Naphthyl       77     30         37      19.6 
11  t-Bu                   76     38         52      20.4 
12  t-Bu                   77     35         47      23.4 
13  Mesityl                    76                31
d
         16      2.5 
14  Mesityl                    77     34
d
         5      1.3 
a
 0.5 mol% catalyst was used in each case. Reactions performed with catalyst 76 were carried out for 
120 min, while those with catalyst 77 for 60 min. 
b
 Conversion determined via 
1
H NMR spectroscopy 
using maleimide as an external standard. 
c
 ee determined via chiral phase HPLC. 
d
 Conversion 
determined via 
1
H NMR spectroscopy using N-benzotriazole as an external standard. 
 
Results showed that the level of the selectivity increased with increasing steric bulk at the C-
3 position (Table 9). A methyl group gave a poor selectivity, giving s factors of 1.8 (Table 9, 
entries 1 and 2). When the substituent size was increased to phenyl or 3,5-dimethyl phenyl, 
the level of selectivity increased to between 3.7 and 4.1 (Table 9, entries 3–6). Excellent s 
factors of 12 and 18 were achieved with o-tolyl or 1-naphthyl substituents (Table 8, entries 7–
10), while the highest s factors of 20–23 were achieved with t-Bu substituent (Table 8, entries 
11 and 12). However, the large mesityl derivative gave very disappointing s factors of 
between 1.3 and 2.5 (Table 9, entries 13 and 14).
75
 
 
1.5 Aims 
Previous work from this group has shown that the oxazaborolidines 76 and 77 are good 
catalysts for desymmetrisation of five-membered meso imides.
73,
 
74,
 
75
 More recently, the 
synthesis and desymmetrisation of the anthracene-maleimide cycloadducts 90 have been 
investigated by a previous research group member. Results from the initial screening of the 
substrates and the catalysts, showed that the B-OMe catalyst 77 gave moderate yield and 
excellent selectivity of the desymmetrised product from the N-PMP substrate (Scheme 34). 
Encouraged by this result, an incomplete synthesis of pyrrolam A was pursued (Scheme 
34).
76
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Scheme 34. Desymmetrisation of meso anthracene-maleimides  
The initial part of this research was aimed at repeating and optimizing the synthesis and 
desymmetrisation of anthracene-maleimide cycloadducts 90. Based on the results obtained, 
the total synthesis of pyrrolidizine alkaloid pyrrolam A would be re-visited. This research 
group has had successes in the past employing chiral anthracenes as stereocontrolling 
auxiliaries for organic transformations.
77,
 
78,
 
79,
 
80
 It is hoped that the anthracene backbone 
directs the regioselectivity of subsequent N-acyl iminium transformations, directing attacks to 
the top face. Finally, retro Diels-Alder using flash vacuum pyrrolysis would furnish the target 
natural product (Scheme 35). 
 
Scheme 35. Desymmetrisation of meso anthracene-maleimides and synthesis of pyrrolam A  
The second part of the research work would target expanding the scope of the five-membered 
ring imides desymmetrisation methodology to six-membered ring glutarimides. As this is the 
first work of its kind in the research group, the initial attempt would be establishing an 
efficient route to the synthesis of various glutarimide substrates from cheap commercially 
available materials (Scheme 36). Attention would be paid to the synthesis of N-PMP and N-
Bn substrates since their five-membered ring counterparts have been proved by earlier work 
to give better yields and selectivity. Once that has been accomplished, the enantioselective 
desymmetrisation of various achiral 3-substituted glutarimides 91 using oxazaborolidines 76 
and 77 would be investigated, assessing the role of the substituent on the C-3 position and 
investigating the role of the nitrogen protecting groups, N-PMP and N-Bn, and any difference 
between the two oxazaborolidine catalysts. The hydroxy-lactams 92, obtained from the 
reduction would be converted to the corresponding lactams by an established procedure for 
ease of analysis (Scheme 36). 
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Scheme 36. Synthesis and desymmetrisation of meso glutarimides  
After the desymmetrisation of the glutarimides has been successfully accomplished, the final 
part of the research work would be to try some functionalisation experiments on a 
representative chiral lactam. The first obvious experiment would be to try various C-3 
functions on the lactam ring through an enolate chemistry that would furnish chiral 3,4-
disubstituted 2-piperidinones 93 (Scheme 37). The stereogenic centre on C-4 is expected to 
control the stereochemistry of the newly formed C-3 stereogenic centre, as attack of the 
electrophile is expected to be from the opposite face. The 3,4-disubstituted 2-piperidinones 
93 would then be reduced to  chiral 3,4-disubstituted piperidines 94 which are important 
structural motifs in biologically active natural products and pharmaceuticals (Scheme 37). 
 
Scheme 37. Synthesis of chiral 3,4-disubstituted piperidines 
The synthesis of 4,6-disubstituted 2-piperidinones 96 would also be attempted by first 
converting the hydroxy-lactam 92 to a sulfonyl function which is known to be a good leaving 
group. The resultant 2-sulfonyl lactam 95 would then be made to undergo nucleophilic 
substitution with various nucleophiles to furnish the corresponding 4,6-disubstituted 2-
piperidinones 96 (Scheme 38). 
 
Scheme 38. Synthesis of chiral 4,6-disubstituted 2-piperidinones 
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Chapter 2 
Desymmetrisation of maleimides 
 
2.1 Synthesis and desymmetrisation of anthracene maleimides 
2.1.1 Background 
Although there have been many reports on the reductive desymmetrisation of 3,4-
disubstituted maleimides or succinimides, the desymmetrisation of un-substituted maleimides 
or succinimides has not been possible due to the tendency of the newly installed stereogenic 
centre to rapidly epimerise before functionalisation is achieved. A way to overcome this 
problem is by the temporary attachment of an anthracene template. Thus N-substituted 
maleimides 97 would undergo a Diels-Alder reaction with anthracene, the resultant 
anthracene-maleimide cycloadducts 90 subjected to enantioselective desymmetrisation and 
functionalisation, finally followed by a retro Diels-Alder to liberate the enantioenriched α,β-
unsaturated lactam 98 (Scheme 39). Another advantage of this method is that the 
stereoselectivity of the functionalisation step has been shown by earlier reports from the 
research group to be enhanced by the anthracene template present in the intermediate before 
the final retro-Diels-Alder reaction.
77,
 
78
   
 
 
Scheme 39. Use of anthracene template for desymmerisation of N-substituted maleimides  
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2.1.2 Synthesis of anthracene-maleimide cycloadducts 
From previous desymmetrisation work, the first obvious candidate would be a substrate 
bearing an N-aryl group, since N-alkyl substrates give poor yields and lower 
enantioselectivity of the desymmetrised products.
76
 The p-(methoxy)phenyl (PMP) group in 
particular was reported to give excellent enantioselectivity of the desymmetrised product. 
Moreover, the N-PMP group could be easily cleaved using CAN. However, a common 
feature of the N-PMP system was the tendency for over-reduction in the desymmetrisation 
step which diminished the yield.
76,
 
74
 Previous studies showed that desymmetrisation of N-
benzyl or N-p-(methoxybenzyl) protected meso-imides gave higher yields of the products but 
an enantiomeric excess of around 80%.
76,
 
74
  
The N-PMP anthracene-maleimide cycloadduct 101 was synthesised, following a procedure 
adapted by a previous research group member, in two steps from commercially available 
maleic anhydride 99 (Scheme 40).
76
 Treatment of maleic anhydride 99 with p-anisidine in the 
presence of HMDS and ZnCl2 and heating under reflux in toluene for 4 hours afforded the N-
protected maleimide 100 in 70% yield. The anthracene-maleimide cycloadduct 101 was 
accessed in 94% yield by heating under reflux a mixture of the maleimide 100 and anthracene 
in toluene for 4 hours (Scheme 40). The yield agrees closely with the previously reported 
yield of 97%.
76
 
 
Scheme 40. Preparation of N-PMP cycloadduct  
For the synthesis of N-Bn 103 and N-PMB 104 derivatives, the above method of preparing 
the corresponding maleimide followed by a Diels-Alder reaction to give the cycloadduct was 
reported to be low yielding. Instead, the reaction steps were reversed, starting with a Diels-
Alder reaction between maleic anhydride 99 and anthracene to furnish the anhydride 
cycloadduct 102 in 97% yield. Treatment of the anhydride cycloadduct 102 with the 
corresponding amine gave the desired N-benzyl or N-PMB imide cycloadducts 103 or 104 in 
89% and 88% yields, respectively, which are comparable yields with the previously reported 
work (Scheme 41).
76
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Scheme 41. Preparation of N-benzyl and N-PMB cycloadducts 
2.1.3 Desymmetrisation of anthracene-maleimide cycloadducts 
Oxazaboroline catalysts derived from cis-aminoindan-2-ol 105 have been used by the Jones 
group as chiral catalysts for the asymmetric reduction of various prochiral ketones.
81,
 
82
  The 
B-OMe catalyst 77 showed excellent yield and enantioselectivity in reduction of 
acetophenone (Scheme 42).
82
  
 
Scheme 42. Enantioselective reduction of acetophenone using B-OMe catalyst 
Both B-OMe 77 and B-Me catalysts 76 were shown to be superior in the desymmetrisation of 
meso-imides 65, 78 ‒ 80 than the traditional CBS catalyst, giving excellent enantioselectivity 
with lower catalyst loadings.
73
 The catalyst B-OMe 77 is easier to prepare and store than the 
analogous B-Me oxazaborolidine 76, being readily prepared under nitrogen as a stock 
solution prior to use from trimethylborate and cis-1-aminoindan-2-ol 105 (Scheme 43). In 
contrast the B-Me oxazaborolidine 76 requires a series of azeotropic distillations under 
nitrogen to facilitate the condensation of cis-1-aminoindan-2-ol with trimethylboroxine. The 
solvent is then removed in vacuo to yield the oxazaborolidine which is diluted to a standard 
solution and used immediately (Scheme 43). 
 
Scheme 43. Preparations of oxazaborolidines from cis-1-aminoindan-2-ol 
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As the aim of this stage of the project was to repeat and optimize the work by an earlier 
research group member, screening of the catalysts was unnecessary since it was established 
that the B-OMe catalyst 77 showed superiority over its B-Me counterpart in both yields and 
enantioselectivity in the desymmetrisation of the maleimide-anthracene cycloadducts 90.
76
 It 
was also established that the optimal catalyst loading was 10 mol% and BH3.THF was the 
hydride source as there was no competing background reaction.
73
 The initial 
desymmetrisation work would therefore focus on optimizing the reaction conditions and 
screening of N-aryl analogues.  
The first desymmetrisation experiment was carried out on the N-PMP cycloadduct 101 using 
oxazaborolidine 77 and employing BH3.THF as borane source, monitoring the reduction step 
by TLC. At room temperature and 0 
o
C, formation of the hydroxy-lactam 106 product was 
observed which reached its highest concentration at 4 hours. Beyond 4 hours the 
concentration of the hydroxy-lactam started to diminish. Prior work showed the hydroxy-
lactam was difficult to purify due to ease of epimerisation and an attempt was made to 
convert the crude hydroxy-lactam to the more stable methoxy aminal 107 by heating at reflux 
in trimethylorthoformate in the presence of Amberlyst-15
® 
for 18 hours. Although a 48% 
yield of the methoxy compound 107 was previously obtained with above method, no 
conversion of the hydroxy-lactam was observed from the 
1
H NMR spectrum of the crude 
after 18 hours. Extending the reaction time to 48 hours showed no appreciable conversion of 
the crude hydroxy-lactam (Scheme 44). 
 
Scheme 44. Attempted desymmetrisation of the N-PMP cycloadduct 101 
Pleasingly, when the reaction was repeated and the crude hydroxy-lactam was treated with 10 
mol% of p-TsOH in methanol and heated at reflux for 18 hours, the 
1
H NMR spectrum 
showed full conversion of the hydroxy-lactam and the methoxy compound 107 was obtained 
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as a single diastereomer in 61% yield over the two steps, which was a significant 
improvement on the earlier reported work (Table 10). The racemic methoxy-lactam was 
prepared using racemic catalyst prepared from equimolar mixture of (1R, 2S) and (1S, 2R) 
cis-1-aminoindan-2-ol. Both the racemic and enantiomeric compounds were successfully 
separated using chiral phase HPLC analysis, giving >99% ee for the enantiomeric reaction 
(Table 10, entry 1). The N-Bn and N-PMB methoxy cycloadducts 108 and 109 were obtained 
as single diastereomers employing the same conditions as above and also separated using 
chiral phase HPLC in 75% yield (95% ee) and 39% yield (97% ee), respectively. Comparing 
this method with the previously reported method of desymmetrisation, in which 
trimethylorthoformate in the presence of Amberlyst-15
®
 was used in the second step 
reaction
76
, this method showed a significant improvement in both yield and enantioselectivity 
of the products (Table 10). The only exception is in the yield of the N-Bn substrate which 
dropped from the previously reported 85% to 75%. However, the enantioselectivity increases 
from the previously reported 75% to 95% (Table 10, entry 2). 
 
 
Scheme 45. Desymmetrisation of anthracene-maleimide cycloadducts  
               Table 10. Screening of substrates against B-OMe catalyst 
              ____________________________________________________________ 
         Entry     OMe compound                Yield (%)           ee (%) 
  ____________________________________________________________ 
 
1.          R = PMP      107            61 (48)          >99 (99) 
2.          R = Bn         108            75 (85)            95 (75) 
3.          R = PMB     109            39 (17)            97 (74) 
  ______________________________________________________________ 
Values in parenthesis represent results from the previously reported work by a research group 
member. 
A solution of the substrate in THF was treated with the catalyst (10 mol%), then BH3.THF 
and allowed to stir at room temperature for 4 hrs. After standard work up, the crude product 
was dissolved in MeOH, treated with p-TsOH.H2O (10 mol%) and heated at a reflux for 18 
hrs. The resultant methoxy compound was purified by flash column chromatography. 
 
The stereochemistry of the newly formed stereogenic centre in the methoxy compounds was 
confirmed as (3R) from crystal structures of N-PMP methoxy cycloadduct 107 and N-Bn 
methoxy cycloadduct 108 performed by a previous group member clearly indicating that the 
37 
 
methoxy group attacked the Re-face of the intermediate iminium ion (Figure 11).
76
 This 
proved the hypothesis which envisaged that the presence of the anthracene would direct 
attack of the nucleophilic methanol to the top face of the molecule leading to the formation of 
the (R)-methoxy aminals.  
 
107 
 
         108 
Figure 11. Crystal structures of methoxy cycloadducts 107 and 108 
 
2.1.4 Stereoablative upgrade of enantioselectivity 
As can be observed from table 9, the highest selectivity was recorded with the N-PMP 
substrate. However, a rapid conversion of the hydroxy-lactam intermediate to the over 
reduced pyrrollidine product 111 was observed during the reduction process, thereby 
confirming the earlier observation on such a substrate. While the crucial role of the nitrogen 
protecting groups in desymmetrisation of meso imides was investigated by the research 
group, the relationship between the excellent selectivity in N-PMP imides and the formation 
of over reduced product was never investigated. A possible explanation was that a 
stereoablative process might be operative in reduction process by selective reduction of one 
enantiomer thereby upgrading the enantiopurity of the product. 
Stereoablation is an enantioselective chemical transformation whereby an existing 
stereocentre in an organic molecule is selectively destroyed.
83
 A catalyst selectively reacts 
with one enantiomer or enantiotopic group in a racemic (or scalemic) mixture, thereby 
eliminating it from the mixture and leaving behind an enantioenriched material.
83
 It was 
proposed that under the normal reduction conditions the N-PMP cycloadduct 101 was 
enantioselectively reduced to a scalemic mixture of the corresponding hydroxy-lactams 106 
and 110 followed by selective reduction of the minor hydroxy-lactam enantiomer 110 to the 
pyrrolidine cycloadduct 111 (Scheme 46). The upgraded enantiopure material was then 
converted to the methoxy aminal 107, essentially as a single enantiomer (Scheme 46). 
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Scheme 46. Stereoablative upgrade of ee 
To investigate this hypothesis, an attempt was made to isolate the hydroxy-lactam 
intermediate 106, which prior work showed was not isolable in appreciable yield. However, 
when the N-PMP cycloadduct was reduced under standard conditions using the (1R, 2S) 
version of the B-OMe catalayst 77, the pure hydroxy-lactam 106 was isolated in 60% yield as 
a single diastereomer (Scheme 47). Comparison of the coupling constants between C-3 
proton and C-4 proton of the hydroxy-lactam (J = 7.9) with that of the methoxy aminal 107 (J 
= 1.2) suggests a dihedral angle of around 0
o
 between C-3 and C-4 protons in the hydroxy-
lactam. This shows that diastereomer 106 of the hydroxy-lactam was the major product.  As 
expected from the CBS Corey model, the oxazaborolidine catalyst will preferentially 
coordinate to the carbonyl oxygen with B-OMe group away from the nitrogen substituent 
(RL) to minimize the steric interaction. This would lead to two possible intermediates A and 
B (Figure 12) in which only the intermediate B can the H
- 
be delivered from the less sterically 
hindered Re-face of the molecule producing the (3S)-enantiomer of the hydroxy-lactam 
intermediate (Figure 12). 
 
Figure 12. Model for the stereoselectivity of N-PMP imide reduction 
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Repeating the reduction with (1S, 2R) version of the same catalyst led to isolation of the 
hydroxy-lactam 110 in 70% yield as a single diastereomer (Scheme 47). To confirm the high 
selectivity of both versions of the catalyst on the N-PMP imide, a portion of each enantiomer 
of the hydroxy-lactam was converted to the methoxy aminal, giving quantitative yields of the 
corresponding methoxy compounds in 100% ee and 93% ee respectively (Scheme 47).      
 
Scheme 47. N-PMP imide reduction with two versions of B-OMe catalyst 
A scalemic homogenous mixture of the two enantiomers of the hydroxy-lactam was prepared 
as a 2:1 ratio of S and R enantiomers. A portion of the scalemic mixture was quantitatively 
converted to methoxy compound and the ee of the resultant scalemic methoxy compound was 
measured. A sample of the scalemic mixture of hydroxy-lactam was then subjected to 
reduction with (1R, 2S) version of the B-OMe catalyst followed by methylation under 
standard reaction conditions. The same procedure was repeated with the (1S, 2R) version of 
the catalyst. The yield and ee of the methoxy compounds were recorded, and the experiment 
carried out in duplicate. The results are summarised in table 11.    
 
Scheme 48. Stereoablation experiment 
Table 11. Results from stereoablation experiment 
_______________________________________________________________________ 
Entry    Scalemic hydroxy-lactam ee (%)
a
   Catalyst    Yield (%)  ee (%) 
___________________________________________________________________________ 
 
1.            34 (35)b        (1R, 2S)      60 (67)b  56 (54)b 
2.            34 (35)b        (1S, 2R)      76 (74)b  33 (32)b 
___________________________________________________________________________ 
a 
Based on derivatisation of a sample of scalemic hydroxy-lactam to the methoxy-lactam and HPLC 
analysis of this compound. 
b
 Values in parenthesis represent results from second experiment. 
A solution of the scalemic mixture of the hydroxy-lactam was treated with the catalyst (10 mol%), 
then BH3.THF and allowed to stir at room temperature for 4 hrs. After standard work up, the crude 
product was dissolved in MeOH, treated with p-TsOH.H2O (10 mol%) and heated at a reflux for 18 
hrs. The resultant methoxy compound was purified by flash column chromatography. 
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When a representative sample from the scalemic hydroxy-lactam mixture (34% ee) was 
subjected to reduction with (1R, 2S) enantiomer of the B-OMe catalyst 77 followed by 
subsequent methylation, the methoxy compound was obtained in 60% yield and 56% ee 
(Table 11, entry 1). This result showed a 40% conversion of the hydroxy-lactam to the over 
reduced pyrrolidine occurred in presence of the catalyst. More importantly, there was an 
upgrade in the ee of the scalemic methoxy compound from 34% to 56%, clearly showing a 
selective reduction of one enantiomer of the hydroxy-lactam (presumably the minor 
enantiomer) to the pyrrolidine compound. 
On the other hand, when the reaction was repeated with (1S, 2R) version of the catalyst, a 
76% yield and 33% ee of the methoxy compound was obtained (Table 11, entry 2). This 
result shows that although there was a conversion of the hydroxy-lactam to the pyrrolidine 
product, the (1S, 2R) catalyst does not discriminate between the two enantiomers of the 
hydroxy-lactam. When the experiments were repeated, a near identical series of results were 
obtained (Table 11, values in parenthesis) proving the validity of the initial result. 
2.1.5 Conclusion 
By using a literature procedure adopted by an earlier research group member, three N-
protected anthracene-maleimides were synthesised in good yields which quite agreed with the 
previously reported work. These maleimide cycloadducts were subjected to desymmetrisation 
using B-OMe oxazaborolidine catalyst derived from cis-aminoindan-2-ol. Results from the 
desymmetrisation showed that the catalyst gave moderate yield and high enantioselectivity of 
the desymmetrised products. Optimization of the second step of the desymmetrisation 
reaction led to significant improvement in both yield and enantioselectivity of the 
desymmetrised products. Desymmetrisation of the N-PMP substrate gave one enantiomer of 
the product but proceeded by rapid conversion of the hydroxy-lactam intermediate to the 
over-reduced pyrrolidine compound when the reduction step was monitored by TLC. 
Investigation on the role of the catalyst in the over reduction of the N-PMP substrate revealed 
an in-situ stereoablative process by the (1R, 2S) version of B-OMe catalyst serving to upgrade 
the enantioselectivity. This process has never before been reported with oxazaborolidine 
catalysed reductions.  
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Chapter 3 
Synthesis of pyrrolam A 
3.1 Investigation towards the synthesis of pyrrolam A 
Pyrrolams A-D 112 – 115 are pyrrolizidine alkaloids (Figure 13) and were first isolated in 
1990 from the bacterial strain Streptomyces olivaceus (strain Tu 3082) by Zeeck and co-
workers by elution with methanol from Amberlite XAD-16 resin followed by further 
purification via column chromatography.
84
 Pyrrolam A was shown to have herbicidal activity 
against wheat and rice seedlings and anti-fertility activity, causing damage to fertilized fish 
(Brachydanio rerio) eggs at a concentration of 5 µg / mL but was inactive against Gram-
positive and Gram-negative bacteria, fungi, moulds and tumour cell lines.
84 
 
 
Figure 13. Pyrrolams A ‒ D 
Since its initial isolation, as many as ten syntheses of pyrrolam A have been reported, most of 
which rely on chiral pool strategies depending on the pre-existing stereogenic centre of 
proline 116 or a derivative. The first total synthesis of pyrrolam A was reported in 1996 by 
Ohta and co-workers.
85
 A chiral pool strategy was employed starting from unnatural (R)-
proline and obtaining pyrrolam A in 7 steps. The key step in this synthesis was the SmI2-
mediated cyclisation of an alkynyl amide 120 to access the pyrrolidinone core. However, the 
use of expensive unnatural proline as a starting material is the major setback (Scheme 49).  
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  Scheme 49. Ohta’s synthesis of pyrrolam A 
 
The second synthesis reported by Murray et al. uses an LDA mediated N-acyl anion 
cyclisation process of a proline derivative 124 to give the corresponding dione 125. This was 
reduced in 95:5 dr using NaBH4 / EtOH to give the exo lactam intermediate 126 in 90% de, 
which afforded (S)-pyrrolam A in two more steps. However, this synthesis has slightly lower 
yield and ee than the previously reported synthesis (Scheme 50).
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Scheme 50. Murray’s synthesis of pyrrolam A 
 
The synthesis by Schobert and Wicklein involved a domino Wittig reaction of the ylide 
Ph2P=C=C=O immobilized on polystyrene resin with the benzyl proline derivative 128, 
prepared from D-proline, as the key step (Scheme 51). The unprotected amino group of the 
benzyl proline 128 was added across the C=C bond of the phosphacumulene ylide followed 
by a subsequent intramolecular Wittig olefination of the acyl ylide to give the pyrrolizidine 
129. Hydrogenative debenzylation of the pyrrolizidine 129 furnished dione 130, which on 
subsequent reduction using sodium borohydride, followed by mesylation, gave sulfonate 132. 
Heating the sulfonate 132 with triethylamine afforded (R)- pyrrolam (Scheme 51).
87
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Scheme 51. Schobert’s synthesis of pyrrolam A 
A synthesis by Palmisano and co-workers again employs the chiral pool strategy from an 
unnatural proline derivative 117. The key intermediate was accessed via Mitsunobu coupling 
of N-Boc protected prolinol 133 with a tricarboxylate. Pyrrolam A was accessed in further 5 
steps in an overall yield of 30% and a single enantiomer of the compound (Scheme 52).
88
  
 
Scheme 52. Palmisano’s synthesis of pyrrolam A 
A synthesis by Nagakawa and co-workers uses L-proline in a chiral pool approach which is 
converted in a 6 step sequence to a chiral diene 139. Ring closing metathesis (RCM) of the 
chiral diene 139 using Grubbs’ catalyst was employed in the last stage of the synthesis to give 
pyrrolam A in 30% overall yield and 100% ee (Scheme 53).
89,
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Scheme 53. Nagakawa’s synthesis of pyrrolam A 
A different chiral pool strategy was adopted by Huang et al., this time utilising relatively 
cheap (S)-malic acid as a starting material. However, the synthesis was slightly longer and 
gave a reduced overall yield (Scheme 54).
91
  
 
Scheme 54. Huang’s synthesis of pyrrolam A 
Two total syntheses of pyrrolam A were reported by Tilve and co-workers both of which are 
chiral pool and employed a Wittig reaction as the key step. The first one used L-proline 
which was converted to N-Cbz-L-prolinol 144 by a known literature procedure. The alcohol 
was treated with PCC/NaOAc and phosphorane in one pot to give α,β-unsaturated ester 145. 
Deprotection of 145 and double bond reduction, followed by cyclization under basic 
condition (cat. NaOEt) furnished dihydropyrrolam 136. A one pot selenium 
addition/elimination process delivered (S)-pyrrolam A (Scheme 55).
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Scheme 55. Tilve’s synthesis of pyrrolam A (I) 
The second synthesis by Tilve also employs a chiral pool strategy, using (S)-prolinol 117. 
The key reaction is an intramolecular Wittig reaction of a phosphorane 149 generated in situ 
from (S)-N-(bromoacetyl)prolinal 148. The synthesis took 5 steps with an overall yield of 
24% (Scheme 56).
93
      
 
Scheme 56. Tilve’s synthesis of pyrrolam A (II) 
There are only two non-chiral pool methods of total synthesis of pyrrolam A reported in the 
literature. The first one, reported by Snyder and co-workers used pyrrolidine as a starting 
material. The key step in this synthesis was the formation of a chiral organolithium 151 by 
asymmetric deprotonation of N-protected pyrrolidine 150 in Et2O. This allowed access to 
pyrrolam A in 3 steps from the starting material in a remarkable overall yield of 63% and 
90% ee (Scheme 57).
94
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Scheme 57. Snyder’s asymmetric synthesis of pyrrolam A 
The latest synthesis of pyrrolam A was by Wang and co-workers reported in 2010.
95
 The 
synthesis involved a diastereoselective nucleophilic addition of the lithium enolate of an α-
diazoacetoacetate 154 to a chiral N-sulfinylimine 153 to afford δ-N-sulfinylamino α-diazo β-
ketoester 155 in 70% yield with 97% de. Removal of the N-sulfinyl group followed by N-
protection gave the N-protected pyrrolidinone 156, which underwent a photo-induced Wolff 
rearrangement to the oxo-vinylpyrrolidinone 157. The (R)-pyrrolam A was obtained in a 
further four steps sequence involving Pd-catalysed deallyloxydecarbonylation and a final 
ring-closing metathesis (Scheme 58).
95
  
 
 
 
Scheme 58. Wang’s synthesis of pyrrolam A  
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As can be seen all but two reported syntheses of pyrrolam A rely heavily on chiral pool 
strategy utilizing proline or its derivative, or in one case a suitable amino acid, to transfer the 
chirality in those molecules to the target compound. Another feature of the syntheses is the 
reliance on the Wittig olefination or Grubb’s ring-closing metathesis for the construction of 
the lactam-conjugated double bond in the pyrrolizidin-3-one ring. A completely different 
approach to the synthesis of pyrrolam A, utilizing enantioselective desymmetrisation of meso 
maleimide and avoiding the traditional olefin metathesis would prove the efficiency and wide 
application of desymmetrisation methodologies in the asymmetric synthesis of natural 
products. 
3.2 Synthesis of pyrrolam A 
The starting desymmetrised material for the synthesis of pyrrolam A was the methoxy N-
PMP maleimide 107 because results from the screening of the nitrogen protected imides 101, 
103 & 104 showed the highest selectivity, a vital criterion for the synthesis, was obtained 
from the desymmetrisation of the N-PMP imide 101 (Table 9). Moreover a reasonable yield 
of 61% of the desymmetrised methoxy compound 107 was not too far away from its close 
candidate, the N-Bn methoxy compound 108 which was obtained in 75% yield, but 95% ee 
(Table 9). It was hoped that the selectivity of transformations throughout the synthesis would 
be controlled by the presence of the anthracene allowing any nucleophilic approach from the 
top face only, thus obtaining the pyrrolam A in high enantioselectivity. 
It was envisioned that pyrrolam A 122 should be accessible from the cycloadduct 165 by a 
retro Diels-Alder reaction (Scheme 59). The synthesis would therefore require accessing the 
pyrrolizidin-3-one ring in the bicyclic compound 165 with the right stereochemistry on the 
bridge carbon. This would be obtained by cyclisation of the allyl moiety in compound 162 
through functional group manipulation 166 (Scheme 59).  
 
Scheme 59. Retrosynthesis of pyrrolam A 
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Although the forward synthesis to the above route was initially pursued by a previous group 
member,
76
 some steps were characterised by low yield of products, and pyrrolam A was not 
isolated. The synthesis would therefore be re-visited, optimizing reaction conditions to get 
maximum yield of products. More importantly, it was hoped that the total synthesis of the 
target compound would be accomplished and pyrrolam A would be isolated in an enantiopure 
form and in reasonable overall yield. 
The forward synthesis started from treatment of methoxy cycloadduct 107 with allyl 
trimethylsilane in the presence of boron trifluoride which gave the allyl substituted lactam 
161 as a single diastereomer in 74% yield.
69
 It was expected that the anthracene would cause 
the attack of the nucleophilic allyl moiety to come from the Re-face, producing the (3R)-
isomer of the N-PMP allyl lactam. From the 
1
H NMR spectrum of the compound obtained 
after purification, the NCH proton and the C-4 proton have a coupling constant of J = 3.0, 
which is close to that observed with the N-PMP methoxy compound 107 suggesting a (3R)-
isomer of the N-PMP allyl product. From here the amide was cleanly deprotected using CAN, 
giving the deprotected amide 162 as a single diastereomer in 81% yield.
96 
Although the NCH 
proton in this compound appears as a multiplet around H 3.08 – 3.12 ppm, the C-4 proton 
coupled with the NCH proton has a coupling constant, J = 3.2, showing a (3R)-
stereochemistry (Scheme 60). 
 
Scheme 60. Formation of allyl cycoadduct 161 and lactam 162 
The deprotected lactam 162 was hydroborated by treatment with BH3.THF followed by 
NaOH / H2O2 to yield the hydroxy-cycloadduct 163.
 
Previous work showed that this 
compound was very difficult to purify by both flash chromatography and recrystallisation.
76
 
Hence, the material was taken forward without purification. The 
1
H NMR spectrum of the 
crude material showed 100% conversion of the lactam 162. The absence of a terminal methyl 
signal expected to appear as a doublet around H 1.10 ppm shows the complete 
regioselectivity of the hydroboration oxidation, producing selectively the primary alcohol. 
The hydroxy-cycloadduct 163 was mesylated by treatment with methane sulfonyl chloride 
and triethylamine to give the mesylated cycloadduct 164. Although there was 100% 
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conversion from the 
1
H NMR spectrum of the crude material the compound was again taken 
forward due to difficulties in purification (Scheme 61). 
 
Scheme 61. Formation of hydroxy compound 163 and mesyl compound 164 
Cyclisation of the crude mesylated compound 164 was achieved by the use of excess 
potassium t-butoxide in ethanol at reflux to give the cyclic compound 165.
76
 Although report 
from the previous work showed 36% yield of the bicyclic lactam 165 was achieved over the 3 
steps, only 10% yield of the compound was repeatedly obtained over 3 steps using these 
reaction conditions (Scheme 62).  
 
Scheme 62. Formation of bicyclic compound 165 
Optimisation experiments were carried out on the last 2 steps in an effort to increase the yield 
of the bicyclic product 165. Tosylation of the crude alcohol 163 was carried out in the 
presence of NEt3 under the same conditions applied previously, and then cyclised using t-
BuOK, applying conditions used as previously. Unfortunately only 5% of the bicyclic 
compound was obtained (Table 12, entry 2). Another tosylation of compound 163 was 
repeated using NEt3 / DMAP followed by cyclisation of the crude product with DABCO and 
DBU, respectively. No conversion of the tosylated compound was observed with DABCO 
while an improved yield of 17% over 3 steps was obtained with DBU (Scheme 63; Table 12, 
entries 3 and 4).   
When the crude hydroxy compound 163 was mesylated using NEt3 / DMAP followed by 
cyclisation of the crude product with DABCO and DBU, a yield of 20% over 3 steps was 
recorded with DBU, while again no conversion of the mesylated compound was observed 
from the 
1
H NMR spectrum when treated with DABCO (Table 12, entries 5 and 6).  
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In another optimisation attempt, the alcohol 163 was converted to the corresponding iodide 
compound using Appel reaction conditions and the crude iodo compound was treated with t-
BuOK, DABCO and DBU respectively. Cyclisation with DBU gave a yield of 15% over 3 
steps. The other two bases gave lower yields than that recorded for DBU (Table 12, entries 7, 
8 and 9). Single diastereoselectivity was observed in all cases of the optimization. 
 
                           
Scheme 63. Optimisation experiment 
Table 12. Optimisation experiments for bicyclic compound 165 
Entry  Step 1
a
       Step 2
b
            Yield of 165 
                    over 3 steps     
                (%) 
1. MsCl (1.3 eq), NEt3 (2.5 eq)  t-BuOK (1.3 eq.), EtOH        10      
2. TsCl (1.3 eq), NEt3 (2.5 eq),            t-BuOK (1.3 eq), EtOH          5 
3. TsCl (1.3 eq), NEt3 (2.5 eq),  DABCO (1.3 eq), EtOH 
DMAP (10 mol%)               - 
4. TsCl (1.3 eq), NEt3 (2.5 eq),  DBU (1.3 eq), EtOH  
 DMAP (10 mol%)             17 
5. MsCl (1.3 eq), NEt3 (2.5 eq)  DABCO (1.3 eq), EtOH 
 DMAP (10 mol%)              - 
6. MsCl (1.3 eq), NEt3 (2.5 eq)  DBU (1.3 eq), EtOH 
 DMAP (10 mol%)             20 
7. PPh3 (1.25 eq), I2 (1.25 eq), 
imidazole (1.25 eq)    t-BuOK (1.3 eq), EtOH       12 
8. PPh3 (1.25 eq), I2 (1.25 eq), 
imidazole (1.25 eq)   DABCO (1.3 eq), EtOH        - 
9. PPh3 (1.25 eq), I2 (1.25 eq), 
 imidazole (1.25 eq)   DBU (1.3 eq)               15 
___________________________________________________________________________ 
a. CH2Cl2, 1 h, -10 
o
C.  b. reflux, 18 h. 
 
To form pyrrolam A 122 from the bicyclic lactam 165, a retro [4 + 2] cycloaddition was 
required. To achieve this, a flash vacuum pyrolysis (FVP) technique was utilised (Scheme 
64).
77
 This process involves the vapourisation of the cycloadduct in an oven under reduced 
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pressure, followed by further heating in a furnace where the retro Diels-Alder reaction 
occurs. Finally, the vapourised material is quickly cooled by passing through a Vigreux 
column where the anthracene is expected to be trapped, and then further cooled via liquid 
nitrogen in the product trap where pyrrolam A 122 is expected to be collected (Figure 14).   
 
 
Scheme 64. Retro Diels-Alder to provide pyrrolam A 
 
Figure 14. Flash vacuum pyrolysis apparatus (courtesy of Hamish McNab) 
Conditions were tested for flash vacuum pyrolysis of the cycloadduct 165. The inlet 
temperature was kept at 226 
o
C (melting point of the cycloadduct) since temperatures below 
that resulted in an inefficient vapourisation of the material and the pressure set at 1 × 10
-2
 
mbar. The initial temperature of the furnace was set at 560 
o
C which initiated the retro Diels-
Alder producing 43 mg of anthracene in the u-tube from 100 mg of starting material. 
However this temperature led to the decomposition of the remainder of the material. A 
similar observation was made when the temperature was lowered to 520 
o
C (Table 13, entries 
1 & 2). At a temperature of 510 
o
C a mixture of anthracene and starting material was obtained 
alongside some decomposed material in the u-tube. Although some peaks of pyrrolam A were 
observed in the crude 
1
H NMR spectrum, the pure material was not successfully isolated 
(Table 13, entry 3). The best result was obtained when the furnace temperature was set at 490 
o
C which led to the isolation of the pure material in 70% yield and no decomposition of 
material was observed. A similar result was obtained when the FVP was repeated at the same 
52 
 
temperature with different weight of the starting material (Table 13, entries 4 & 5). When the 
temperature was further lowered to 470 
o
C a retro Diels-Alder failed to occur returning only 
the starting material in the u-tube, indicating the narrow range of temperature at which the 
retro-Diels would occur. 
To obtain the racemic product needed for optimizing the HPLC conditions, the synthesis was 
repeated with the racemic methoxy compound prepared from the racemic version of the 
catalyst. Both the racemic and the enantiomeric pyrrolam A materials were successfully 
separated by chiral phase HPLC analysis, giving the enantiomeric product in a 94% ee.  
Table 13. Flash vacuum pyrolysis of cycloadduct 165 
Entry Wt. of         Furnace       Time    Recovered   Starting      Wt. of           Wt. of    
  material     temp.       (min)    crude          material     anthracene    pyrrolam A 
    (mg)         (
o
C)              (mg)           (mg)            (mg)                (mg) 
   
1.     100             560               20          74                  -                  43          Decomposition 
2.             300             520               30          288                -                  107        Decomposition 
3.             177             510               20          151               88                12          Decomposition 
4.             150             490               30          124               33                45          43 (70% Yield) 
5.             200             490               30          195               60                81          56 (69% Yield) 
6.             150             470               40          130               130               -                   -  
Inlet temperature of 226 
o
C at a pressure of 1 × 10
-2
 mbar. Reactions performed over a period of 20–
40 mins until no further sublimation of the starting material was observed.
 
 
3.3 Conclusion 
The total synthesis of (-)-(R)-pyrrolam A 122 was accomplished in six steps from the 
desymmetrised material 107 in 8.4% overall yield and 94% ee. The slight drop in the ee of 
product compared to starting material (94% from 99%) is probably due to the stability of the 
product as reported in previous isolation and synthetic studies on this molecule.
97 
The overall 
yield is also hampered by the low yield obtained in the cyclisation step which is probably due 
to competing reactions. This illustrates the synthetic potentials of the desymmetrisation of 
meso-imides.  
 
 
 
 
53 
 
Chapter 4 
Desymmetrisation of glutarimides 
4.1 Background 
The desymmetrisation of glutarimides is relatively unexplored. Although there have been 
many reports on the use of the oxazaborolidines derived from cis-1-aminoindan-2-ol for the 
desymmetrisation of five-membered meso-imides from the Jones research group, this work is 
the first attempt to extend such investigations to glutarimides. The excellent results obtained 
so far with five membered ring meso-imides had been a source of inspiration to explore the 
synthesis and desymmetrisation of these simple compounds that would open avenues for the 
synthesis of important natural products and pharmaceuticals. 
4.2 Synthesis of glutarimides 
For this investigation a variety of 3-substituted glutarimides was required, possessing 
different steric and electronic effects and accessible from commercially available starting 
materials. Previous work from the Jones research group on five-membered ring imides had 
shown that N-aryl versions gave good yields and excellent enantioselectivity compared to 
their N-alkyl counterparts.
74
  The synthesis, therefore, focused on the N-p-methoxyphenyl (N-
PMP) and N-benzyl (N-Bn) derivatives 167 – 170 (Figure 15). Earlier work on five-
membered ring imides also revealed that the N-Bn derivatives showed higher yields of the 
desymmetrised products than the N-aryl imides, however with a slight decrease in 
selectivity.
74
 Thus it was hoped that modifying the benzyl group would increase the 
selectivity without compromising the yields. 
 
Figure 15. Glutarimdes targeted 
4.2.1 Synthesis of 3-phenyl glutarimides 
The commercially-available and inexpensive 3-phenylglutaric acid 171 was used as the 
starting material for the initial investigation of the route to the synthesis of glutarimides. The 
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3-phenylglutarimides 173 ‒ 176 were accessed following literature procedures by first 
converting the 3-phenylglutaric acid to the corresponding anhydride 172 by the dehydrative 
cyclisation in acetyl chloride for 48 hours to give the anhydride in 84% yield after 
recrystallisation from ethyl acetate / hexane mixture. Condensation of the respective amines 
with the glutaric anhydride gave the corresponding glutarimides in excellent yields after 
recrystallisation from ethyl acetate / hexane mixture (Scheme 65, Table 14).
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Scheme 65. Synthesis of 3-phenylglutarimides  
                              Table 14. Yields of 3-phenylglutarimides obtained according to Scheme 65 
______________________________________________ 
     Entry R        Yield (%) 
______________________________________________ 
        1.           4-MeOC6H4        173         80 
        2.           Benzyl         174         85 
        3.           2-methylbenzyl        175         71 
        4.           2-methoxybenzyl     176         60 
_______________________________________________ 
 
 
 
4.3 Desymmetrisation of glutarimides 
 
The initial investigation for the desymmetrisation experiments started with the four 
glutarimides readily obtained from the commercially-available 3-phenylglutaric acid. It has 
been established by the Jones research group that BH3.THF is the optimal borane source for 
the desymmetrisation of five membered meso-imides as there was no competing background 
reaction and the optimal catalyst loading was 10 mol%.
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 Hence BH3.THF was employed as 
the hydride source and a catalyst loading of 10 mol% was used throughout this research 
work. Furthermore reduction of the N-PMP-3-phenyl glutarimide 173 and N-Bn-3-phenyl 
glutarimde 174 were separately performed with BH3.THF and the result showed no 
background reaction in both cases after 24 hour reaction time. The desymmetrisation process 
therefore involved reduction of a glutarimide with 1 equivalent of BH3.THF in the presence 
of 10 mol% catalyst at room temperature to give the corresponding hydroxy-lactam. The 
hydroxy-lactam was further reduced to the corresponding lactam by reaction with Et3SiH / 
TFA for ease of analysis.  
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The corresponding racemic lactams needed for optimising chiral phase HPLC conditions 
were prepared by reduction of glutarimides with 1 equivalent of BH3.THF in the presence of 
10 mol% of racemic oxazaborolidine 76 or 77, which was prepared by reacting racemic cis-1-
aminoindan-2-ol with trimethyl boroxine in the case of B-Me catalyst 76 or trimethyl borate 
in the case of B-OMe catalyst 77 to furnish the corresponding hydroxylactams which were 
further reduced to the target lactams by reduction using TFA and triethylsilane (Scheme 66). 
 
Scheme 66. Desymmetrisation of meso-imides with racemic catalysts 
 
4.3.1 Desymmetrisation of N-PMP glutarimide 
The initial screening for the best desymmetrisation conditions was first carried out on N-PMP 
protected 3-phenylglutarimide 173 using both B-Me catalyst 76 and B-OMe catalyst 77 
employing BH3.THF as borane source and reduction monitored by TLC. Careful monitoring 
of the reaction by TLC showed a build-up in the concentrations of both the hydroxy-lactam 
intermediate 177 and the over-reduced piperidine product 178 through a 3-hour reaction 
period. Beyond 3 hours the concentration of the hydroxy-lactam started to diminish with an 
increase in the concentration of the over-reduced piperidine product, suggesting a rapid 
conversion of the hydroxy-lactam to the undesired product 178 (Scheme 67).  
 
Scheme 67. Initial reduction of N-PMP meso-glutarimide  
This rapid formation of the doubly reduced product confirmed the earlier observation made 
on the N-PMP five membered imides by the research group, which was attributed to the 
electronics of the aryl ring system directly bonded to the nitrogen atom of the imide. As the 
aryl ring is electron withdrawing, the nitrogen lone pair becomes engaged with the aryl ring 
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system rather than with carbonyl groups making both carbonyls more electropositive, hence 
susceptible to nucleophilic attack (Scheme 68). 
74
 
 
Scheme 68. Electron withdrawing of N-aryl substituents 
The reaction was therefore repeated stopping the reduction after 3 hours and taking the 
hydroxy-lactam to the more stable 2-piperidinone 179 (Scheme 69). Two methods of 
preparing the catalysts were employed. The first involved preparing the catalyst in situ at 
room temperature and using it straight away while the second way involved repeated 
distillations to azeotropically remove borate impurities before the final stock solution of the 
catalyst was made. The results are summarised in table 15. 
 
Scheme 69. Desymmetrisation of N-PMP-3-phenylglutarimide using B-Me and B-OMe catalysts 
Table 15. Screening catalysts for desymmetrisation process of N-PMP glutarimide 
Entry Catalyst   Method   Starting                     179              ee                 178   
      Material (%)        (% Yield)       (%)           (% Yield)   
1. B-Me        in situ              66                          18                53                  10 
2. B-Me        distilled        28                          33                95                  30 
3. B-OMe       in situ        20                          48                99                  21 
4. B-OMe       distilled        37                          43              >99                  15 
 
in situ: A 5 cm
3
 stock solution of the B-OMe or B-Me catalyst in dry THF was prepared under N2 
atmosphere at room temperature. A solution of the glutarimide in dry DCM was treated with 10 mol% 
of the catalyst and BH3.THF at rt for 3 hours, followed by treatment of a solution of the crude 
hydroxy-lactam in DCM with Et3SiH / TFA for 1 hour to give the lactam product.   
distilled: A 5 cm
3
 solution of the B-OMe or B-Me catalyst in dry toluene was prepared under N2 
atmosphere at room temperature. It was distilled until approximately 2 cm
3
 of solvent remained. 5 cm
3 
of dry toluene was added and distilled as above. The distillation procedure was repeated twice before 
the final 5 cm
3 
stock solution of the catalyst was made. The reduction of the glutarimide was then 
carried out as above. 
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In both cases and for both catalysts a desymmetrisation product was isolated together with an 
undesired over reduced product 178 at a reaction time of 3 hours. For the B-Me catalyst 76, a 
significant difference in both yield and enantioselectivity was observed from the two methods 
of preparing the catalyst. Only 18% yield and 53% ee of the desired product was obtained 
when the catalyst was prepared in situ at room temperature with a significant mass return of 
the starting material (66%), while for the method involving distillation at elevated 
temperature, 33% yield of the desired product was obtained with a remarkable increase in 
enantioselectivity (95% ee). The undesired over reduced product also increased from 10% 
yield to 30% yield (Table 15, entries 1 & 2). For the B-OMe catalyst 77, both methods gave 
excellent ee's, however the in situ method produced the 2-piperidinone in a 48% yield and the 
undesired piperidine was isolated in a 21% yield (Table 15, entry 3) while the distillation 
method gave 43% yield of the desired product and 15% of the undesired product (Table 15, 
entry 4). Generally, excellent selectivities were obtained with both catalysts; however the 
yields of the desymmetrised products were greatly hampered by the formation of the over-
reduced product which is characteristic of N-PMP imide substrates.  
The relationship between excellent enantioselectivity and formation of over-reduced 
piperidine product 178 in the N-PMP substrate 173 was investigated by performing an 
experiment similar to the one carried out on the N-PMP anthracene-maleimide counterpart. 
The B-Me catalyst was chosen for the investigation, employing repeated distillation 
procedure since the highest yield of the over reduced compound with a significant change in 
selectivity was observed in that case. Firstly, an attempt was made to isolate pure samples of 
hydroxy-lactams by reducing the N-PMP glutarimide substrate 173 using both versions of the 
B-Me catalyst 76 under standard conditions. The two enantiomers of the hydroxy-lactam 
were obtained, both in 2:1 dr, in 20% yield for (1R, 2S) catalyst and 27% yield for (1S, 2R) 
catalyst, respectively (Scheme 70). 
 
Scheme 70. Reduction of N-PMP substrate to hydroxy-lactam 
The poor yield of hydroxy-lactams obtained may be attributed to poor yields of the 
desymmetrisation products earlier observed with both B-OMe and B-Me catalysts for the N-
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PMP substrate (Table 14). To confirm the high selectivity of both versions of the catalyst on 
the N-PMP glutarimide, a portion of each enantiomer of the hydroxy-lactam was converted to 
the corresponding lactam by treatment with TFA / Et3SiH under standard conditions, giving 
quantitative yields of the lactams in 98% ee and 94% ee respectively (Scheme 71).      
 
Scheme 71. Testing selectivity of both versions of B-Me catalyst on N-PMP substrate 
A scalemic homogenous mixture of the two enantiomers of the hydroxy-lactam was then 
prepared in a 2:1 ratio (1R, 2S:1S, 2R). A portion of the scalemic mixture was quantitatively 
converted to the lactam and the ee of the resultant scalemic lactam compound was obtained. 
A sample of the scalemic mixture was then subjected to reduction with (1R, 2S) version of 
the B-Me catalyst followed by further reduction to the corresponding lactam under standard 
reaction conditions. The same procedure was repeated with the (1S, 2R) version of the 
catalyst. The yield and ee of the N-PMP lactam compounds were recorded. The results are 
summarised in table 16.     
 
Scheme 72. Stereoablation experiment on N-PMP glutarimide 
Table 16. Results from stereoablation experiment 
_______________________________________________________________________ 
Entry Scalemic hydroxy-lactam ee (%)
a
   Catalyst    Yield (%)  ee (%) 
___________________________________________________________________________ 
 
1.            31         1R, 2S         73       60  
2.            31         1S, 2R         75      14  
___________________________________________________________________________ 
a 
Based on derivatisation of a sample of scalemic hydroxy-lactam to the lactam and HPLC analysis of 
this compound.  
A solution of the scalemic mixture of the hydroxy-lactam was treated with the catalyst (10 mol%), 
then BH3.THF and allowed to stir at room temperature for 3 hrs. After standard work up, the crude 
product was treated with Et3SiH / TFA at room temp. for 1 hr. The resultant N-PMP lactam was 
purified by flash column chromatography. 
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When a representative sample from the scalemic hydroxy-lactam (31% ee) was subjected to 
reduction with (1R, 2S) enantiomer of the B-Me catalyst 76 followed by subsequent reduction 
with Et3SiH, the lactam was obtained in 73% yield and 60% ee (Table 16, entry 1). This 
result showed that a portion of the scalemic hydroxy-lactam was converted to the over 
reduced piperidine product by the BH3.THF in presence of the (1R, 2S) catalyst. As observed 
with the anthracene-maleimide, there was an upgrade in the ee of the scalemic hydroxy-
lactam from 31% to 60%, showing a stereoablative reduction of one enantiomer of the 
hydroxy-lactam by the (1R, 2S) catalyst (presumably the minor enantiomer) to the piperidine 
compound. 
On the other hand, when the reaction was repeated with (1S, 2R) version of the catalyst, a 
near identical yield of 75% of the lactam compound was obtained. However, unlike in the 
anthracene-maleimide case where the ee of the scalemic hydroxy-lactam remained the same 
with this version of the catalyst, the ee of the scalemic hydroxy-lactam in this case eroded to 
14% (Table 16, entry 2). This shows that the (1S, 2R) catalyst selectively reduces the opposite 
enantiomer of the hydroxy-lactam, the major enantiomer this time around, to the piperidine 
compound; thereby diminishing the ee of the scalemic hydroxy-lactam. Thus a double stereo-
differentiation process was shown to be operative whereby matched and mismatched cases 
were observed in the two versions of the B-Me catalyst. The upgrade in selectivity observed 
in the former case could be regarded as the matched case where the (1R, 2S) enantiomer of 
the catalyst selectively eliminated the minor enantiomer of the hydroxy-lactam thus leading 
to enantio-enrichment of the product, while the downgrade in selectivity observed in the latter 
case might be because of the same process on the major enantiomer of the hydroxy-lactam 
(mismatched case) by the (1S, 2R) version of the B-Me catalyst. The near identical yields of 
the lactam products obtained (73% & 75%) under the same experimental condition suggests 
similar reaction rates of the two catalysts in the stereoablation reaction.   
4.3.2 Desymmetrisation of N-Bn glutarimides 
To investigate the performances of the two catalysts under these conditions further, the 
nitrogen protecting group was switched from p-(methoxy)phenyl to benzyl. It was hoped that 
a better yield of the product would be obtained with the N-benzyl imide while keeping the 
ee's high. The desymmetrisation of N-benzyl glutarimide analogue 174 was thus examined 
using both B-Me and B-OMe catalysts applying conditions employed earlier for the N-PMP 
counterpart. Again, the reduction step was monitored by TLC. An important observation 
made was a very slow build-up in the concentration of the over reduced product 181 even 
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after 3 hours. This allowed the reaction time to be extended to as long as 24 hours. The result 
of the desymmetrisation experiment is summarised in table 17. 
 
Scheme 73. Desymmetrisation of N-Bn-3-phenylglutarimide using B-Me and B-OMe catalysts 
Table 17. Screening catalysts for desymmetrisation process of N-Bn glutarimide 
Entry Catalyst  Method     Starting         Yield 180       ee     Undesired Product 181   
             Material (%)     (%)            (%)     (% Yield)   
1. B-Me        in situ              62                20               80                  9 
2. B-Me        distilled        20                60               90                 12 
3. B-OMe       in situ        60                34               85                  5 
4. B-OMe       distilled        59                30               92                  5 
in situ: A 5cm
3
 stock solution of the B-Me or B-OMe catalyst in dry THF was prepared under N2 
atmosphere at room temperature. A solution of the glutarimide in dry DCM was treated with 10 mol% 
of the catalyst and BH3.THF at rt for 24 hours, followed by treatment of a solution of the crude 
hydroxy-lactam in DCM with Et3SiH / TFA for 1 hour to give the lactam product.   
distilled: A 5cm
3
 solution of the B-Me or B-OMe catalyst in dry toluene was prepared under N2 
atmosphere at room temperature. It was distilled until approximately 2 cm
3
 of solvent remained. 5cm
3 
of dry toluene was added and distilled as above. The distillation procedure was repeated twice before 
the final 5cm
3 
stock solution of the catalyst was made. The reduction of the glutarimide was then 
carried out as above.   
 
As was expected, a slight decrease in selectivity was observed in both catalysts showing 
consistency with observations from earlier work on five-membered meso-imides. The B-OMe 
catalyst gives a rather disappointing result with N-benzyl imide as there was a decrease in 
both yields and selectivity. However, a remarkable change was observed with B-Me catalyst. 
Although the yield of the desired product obtained from the in situ preparation of the catalyst 
remains approximately the same as obtained in the N-PMP substrate, the enantioselectivity 
remarkably increased from 53% to 80% ee. Encouragingly, repeated distillation in the 
preparation of B-Me catalyst led to significant increase in the yield of the desymmetrised 
product, from 33% (Table 15, entry 2) to 60% with a slight decrease in enantioselectivity 
(Table 17, entry 2). In an effort to increase the yield of the product, the reduction was 
repeated with B-Me catalyst, employing repeated distillation procedure but extending the 
reaction time to 48 hours. However, only 50% of the lactam product was obtained. 
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Results from these optimization studies of the two oxazaborolidine catalysts using N-PMP 
and N-Bn imides show that both the in situ and the distilled methods are the optimal methods 
of preparing the B-OMe catalyst while the B-Me catalyst works best with successive 
azeotropic distillations. As observed earlier, the B-alkylated CBS oxazaborolidines are 
sensitive to any residual water which therefore needs complete removal by azeotropic 
distillations. Furthermore any trace of unreacted amino alcohol or borate decreases the 
enantioselectivity which may account of the significant difference in enantioselectivity 
observed in B-Me catalyst between the two methods of preparation. Overall, catalyst 76 gives 
the best result with N-benzyl-3-phenylglutarimde making it a better candidate than its B-OMe 
counterpart. The overall low yield observed in B-OMe catalyst was thought to be due to 
donation of the oxygen lone pairs from the methoxy group in to the empty p-orbital of the 
boron atom. This reduces the Lewis acidity of the boron atom which hinders the binding of 
the catalyst to the carbonyl group of the imide.
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Modification of the benzyl protecting group to 2-methylbenzyl and 2-methoxybenzyl and 
reduction with B-Me catalyst using repeated distillation procedure led to a significant 
decrease in yield (25% and 21%, respectively) but kept the ee’s high (Table 17, entries 3 & 
4). This further proves the delicate nature of the N-protecting groups in influencing the yield 
and / or selectivity of the oxazaborolidine catalysts in desymmetrisation of imide substrates. 
A summary of the results of desymmetrisation of 3-phenylglutarimides using B-Me catalyst 
employing the repeated distillation procedure is shown in table 18. Hence N-benzyl was 
chosen as the protecting group for the rest of the glutarimide synthesis and the B-Me catalyst 
76 was used for the remaining desymmetrisation processes.  
 
 
 
Scheme 74. Desymmetrisation of achiral 3-phenylglutarimides using B-Me catalyst (see Table 18   
next page) 
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Table 18. Result of desymmetrisation of achiral 3-phenylglutarimides using B-Me catalyst (see 
Scheme 74 on the preceeding page) 
        Entry    Imide       Yield of product             ee  
 1.  N-PMP*          173        (179)   33%                      95%   
 2.  N-Benzyl               174                 (180)   60%   90%   
 3.  N-(2-MethylBn)      175        (182)   25%              88% 
 4.  N-(2-MethoxyBn)   176        (183)   21%   90% 
A 5cm
3
 solution of the B-Me catalyst in dry toluene was prepared under N2 atmosphere at room 
temperature. It was distilled until approximately 2 cm
3
 of solvent remained. 5cm
3 
of dry toluene was 
added and distilled as above. The distillation procedure was repeated twice before the final 5cm
3 
stock 
solution of the catalyst was made. A solution of the glutarimide in dry DCM was treated with 10 
mol% of the catalyst and BH3.THF at rt for 24 hours, followed by treatment of a solution of the crude 
hydroxy-lactam in DCM with Et3SiH / TFA for 1 hour to give the lactam product.   
* Reaction time of 3 h in the first step. 
 
Although the stereoablation process has not been investigated at this time in the N-Bn 
substrates used in this research work, an additional reason to account for the difference in the 
selectivity of the products from N-aryl and N-Bn imides might be in the mode of catalyst 
binding to the two substrates which was explained by the transition state model put forward 
by Speckamp for desymmetrisation of imides using prolinol catalyst.
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 In this system the 
small substituent is considered to be the cyclic backbone of the imide and the large group is 
considered to be the nitrogen substituent (Figure 16). Using this model the sense of 
enantioselectivity can be broadly explained as the substituent size is increased from benzyl 
(N-CH2-) to p-methoxyphenyl (N-Ph) there is an increase in enantioselectivity. Furthermore 
the limited rotation about the C-N bond in N-PMP substrate allows the substituent to adopt a 
conformation where the substituent presents a large group towards the oxazaborolidine 76, 
without compromising binding (Figure 16, intermediate A). This results in a large energy 
difference between the two transition states giving access to only one enantiomer of the 
corresponding lactam. However as the rotation about the C-N bond becomes easier in N-Bn 
case (Figure 16, intermediate B), the catalyst has a better chance of approaching the substrate 
and binding with it from the two faces making the energy difference between the two 
diastereomeric transition states to decrease. The net result is higher yield and a decrease in 
selectivity. In fact, N-methyl substrate was observed to give comparable yield of the 
desymmetrised product with N-benzyl counterpart in desymmetrisation of five membered 
imides using oxazaborolidines employed in this work.
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Figure 16. Transition state adopted by aryl and benzyl imides 
 
4.4 Synthesis and desymmetrisation of 3-substituted glutarimides 
 
Having synthesised the 3-phenylglutarimides from the diacid 171 in a short number of steps 
and in good yields, attention now focused on the synthesis of aryl and substituted aryl glutaric 
acids that could provide direct access to the corresponding aryl and substituted aryl 
glutarimides. The o-substituted phenyl glutaric acids 188 and 190 and 1-naphthyl glutaric 
acid 192 (Table 19) were synthesised from the corresponding aldehydes, using literature 
procedures. The aldehydes starting materials 184 were first converted to the corresponding 
benzylidenemalonates 185 through a solvent-free Knoevenagel condensation with diethyl 
malonate in the presence of AlCl3, and the benzylidenemalonates were then made to undergo 
Michael addition by further reaction (neat) with diethylmalonate at 60 
o
C in the presence of 
AlCl3 to yield dimalonates 186. The resultant dimalonates 186 were subjected to acid 
hydrolysis and decarboxylation in one pot to obtain the corresponding glutaric acids, without 
further purification, in 51%, 52% and 60% yields, respectively, over 3 steps (Scheme 75, 
Table 19, entries 1, 3 & 5).
98
  
 
 
 
Scheme 75. Synthesis of 3-Arylglutaric acids 
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    Table 19. Summary of yields of 3-substituted glutaric acids 
   _______________________________________________________________________ 
    Entry Method    R             Yield of Glutaric acid (%) 
           (over 3 steps) 
   ____________________________________________________________________ 
 
      1.     A             2-F-C6H4           188           51% 
      2.     B  4-F-C6H4    189           55% 
      3.     A  2-CH3-C6H4    190           52% 
      4.     B  4-CH3-C6H4    191           57% 
      5.     A  1-Naphthyl    192           60% 
      6.     -  
*
CH3-    193            - 
      7.     C  (CH3)2CH-    194           34% 
      8.     D  (CH3)3C-   195           58% 
 _________________________________________________________________________ 
   *
commercially available 
Method A: Solvent-free Knoevenagel condensation of the aldehyde starting material with diethyl 
malonate / AlCl3 at room temperature followed by solvent-free Michael addition with diethyl 
malonate at 60 
o
C temperature to give corresponding tetracarboxylate, which underwent acid 
hydrolysis and decarboxylation at reflux to the diacid. 
Method B: Drop-wise addition of the solution of aldehyde starting material in toluene to diethyl 
malonate / AlCl3 solution in toluene at room temperature followed by solvent-free Michael addition 
with diethyl malonate at 60 
o
C temperature to give corresponding tetracarboxylate, which underwent 
acid hydrolysis and decarboxylation at reflux to the diacid. 
Method C: Knoevenagel condensation of the aldehyde starting material with diethyl malonate / 
piperidine (0.1 equiv.) in pyridine at 70 
o
C temperature followed by solvent-free Michael addition 
with diethyl malonate at 60 
o
C temperature to give corresponding tetracarboxylate, which underwent 
acid hydrolysis and decarboxylation at reflux to the diacid. 
Method D: Knoevenagel condensation of  the aldehyde starting material with ethylcyanoacetate / 
piperidine in toluene at reflux followed by Michael addition with dimethylsodiomalonate at reflux to 
give corresponding tetracarboxylate, which underwent acid hydrolysis and decarboxylation at reflux 
to the diacid. 
 
However, in the case of more reactive  p-fluoro and p-methylbenzaldehyde starting materials, 
the solvent-free conditions repeatedly led to the isolation of a white solid in the Knoevenagel 
condensation step (instead of the usual oily liquid product), which was identified by 
1
H NMR 
and 
13
C NMR analysis as the corresponding benzoic acid in 47% and 42% yields, 
respectively. It was thought that the electron donating effect of the methyl and fluoro 
substituents may change the course of the reaction by causing an intermolecular hydride
 
transfer between two molecules of aldehydes leading to a self-redox (Cannizzaro) reaction.  
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Pleasingly, a drop-wise addition of a solution of the aldehyde in toluene to the mixture of 
diethyl malonate and AlCl3 in toluene at room temperature led to the formation of the 
required benzylidenemalonate products. The dimalonates 186 were then accessed using the 
procedure described for o-substituted benzaldehydes. A one pot acid hydrolysis and 
decarboxylation of the dimalonates led to the synthesis of the p-substituted glutaric acids 189 
and 191 in 55% and 57% over 3 steps, respectively (Scheme 75, Table 19, entries 2 & 4). All 
efforts to synthesise 9-anthracyl glutaric acid using the procedures described above proved 
unsuccessful. The reason for the unreactivity of 9-anthraldehyde is most likely attributed to 
steric repulsion by the bulky anthracene moiety. 
The synthesis of alkyl glutaric acids using the developed conditions gave extremely low 
yields of the Knoevenagel products. Hence, for the preparation of isopropyl malonate 197, a 
modified procedure was employed by reacting the isobutyraldehyde 196 with the diethyl 
malonate in the presence of piperidine (0.1 equiv.) in pyridine at 70 
o
C for 48 h which gave 
the crude isopropyl malonate in appreciable quantities, and this was taken forward using the 
method described in scheme 76 to yield the isopropyl glutaric acid 194 in 34% yield over 
three steps (Table 19, entry 7). 
  
 
 
Scheme 76. Synthesis of 3-isopropylglutaric acid 194 
 
Unfortunately, trimethylacetaldehyde 199 did not give the corresponding Knoevenagel 
product even with the above modification. Hence the method of Theisen and Heathcock was 
adopted for the synthesis of tert-butylglutaric acid 195.
52
 A solution of the aldehyde in 
toluene was reacted with ethyl cyanoacetate in presence of piperidine (0.01 equiv.) at 
elevated temperature for 4 hours to give the Knoevenegel product which underwent the 
Michael addition with sodium dimethylmalonate at reflux temperature for 17 h to yield the 
tert-butyl cyanotricarboxylate 200. The cyanotricarboxylate obtained was then converted to 
tert-butyl glutaric acid 195 in 58% yield over 3 steps (Scheme 77, Table 19, entry 8).  
Methylglutaric acid 193 was commercially available and used as purchased. 
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Scheme 77. Synthesis of 3-tert-butylglutaric acid 195 
 
The synthesised glutaric acids were then smoothly taken to the corresponding N-benzyl-3-
substituted glutarimides using the method described earlier for the synthesis of 3-phenyl 
glutarimides (Scheme 78).
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 The anhydrides were accessed in 70 ‒ 93% yield, after 
recrystallisation from ethyl acetate / hexane mixture, by heating at reflux the corresponding 
glutaric acids in acetyl chloride for 48 hours (Table 20). The isopropyl anhydride 207 and 
tert-butyl anhydride 208 were obtained as brown liquids which were purified by vacuum 
distillation. However, they were found to be slightly unstable under the distillation 
conditions. Hence, some minor peaks of the corresponding diacids were noticed in both the 
1
H and 
13
C NMR spectra showing a small portion of the anhydrides might have been 
converted back to the corresponding diacids. The anhydrides were converted to the 
corresponding N-Bn glutarimides over two steps by reacting them with benzylamine in THF 
under reflux in the presence of NEt3 for 24 h and the resultant amido-carboxylic acids heated 
in acetyl chloride at 60 
o
C temperature for an additional 24 h to obtain the glutarimides in 52 
‒ 89% yields after recrystallisation from ethyl acetate / hexane mixture, except isopropyl and 
tert-butyl glutarimides 215 and 216 which were purified by flash column chromatography 
(Table 20).   
 
 
 
Scheme 78. Synthesis of N-Bn 3-substituted glutarimides 
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Table 20. Summary of yields of 3-subsitituted glutaric anhydrides and imides 
_________________________________________________________________ 
Entry          R             Anhydride     Imide                                
                   Yield (%)          Yield (%) 
__________________________________________________________________ 
     
     1.     2-F-C6H4                   73     201              60     209 
                 2.     4-F-C6H4                85     202      67     210 
                 3.     2-CH3-C6H4               75     203      87     211 
                 4.     4-CH3-C6H4               93     204      71     212 
                 5.     1-Naphthyl                 80     205      52     213 
                 6.     CH3-                79     206      70     214 
                 7.     (CH3)2CH-                 76     207      67     215 
                 8.     (CH3)3C-                 70     208      57     216 
_________________________________________________________________ 
 
Desymmetrisation of the N-benzyl glutarimides 209 ‒ 216 was explored using B-Me catalyst 
76 employing BH3.THF as the hydride source. The resultant hydroxy-lactam was converted 
to the 4-substituted 2-piperidinone for ease of analysis. Under the reaction conditions, the N-
Bn-4-aryl substrates 209 ‒ 212 furnished the chiral 2-piperidinones 217 ‒ 220 in moderate 
yields (51 ‒ 61%) and good enantioselectivities of 82 ‒ 92% ee (Table 21, entries 1‒ 4). A 
change of substitution around the phenyl group does not seem to affect much the overall yield 
or enantioselectivity.  
A switch from 4-substituted aryls to 4-substituted alkyls 222 ‒ 224 surprisingly kept the 
selectivity at high level, although the yields of the products dropped (Table 21, entries 6 ‒ 8).  
 
 
 
Scheme 79. Desymmetrisation of N-Bn glutarimides using B-Me catalyst 
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Table 21. Desymmetrisation of N-benzyl-3-substituted glutarimides using B-Me catalyst 
______________________________________________________________________ 
         Entry       R                  Yield (%)          ee (%)  
_______________________________________________________________________ 
 1.  2-F-C6H4  217     51   82   
 2.  4-F-C6H4  218   54   92   
 3.  2-CH3-C6H4  219   61   86 
 4.  4-CH3-C6H4  220   51   88 
 5.  1-Naphthyl 221   20   54 
 6.  CH3-   222   46   90 
 7.  (CH3)2CH-  223   41   86 
 8.  (CH3)3C-  224   46    87 
A solution of the glutarimide in dry DCM was treated with 10 mol% of the catalyst at rt for 24 h, 
followed by treatment of a solution of the crude hydroxy-lactam in DCM with Et3SiH / TFA for 1 
hour. Purification by flash column chromatography after a standard work up gave the lactam product.   
 
 
Notable is the significant change observed when the aryl group was changed to 1-naphthyl 
which resulted in sharp decrease in both yield and ee (Table 21, entry 5). This shows that 
steric hindrance at the stereogenic centre in question may affect the catalyst binding ability as 
well as its approach to the substrate despite it been distant from the binding site. 
 
4.5 Establishing stereochemistry 
The absolute configuration of the stereogenic centre for N-PMP-4-phenylpiperidin-2-one 179 
(Table 22, entry 1) was assigned as (4R) by comparison of its optical property with that of a 
closely related known compound, N-PMP-4-(4-fluorophenyl)piperidin-2-one (Table 22, entry 
2). The N-benzyl-4-phenyl lactam 180 (Table 22, entry 3) and N-benzyl-4-(4-fluorophenyl) 
lactam 218 (Table 22, entry 7) have their optical properties matching with known compounds 
in the literature and are also assigned as (4R). The rest of the chiral desymmetrisation 
products have their optical properties comparable to compounds 180 and 218 (Table 22), 
hence are assigned the same configurations. The only exception is the N-benzyl-4-(1-
naphthyl) lactam 221 which has small negative alpha-D value (Table 22, entry 10).  
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Table 22. Comparing optical properties of some representative chiral lactams 
___________________________________________________________________________ 
Entry   Ar                       R                      Measured [𝛂]𝐃
𝟐𝟎          Literature [𝛂]𝐃
𝟐𝟎     
___________________________________________________________________________ 
1.         C6H5-                     PMP (179)           +6.0 (c 1.3, CHCl3)        unknown 
2.          (4R)-F-C6H4-         PMP                           -                                +8.0 (c 1.3, CHCl3)
99                                     
 
3.          (4R)-C6H5-             Bn (180)              +33.0 (c 1.1, CHCl3)     +35.0 (c 1.1, CHCl3)
100   
 
4.          C6H5-                     2-MeBn (182)  + 26.6 (c 0.8, CHCl3)        unknown  
5.          C6H5-                     2-OMeBn (183)   + 21.7 (c 1.0, CHCl3         unknown 
6.          2-F-C6H4                Bn (217)   + 20.1 (c 2.1, CHCl3)       unknown      
7.          (4R)-4-F-C6H4        Bn           (218)   +30.0 (c 1.1, CHCl3)     +33.0 (c 1.1, CHCl3)
100       
 
8.          2-CH3-C6H4            Bn (219)   + 39.4 (c 0.3, CHCl3)        unknown 
9.          4-CH3-C6H4            Bn (220)   + 33.6 (c 1.1, CHCl3)        unknown 
10.        1-Naphthyl             Bn (221)   -13.3 (c 0.5, CHCl3)          unknown 
11.        CH3-                     Bn (222)   + 46.6 (c 3.3, CHCl3)        unknown 
12.       (CH3)2CH-              Bn (223)   + 44.3 (c 1.9, CHCl3)        unknown 
13.       (CH3)3C-                 Bn (224)   + 36.8 (c 1.4, CHCl3)        unknown  
___________________________________________________________________________ 
Specific rotations were performed on an Optical Activity Ltd. AA-10 automatic polarimeter at 589nm 
(Na D-Line) and measured at 20 
o
C. 
 
 
To explain the stereochemical outcome, two possible transition states A and B involving the 
imide and the oxazaborolidine catalyst were proposed using Chem3D after simple molecular 
mechanics minimisation of the pre-transition state intermediate (Figure 17). Two important 
assumptions play a key role in selecting such an intermediate with the least energy; i) the 
catalyst is co-ordinated to the least hindered carbonyl lone pair and ii) the phenyl group of the 
2-piperidinone ring occupies the equatorial position. In intermediate A, there is clearly severe 
steric hindrance between the oxazaborolidine and the phenyl moiety and is therefore not 
favoured. The intermediate B on the other hand, has less steric hindrance between the 
oxazaborolidine and the equatorial C-4 phenyl of the 2-piperidinone ring. This is therefore 
the most likely intermediate giving the (4R) enantiomer of the product (Figure 17). 
70 
 
   
                      A (unfavoured)                          B (favoured) 
Figure 17. Transition states for asymmetric reduction of imides  
 
Comparison of the performance of the B-Me oxazaborolidine catalysts 76 and 77 with CBS 
catalyst 22 was conducted. The desymmetrisation of N-benzyl-4-phenylpiperidin-2,5-dione 
174 was carried out with CBS catalyst 22 prepared in situ from (S)-(–)-α,α-diphenyl-2-
pyrrolidinemethanol 20 using similar conditions employed for B-Me catalyst. The hydroxy-
lactam was further reduced to the corresponding lactam 180. Results from the 
desymmetrisation experiment showed only 13% yield and 14% ee of the lactam product 
(Scheme 80). Comparison of the results obtained from desymmetrisation of the same 
substrate with B-Me catalysts 76 and B-OMe catalyst 77 (Table 17) shows the remarkable 
superiority of both catalysts derived from cis-1-amino-indan-2-ol over the traditional CBS 
catalyst derived from (S)-(–)-α,α-diphenyl-2-pyrrolidinemethanol in desymmetrisation of 
glutarimides.   
 
 
Scheme 80. Comparison of performance of catalysts  
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4.6 Conclusion 
By adapting existing literature methodology, and some modifications where possible, various 
N-benzyl glutarimides have been successfully synthesised. This route could equally serve for 
the synthesis of 3-substituted glutaric acids and anhydrides. Anhydrides in particular are 
highly used for desymmetrisation processes.
51,
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The work has also shown that oxazaborolidines 76 and 77 gave excellent selectivity but a low 
yield in the desymmetrisation of N-PMP-3-phenyl glutarimide. The low yield was attributed 
to the formation of over reduced piperidine product. Investigation into correlation between 
high selectivity and formation of the over reduced product revealed that a stereoablative 
process is partly responsible for upgrade of ee in both versions of B-Me oxazaborolidine 
catalyst. A double stereo-differentiation process with strong matched and mismatched 
catalytic reductions in the two enantiomers of the catalyst was noted with N-PMP-3-phenyl 
glutarimide substrate.  
Switching the nitrogen protecting group from N-PMP to N-benzyl, the B-Me catalyst 76 was 
shown to give a superior yield of the desymmetrised product than the B-OMe counterpart. 
The same catalyst was also shown to be effective in the desymmetrisation of various 3-
substituted-N-benzyl glutarimides, giving good yield and excellent enantioselectivity of the 
chiral lactam products. The work also revealed that sterics at position-3 of the glutarimide 
can affect the catalyst performance as 3-(1-naphthyl) glutarimide 213 gave both poor yield 
and enantioselectivity of the desymmerised product. 
4.7 Future work 
The effect on structure for the desymmetrisation of 5 membered meso-imides 225 using 
oxazaborolidines as catalysts for the reduction has been fully investigated. The result showed 
that to obtain excellent stereocontrol the nitrogen protecting group has to be aryl and where R 
is a cyclic backbone, the meso-imide has to be based on a fused cyclohexyl group (Figure 
18). 
 
Figure 18. Five membered ring meso imides 
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Prior to this work, the desymmetrisation of six membered imides using oxazaborolidines has 
not been explored. An extension of this work would be to investigate the catalyst structure by 
using various oxazaborolines for the desymmetrisation process. Optimisation of the reaction 
conditions to minimize over reduction of the imide which could lead to higher yield of the 
product could also be performed. meso Glutarimides 226 and glutarimides 228 could also be 
targeted for desymmetrisation, assessing what controls the desymmetrisation of such systems. 
Variation of the functionalisation at the nitrogen atom and the stereogenic positions could be 
investigated (Scheme 81). 
 
 
Scheme 81. Desymmetrisation of disubstituted imides 
Further investigation on the stereoablative properties of both versions of B-Me and B-OMe 
catalysts on N-benzyl substrates could be investigated. 
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Chapter 5 
Preparation of piperidine-containing structures 
 
5.1 Background 
Having successfully utilised desymmetrisation methodology for the synthesis of enantio-
enriched 4-substituted lactams, investigations were directed towards functionalisation of the 
chiral lactams to 3,4-disubstituted 2-piperidinones that could give access to chiral piperidines. 
Piperidines and their derivatives have become increasingly popular building blocks in a vast 
array of synthetic protocols because they are very important sub-units in natural products and 
synthetic pharmaceuticals.
106
 During a recent 10-year period, several thousand piperidine 
compounds have been mentioned in clinical and preclinical studies.
107
 Besides their 
interesting structural features, these compounds are also of pharmaceutical interest as they 
exhibit a wide range of biological activities.
107
  Piperidinones serve a role as advanced 
intermediates prior to their conversion to piperidines.
108 
Examples of natural products 
containing the piperidine ring include quinine 230, hirsuteine 231 and dienomycin C 232, all 
of which have potent biological activity (Figure 19).
109,
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Figure 19. Some important natural products containing piperidine moiety 
 
Pharmaceuticals containing piperidine moiety include psychotrine 236, an HIV-1 reverse 
transcriptase inhibitor, paroxetine 233 and femoxitine 234, which are selective serotonin 
uptake inhibitors and used as antidepressants.
112,
 
113
 Paroxetine is also used in the treatment 
of Parkinson’s disease (Figure 20).114   
The absolute configurations at the C-3 and C-4 positions of the piperidine ring are critical for 
the activity of these compounds and 4-arylpiperidine in particular is an important structural 
motif in many biologically active compounds including paroxetine 233, femoxetine 234 or 
Roche-1 235 and psychotrine 236.
114
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Figure 20. Some important pharmaceuticals containing piperidine moiety 
 
In this work, the N-benzyl-4-phenyl lactam 180 was chosen as the representative compound 
for the functionalisation reactions. The first strategy was to attempt enolate chemistry by base 
abstraction of the acidic α-proton of the chiral lactam. The resultant enolate intermediate 237 
generated in situ would then be reacted with an appropriate electrophile to generate a second 
stereogenic centre, thus giving a 3,4-disubstituted lactam 238. The lactam could then be 
reduced to the corresponding 3,4-disubstituted piperidine 239 (Scheme 82). 
 
Scheme 82. Substitution on position-3 
The second strategy was to try functionalisation at C-2. This could be accomplished by first 
performing an enantioselective desymmetrisation on the representative imide 174 using the 
B-Me catalyst 76, employing conditions used for desymmetrisation. The resultant hydroxy-
lactam 240 would then be reacted with phenylsulfinic acid to give the sulfone compound 241, 
which would be made to undergo nucleophilic substitution on C-2 to give 2,4-disubstituted 
lactam 241. Reduction of the lactam 241 would give the 2,4-disubstituted piperidine 243 
(Scheme 83).   
 
              
Scheme 83. Substitution on position-2 
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5.2 Enolate chemistry 
The representative chiral lactam 180 was first reacted with LDA at ‒78 oC for 30 minutes to 
generate the enolate intermediate 244 in situ. Then methyl iodide was added as the 
electrophile (Scheme 85). After work-up the 
1
H NMR spectrum of the crude material showed 
the formation of the 3-methyl substituted lactam product in 10:1 diastereomeric ratio. 
Purification by column chromatography led to isolation of the chiral 3-methyl lactam 
compound 245 as a single diastereomer in 61% yield (Scheme 84). 
 
 
Scheme 84. α-Methylation of a representative chiral lactam 
The C-3 configuration was established by COSY and nOe experiments. The nOe analysis 
showed a direct relationship of the C-3 methyl group with Ha and Hb protons (Figure 21). 
Irradiation of the methyl protons appearing as doublet at δH 2.20 led to enhancement in the 
signals of Ha as well as Hb protons. No enhancement was observed in any of the aromatic 
protons. This result suggests a trans-relationship between the C-3 methyl and the phenyl 
group on position-4 (Figure 21).   
 
 
Figure 21. trans-Relationship between 3-methyl & 4-phenyl observed 
A cis-relationship would have resulted in an enhancement in Ha proton signal due to gem-
relationship with the irradiated methyl group, but should produce no effect on Hb proton 
which is distant to the methyl group. Furthermore, some of the C-4 phenyl protons would be 
affected (Figure 22).  
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Figure 22. No cis-relationship between 3-methyl & 4-phenyl observed 
The C-3 configuration may be explained as a result of the nucleophilic attack of the enolate 
ion on the electrophile from the opposite face of the phenyl on position-4 to avoid steric 
interactions (Figure 23).  
 
Figure 23. Attack of electrophile from opposite face of phenyl 
5.2.1 Synthesis of piperidines 
Having successfully transformed the 4-phenyl lactam 180 to the 3-methyl-4-phenyl lactam 
245 in good yield, the versatility of the method was tested by deprotonating the representative 
lactam 180 and quenching with various electrophiles. The 3,4-disubstituted lactams 246 ‒ 
248 were isolated in good yields and excellent diastereoselectivity (Table 23). The 3-allyl 
lactam 246 and 3-benzyl lactam 247 were obtained as single diastereomers as observed by 
crude 
1
H NMR spectra, while 3-methyl lactam 245 and 3-ethyl carboxylate lactam 248 were 
obtained as a 10:1 dr as observed in crude 
1
H NMR spectra but only the major diastereomer 
was isolated (Table 23). The configuration of the 3-allyl-4-phenyldisubstituted lactam 246 
was assigned as (3S, 4R) based on the configuration assigned for the 3-methyl-4-phenyl 
lactam 245. The 3-benzyl-4-phenyl derivative 247 is a known compound, however the optical 
rotation was not given in the literature but the coupling constant for CHPh proton (J = 9.7) 
matches closely with the literature value (J = 9.6)
 115
, and was therefore assigned (3S, 4R).    
 
Scheme 85. Preparation of chiral 3-substituted-4-phenyl lactams 
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  Table 23. Yields and optical properties of chiral 3-substituted-4-phenyl lactams 
  ____________________________________________________________________ 
  Entry    Electrophile             Yield (%) dr (crude)               [𝛂]𝐃
𝟐𝟎  
  ____________________________________________________________________ 
  1.         CH3I      61   (245)   10:1         +26.1 (c 0.7 CHCl3) 
  2.   CH2=CHCH2MgBr       62   (246) 100:0         +37.2 (c 1.2 CHCl3) 
  3.         PhCH2Br      57   (247)     100:0        -4.6 (c 4.0 CHCl3) 
  4.         ClCO2Et      71   (248)    10:1        +3.0 (c 0.1 CHCl3) 
  _______________________________________________________________ 
A solution of LDA (1.5 equiv.) was added drop-wise to the solution of the substrate 
in dry THF at - 78 
o
C and stirred for 20 minutes. Then the electrophile (1.0 equiv.) 
was slowly added and the mixture stirred at - 78 
o
C for 2 h, allowed to warm to room 
temperature slowly and further stirred for 18 h. The product was purified by flash 
column chromatography 
 
For the 3-ethyl carboxylate lactam 248, the relative configuration of the major diastereomer 
was also confirmed as trans by COSY and nOe experiments. Irradiation of the Ha proton 
appearing as doublet around δH 3.66 (J = 11.0) led to enhancement in the signal of the two 
aromatic protons appearing as (AX)2 around δH 7.22, showing a trans-relationship between 
the phenyl on position-4 and the carboxylate group on position-3 (Figure 24). Furthermore, 
the coupling constant for Ha (J = 11.0) matches the literature value for the closely-related 
compound (3S)-methylcarboxylate-(4R)-phenyl lactam 249 (J = 11.6) (Figure 24).
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Figure 24. trans-relationship between 3-ethylcarboxylate & 4-phenyl observed 
The chiral 3-substituted-4-phenyl lactams 245 ‒ 248 were reduced to the corresponding 
piperidines by heating at reflux in the presence of lithium aluminium hydride as reducing 
agent for 18 hours. In the case of 3-methyl substituted lactam 245 and the 3-carboxylate 
lactam 248, the reduction products could not be isolated in a reasonable yield when reduced 
with LiAlH4.  However, they were smoothly reduced by BH3.THF to give the corresponding 
piperidines in moderate yields (Table 24).  The methyl piperidine 249 was surprisingly 
obtained in a 10:1 diastereomeric ratio, due to epimerisation during the reaction (Table 24, 
entry 1). All the piperidines have their CHPh proton coupling constant around J = 11.0, 
showing a 3,4-trans relationship. The exception is the 3-benzyl derivative 251 in which the 
proton merges with another proton to give a multiplet. 
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Scheme 86. Preparation of chiral 3-phenyl-4-substituted piperidines 
Table 24. Yields and optical properties of chiral 3-substituted 4-phenyl piperidines 
_______________________________________________________________________________ 
Entry      R                    Reducing agent    Yield (%)     dr                 [𝛂]𝐃
𝟐𝟎  
_______________________________________________________________________________ 
1. -CH3           (249)            BH3.THF              65     10:1           -24.5 (c 1.8 CHCl3) 
2.     CH2=CHCH2-   (250)            LiAlH4              52     100%         -15.0 (c 0.4 CHCl3) 
3. PhCH2-         (251)            LiAlH4              61     100%         -16.6 (c 2.9 CHCl3) 
4.       -CH2OH          (252)           BH3.THF                55           100%         -22.2 (c 0.2 CHCl3) 
_________________________________________________________________________ 
BH3.THF (3 equiv.) or LiAlH4 (3 equiv.) was added to a solution of the piperidin-2-one in dry THF. 
The mixture was heated at reflux for 5 hours (BH3.THF) or 24 hours (LiAlH4) and cooled to room 
temperature. The product was purified by flash column chromatography. 
 
5.3 Aldol Reaction 
Another important reaction in organic synthesis that utilizes enolate chemistry is the aldol 
condensation. The aldol addition reaction is a useful tool for the synthesis of biologically 
important natural products and considerable attention has been paid to the development of 
aldol methodology.
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In an effort to widen the scope of the lactam enolate chemistry, the representative lactam 180 
was deprotonated using the standard procedure and the in situ generated enolate was 
quenched with benzaldehyde. After the normal work up, purification by flash column 
chromatography led to the isolation of the aldol adduct 253 in 62% yield as a single 
diastereomer (Scheme 87). 
 
Scheme 87. Aldol reaction of the lactam 180 
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Although efforts to obtain crystals of the compound for a single crystal structure analysis 
failed, the configuration of the newly formed hydroxy benzylic stereogenic centre in the 
molecule was assigned as [(R)-hydroxyphenylmethyl] based on comparison of the coupling 
constants of a compound containing similar stereochemistry in the literature. The aldol 
product 253 is assumed to exist as intramolecularly H-bonded six-membered ring structure 
(Figure 25) as observed with comparable compound in the reference literature.
117
  The proton 
(Ha) on position-3 of the piperidin-3-one ring appeared at δ 3.44 as a double doublet retaining 
its trans coupling (J = 11.7) with the Hb proton on position-4 [δ 2.66 (1H, td, J 11.7, 4.4] as 
observed in the 3-ethyl carboxylate lactam 248 and the rest of the piperidines, demonstrating 
a (3S, 4R) stereochemistry (Figure 25). The benzylic proton (Hc) appeared at δ 4.61 as a 
doublet coupled with Ha with J = 4.4 (Figure 25, Table 25). This matches closely with a 
similar proton of the erythro-isomer of a comparable compound 254 reported by House et al. 
(Figure 26, Table 25).
117
 Furthermore, a Newman projection of the benzylic stereochemistry 
suggests a dihedral angle of 60
o
 between Ha and Hc which according to Karplus relationship 
will have a J value between 2 ‒ 5 Hz (Figure 25). 
 
Figure 25. Comparing protons coupling constants in the aldol product 253 
      Table 25. Reference protons coupling constants 
_______________________________________________________ 
     Entry Proton δ  Multiplicity Coupling constant (J) 
     _______________________________________________________ 
       1     Ha            3.44       dd   11.7, 4.4 
       2     Hb            2.66       td   11.7, 4.4 
       3     Hc            4.61       d   4.4 
    ________________________________________________________ 
    Spectrum measured in CDCl3 using 400 MHz spectrometer 
 
In the reference work, the coupling constants of benzylic protons of the threo and erythro 
isomers of the aldol product 254, existing as intramolecularly H-bonded six-membered ring 
structures, were compared in different solvents (Figure 26).
117
 The coupling constant of the 
benzylic proton in the threo-isomer 254(a) was found to be higher, at around J = 8.4 in all the 
three solvents (Table 26). The coupling constant of the benzylic proton in the erythro-isomer 
254(b) on the other hand has a coupling constant of J = 2.4 ‒ 4.3, which is comparable with 
the observed coupling constant of the Hc proton of the aldol adduct 253 in this work (Figure 
26).        
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Figure 26. Threo and erythro isomers of the ketone 254 
Table 26. Reference benzylic protons in the aldol adduct 254 
___________________________________________________________________________ 
  Entry  Solvent          Benzylic proton Hc 
      _______________________________________ 
          254(a)               254(b) 
__________________________________________________________________________ 
   1                            D2O    δ 4.68 (d, J 8.4) δ 5.30 (d, J 2.4) 
   2                            C6D6    δ 4.80 (d, J 8.4) δ 5.38 (m) 
   3                            CH3OD   δ 4.95 (d, J 8.5) δ 5.25 (d, J 4.3) 
___________________________________________________________________________ 
 
The transition state of the aldol reaction can therefore be pictured as a six-membered ring in a 
chair conformation with the electropositive lithium chelated between the two oxygen atoms 
of the two reacting molecules (Figure 27). The approaching benzaldehyde is oriented such 
that the large phenyl moiety is directed away from the C-4 phenyl substituent in the 2-
piperidinone ring to minimise steric interaction. This makes the phenyl group in the aldehyde 
to adopt a pseudo-axial conformation in the six-membered transition state, thereby favouring 
the formation of the erythro-diastereomer.    
 
Figure 27. Proposed transition state for the aldol reaction 
5.4 Formal synthesis of (-)-paroxitine and (-)-femoxetine 
(-)-Paroxetine hydrochloride 233 marketed as Paxil/Seroxat, and (-)-femoxetine 234 (Figure 
28) are selective serotonin reuptake inhibitors used in the treatment of depression, obsessive 
compulsive disorder, and panic. (-)-Paroxetine hydrochloride was reported to have generated 
sales in excess of over $1.0 billion/year.
112
  
There have been a number of reported syntheses of these two pharmaceuticals showing 
different ways of enantioselective constructions of the (3S)- and (4R)-stereogenic centres.
113
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These ways include kinetic resolutions,
118,
 
119
 chiral auxiliaries,
120
  chiral bases,
121,
 
115
 the use 
of chiral pool,
122
 enantioselective catalysis,
100, 123
 and enzymatic asymmetrisations.
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Figure 28. (3S, 4R) (-)-paroxetine hydrochloride and (-)-femoxetine 
The desymmetrisation methodology has also been employed as an effective way of 
constructing these two stereogenic centres in paroxetine by some research groups. Various 
asymmetric desymmetrisations of a variety of achiral substrates (Figure 29) have been 
employed for that purpose. Yu et al. employed a porcine liver esterase (PLE) mediated 
asymmetric desymmetrisation of glutaric acid bis methyl ester 255,
112
 Liu et al. used 
desymmetrisation of 3-substituted glutaric anhydride 202 with (S)-methylbenzylamine.
103 
Desymmetrisation of
 
glutarimides have also been employed for the synthesis of (-)-
paroxetine. Ikariya et al. used ruthenium catalysed asymmetric hydrogenation of glutarimide 
256
124
 while Simpkins and co-workers employed a chiral lithium amide base 
desymmetrisation of glutarimide 210
68
 all for the synthesis of (-)-paroxetine. 
 
Figure 29. Substrates used for desymmetrisation methodology in the synthesis of (-)-paroxetine 
The desymmetrisation of glutarimides and their subsequent functionalisation to (3S, 4R) 
lactams carried out in this research work provides yet another convenient route to the 
construction of the two important stereogenic centres in these important pharmaceuticals. The 
4-(p-fluorophenyl) lactam 218 obtained as the desymmetrisation product from the 
corresponding glutarimide 210 in 54% yield and 92% ee could serve as an important 
intermediate for (-)-paroxetine. Deprotonation of the lactam and quenching with ethyl 
chloroformate provided the corresponding carboxylate 257 in 62% and 10:1 diastereomeric 
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ratio (Scheme 89). The carboxylate intermediate 257 could be converted to (-)-paroxetine 
233-HCl in four steps by the method of Yu et al.
112
 (Scheme 88). 
 
 
Scheme 88. Formal synthesis of (3S, 4R) (-)-paroxetine  
In the same way, the desymmetrised product 180 obtained in 60% yield and 90% ee from the 
corresponding glutarimide 174 could provide direct access to (-)-femoxetine 234. The 
carboxylate intermediate 248 from the C-3 functionalisation of N-Bn lactam 180 was 
obtained in 71% yield and 10:1 dr. Subsequent borane reduction of the carboxylate 
compound gave  the alcohol 252 in 55% yield as a single diastereomer (Scheme 89). The 
alcohol intermediate 252 could be converted to (-)-femoxetine in four steps by the method of 
Johnson, T. A et al.
115
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Scheme 89. Formal synthesis of (3S, 4R) (-)-fermoxetine 
 
5.5 Substitution on carbon-2 
Having achieved success in the enolate chemistry, attention was focused on C-2 
functionalisation. The initial attempt was the synthesis of the 2-benzenesulfonyl compound 
241 that could provide access to other C-2 functions. The representative imide 174 was 
subjected to reduction under standard conditions followed by treatment of the resultant crude 
hydroxy-lactam with phenylsulfinic acid in presence of CaCl2 at room temperature for 18 
hours. After standard work up and purification by flash column chromatography, the 4-
phenyl lactam 180 was isolated in 30% yield instead of the expected sulfonyl compound 
(Scheme 90). Another attempt still led to isolation of the lactam 180. An alternative route to 
the sulfonyl compound 241, using literature procedure, was the conversion of the imide to the 
ethoxy lactam 258 which would then be converted to the sulfonyl compound 241 (Scheme 
91).
125
 Reduction of the phenyl imide 174 under standard conditions followed by treatment of 
the crude mixture with 2 M H2SO4 / EtOH for 3 hours at room temperature did not lead to the 
isolation of the ethoxy product 258. The reaction was repeated and the crude product was 
treated with phenylsulfinic acid in presence of CaCl2 at room temperature for 18 hours. 
Purification of the product surprisingly led to isolation of the phenyl lactam 180, again in 
30% yield, instead of the required C-2 substituted compound (Scheme 90).  
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Scheme 90. Attempted substitution of phenyl sulfonyl on C-2 
5.6 Conclusion 
Functionalisation of a representative chiral desymmetrised product led to the synthesis of 
various (3S, 4R)-disubstituted 2-piperidinones in good yield and excellent 
diastereoselectivity. Reduction of the 2-piperidinones gave (3S, 4R)-disubstituted piperidines 
which are important structural motifs in many biologically active natural products and 
pharmaceuticals. Two of the piperidines could provide direct access to (3S, 4R)-(-)-
paroxetine and (-)-femoxetine which are important antidepressants. 
Attempts on the functionalisation of a representative hydroxy-lactam intermediate on carbon-
2 persistently led to isolation of the corresponding 2-piperidinone. 
 
5.7 Future work 
Functionalisation of the chiral lactams on C-3 applying an enolate methodology was found to 
occur readily. Functionalisation on C-2, however was more challenging. Investigation in to 
the optimised conditions that could convert the unstable hydoxy-lactam 240 to a more stable 
lactam which would then be converted to various C-2 functions could be carried out (Scheme 
91).  
 
 
Scheme 91. Substitution on C-2 
85 
 
The optimised functionalisation methodologies could be applied to the construction of 2-
azabicyclo[3.3.1]nonane ring system, which is a core skeleton of biologically active alkaloid 
natural products (Scheme 92). 
 
 
 
              
 
 
Scheme 92. Route to the construction of 2-azabicyclo[3.3.1]nonane 
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Chapter 6 
Experimental 
6.1 General 
All solvents were obtained dry from a Grubbs dry solvent system and glassware was flame 
dried and cooled under vacuum before use. All dry reactions were carried out under nitrogen. 
TLC was carried out using Merck aluminium TLC sheets (silica gel 60 F254), visualisation of 
TLC plates was performed using a UV lamp or by dipping in KMnO4 then exposure to heat. 
Flash column chromatography was carried out with silica gel 40-63 60Å (Fluorochem 
Limited). 
1
H and 
13
C NMR spectra were measured using CDCl3 as solvent unless otherwise 
stated, on a Brüker 250 or 400 MHz machine with an automated sample changer (unless 
otherwise stated). Chemical shifts for carbon and hydrogen are given on the  scale relative to 
TMS (tetramethylsilane, δ = 0 ppm). Coupling constants were measured in Hz. 13C NMR 
spectra were recorded using the JMOD method. Specific rotations were performed on an 
Optical Activity Ltd. AA-10 automatic polarimeter at 589nm (Na D-Line) and measured at 
20 
oC unless otherwise stated. [α]D values are given in 10
-1
 deg cm
2
 g
-1
. Infrared spectra were 
recorded on a Perkin-Elmer 1600 FT-IR machine using 0.5mm NaCl cells and mass spectra 
were recorded on a Kratos instrument using electrospray technique unless otherwise stated. 
HPLC was carried out on a Gilson analytical system using a Chiralcel (4.8 mm × 250 mm) 
column with 10% or 20% IPA in hexane as the solvent. The flow rate was 1.00 cm
3
 per 
minute and the detector was set at 220 nm or 254 nm. All chemicals were used as received 
without further purification except (1R, 2S)-cis-1-amino-2-indanol, (1S, 2R)-cis-1-amino-2-
indanol and anthracene which were recrystallised from hot toluene prior to use. Borane-THF 
was used as a 1M solution in THF. 
Where compounds have been previously reported in the literature citing full analytical data, 
LRMS instead of HRMS is recorded and elemental analysis may not be carried out. However 
if a compound has been reported lacking data, the missing information has been recorded. 
Also, if elemental analysis is carried out LRMS instead of HRMS may be recorded. 
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6.2 Experimental for the synthesis and desymmetrisation of meso-malimides 
N-(p-Methoxyphenyl)-maleimide 100
126
 
 
A solution of maleic anhydride (11.15 g, 0.114 mol) in toluene (200 cm
3
) was treated with p-
anisidine (14.00 g, 0.114 mol) and allowed to stir at room temperature for 1 hr. Dry zinc (II) 
chloride (15.49 g, 0.114 mmol) was added, the reaction warmed to 80 
o
C and 
hexamethyldisilazane (35.00 cm
3
, 0.168 mol) was added portion-wise over a 40 min period. 
The reaction was heated at reflux for a further 4 hr, allowed to cool to room temperature and 
added to 1M HCl (130 cm
3
). The product was extracted with EtOAc (3 × 50 cm
3
) and the 
combined organic extracts were washed with saturated NaHCO3 (3 × 50 cm
3
), brine (3 × 50 
cm
3
) and dried over MgSO4. After filtration, the solvent was removed in vacuo to afford the 
pure imide as a green crystalline solid (16.11 g, 70%). Mpt 134 ‒ 136 oC (lit.127 136 – 138 
o
C); vmax (ATR)/cm
-1
 1703, 1510; 
1
H NMR (250 MHz; CDCl3) δH 3.85 (3H, s, OCH3), 6.85 
(2H, s, 2 × CH), 6.98 [2H, (AX)2, ArCH], 7.23 [2H, (AX)2, ArCH); 
13
C NMR (100 MHz; 
CDCl3) δC 55.5 (CH3), 114.5 (2 × ArCH), 123.8 (ArC), 127.6 (2 × ArCH), 134.2 (2 × 
C=CH), 159.2 (ArC), 169.8 (2 × C=O); m/z (TOF MS ES
+
) 204 (100%, MH
+
 C11H10NO3). 
All data was in accordance with the literature. 
N-(p-Methoxyphenyl)-9,10-dihydro-9,10-ethanoanthracene-1’,2’-dicarboximide 101128 
 
Recrystallised anthracene (8.70 g, 49 mmol) and N-(p-methoxyphenyl)-maleimide  100 (10.0 
g, 49 mmol) were suspended in toluene (350 cm
3
). The suspension was heated at reflux for 5 
hrs, cooled and the solvent was removed in vacuo to give a pale brown powder. The pure 
cycloadduct was obtained via recrystallisation from EtOAc to give the title compound as 
white powder (17.5 g, 94%). Mpt 240 – 242 oC (lit.128 258 oC); vmax (ATR)/cm
-1 
2362, 1708, 
1608, 1511; 
1
H NMR (400 MHz; CDCl3) δH 3.39 [2H, (AX)2, 2 × CHCO], 3.77 (3H, s, 
OCH3), 4.92 [2H, (AX)2, 2 × CH], 6.43 (2H, d, J 8.9, ArCH), 6.83 (2H, d, J 8.9, ArCH), 7.22 
– 7.25 (4H, m, ArCH), 7.37 [2H, (AX)2, ArCH], 7.45 [2H, (AX)2, ArCH]; 
13
C NMR (100 
MHz; CDCl3) δC 45.9 (2 × CH), 47.0 (2 × CHCO), 55.4 (OCH3), 114.5 (2 × ArCH), 124.0 
(ArC), 124.4 (2 × ArCH), 125.2 (2 × ArCH), 126.9 (2 × ArCH), 127.1 (2 × ArCH), 127.6 (2 
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× ArCH), 138.8 (ArC), 141.3 (2 × ArC), 159.6 (2 × ArC), 176.4 (2 × C=O); m/z (TOF MS 
ES
+
) 382.1437 (100%, MH
+
 C25H20NO3 requires 382.1443). All data was in accordance with 
the literature. 
9,10-Dihydro-9,10-ethano-anthracene-11,12-dicarboxylic acid anhydride 102
128
 
 
Maleic anhydride (11.0 g, 0.11mol) and anthracene (20.0 g, 0.11 mol) were suspended in 
toluene (500 cm
3
) and heated at reflux for 6 hrs. Once cooled to rt, the solvent was removed 
in vacuo to yield a white powder. This was purified by recrystallisation from CH2Cl2 : 
petroleum ether (60-80) to give the title compound as white crystals (29.5 g, 97%). Mpt 256 ‒ 
258 
o
C (lit.
129
 261
o
C); vmax (ATR)/cm
-1
 3069, 3021, 2977, 2161, 2032, 1834, 1768; 
1
H NMR 
(400 MHz; CDCl3) δH 3.55 [2H, (AX)2, 2 × CHCO], 4.86 [2H, (AX)2, 2 × CH], 7.20 – 7.26 
(4H, m, ArCH), 7.36 (2H, dd, J 5.4, 3.2, ArCH), 7.42 (2H, dd, J 5.4, 3.2, ArCH); 
13
C NMR 
(100 MHz; CDCl3) δC 45.4 (2 × CHCO), 48.0 (2 × CH), 124.4 (2 × ArCH), 125.2 (2 × 
ArCH), 127.2 (2 × ArCH), 127.8 (2 × ArCH), 138.1 (2 × ArC), 140.6 (2 × ArC), 170.5 (2 × 
C=O); m/z (TOF MS ES
-
) 275.0697 [100%, M
- 
(-H
+
) C18H11O3 requires 275.0708], 293 (50), 
302 (40). All data was in accordance with the literature. 
N-(Benzyl)-9,10-dihydro-9,10-ethanoanthracene-1’,2’-dicarboximide 103 
 
Cycloadduct 102 (15.0 g, 53.4 mmol) was suspended in acetic acid (175 cm
3
) followed by the 
addition of N-benzylamine (5.80 cm
3
, 53.4 mmol). The resulting white suspension was heated 
at reflux overnight. Once cooled to RT the solution was added to an ice water mixture (200 
cm
3
) and stirred vigorously. The white precipitate formed was collected, and identified as the 
title compound that required no further purification (17.4 g, 89%). Mpt 221 – 223 oC; vmax 
(ATR)/cm
-1
 3062, 3034, 2966, 1770, 1690; 
1
H NMR (400 MHz; CDCl3) δH 3.25 [2H, (AX)2, 
2 × CHCO), 4.31 (2H, s, NCH2), 4.80 [2H, (AX)2, 2 × CH], 6.71 [2H, (AX)2, ArCH], 7.02 
[2H, (AX)2, ArCH], 7.15 ‒ 7.22 (7H, m, ArCH), 7.15 ‒ 7.22 (2H, m, ArCH); 
13
C NMR (100 
MHz; CDCl3) δC 42.1 (NCH2), 45.4 (2 × CHCO), 46.9 (2 × CH), 124.2 (2 × ArCH), 124.9 (2 
× ArCH), 126.7 (2 × ArCH), 127.1 (2 × ArCH), 127.3 (ArCH), 127.7 (2 × ArCH), 128.4 (2 × 
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ArCH), 134.9 (ArC), 138.5 (2 × ArC), 141.7 (2 × ArC), 176.5 (2 × C=O); m/z (TOF MS ES
+
) 
366.1478 (100%, MH
+
 C25H20NO2 requires 366.1494). 
N-(p-Methoxybenzyl)-9,10-dihydro-9,10-ethanoanthracene-1’,2’-dicarboximide 104130 
 
Cycloadduct 102 (15.0 g, 41.1 mmol), was suspended in acetic acid (175 cm
3
) followed by 
addition of p-methoxy benzylamine (5.40 cm
3
, 41.1 mmol). The resulting white suspension 
was heated at reflux overnight. Once cooled to rt the solution was added to an ice water 
mixture (200 cm
3
) and stirred vigorously. The white precipitate was collected, which was 
identified as the title compound that required no further purification (14.3 g, 88%). Mpt 221 – 
223 
o
C (lit.
130
 224 – 226 oC); vmax (ATR)/cm
-1
 3034, 2970, 2939, 2838, 1775, 1702, 1618, 
1516; 
1
H NMR (400 MHz; CDCl3) δH 3.22 [2H, (AX)2, 2 × CHCO], 3.79 (3H, s, OCH3), 
4.23 (2H, s, NCH2), 4.79 [2H, (AX)2, 2 × CH], 6.68 [4H, (AX)2, ArCH], 7.00 [2H, (AX)2, 
ArCH], 7.18 [4H, (AX)2, ArCH], 7.38 [2H, (AX)2, ArCH]; 
13
C NMR (100 MHz; CDCl3) δC 
41.6 (NCH2), 45.4 (2 × CH), 46.9 (2 × CH), 55.3 (CH3), 113.8 (2 × ArCH), 124.2 (2 × 
ArCH), 124.8 (2 × ArCH), 126.7 (2 × ArCH), 127.0 (2 × ArCH), 127.3 (ArC), 129.4 (2 × 
ArCH), 138.5 (2 × ArC), 141.7 (2 × ArC), 158.8 (ArC), 176.6 (2 × C=O). m/z (TOF MS ES
+
) 
396.1586 (100%, MH
+
 C26H22NO3 requires 396.1600). All data was in accordance with the 
literature. 
 
Background reaction of N-(p-Methoxyphenyl)-9,10-dihydro-9,10-ethanoanthracene-
1’,2’-dicarboximide 101 with BH3.THF 
 
 
N-(p-Methoxyphenyl)-9,10-dihydro-9,10-ethanoanthracene-1’,2’-dicarboximide 101 (0.18 
mg, 0.50 mmol) was dissolved in THF (4 cm
3
), treated with BH3.THF (0.50 cm
3
, 0.50 mmol) 
and allowed to stir at rt for 18 hrs. The reaction was quenched by addition of 1M HCl (1 cm
3
) 
and H2O (1 cm
3
), the product was extracted with CH2Cl2 (3 × 5 cm
3
) and the organic extracts 
dried over MgSO4. After filtration, the solvent was removed in vacuo to give a white powder. 
1
H NMR analysis showed only 2% conversion to the corresponding hydroxy-lactam. 
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General Procedure A for the asymmetric reduction of imide cycloadducts using B-OMe 
catalyst 77 followed by conversion to the corresponding -OMe aminal 
 
 
 
A solution of (1R,2S)-cis-1-aminoindan-2-ol (0.19 g, 1.25 mmol) in THF (3 cm
3
) was treated 
with trimethylborate (0.30 cm
3
, 1.25 mmol) and allowed to stir for 45 mins. The solution was 
then diluted to 5 cm
3
 by further addition of THF, to give the catalyst 77 as a stock solution. 
The cycloadduct (2.5 mmol) was dissolved in dry THF (20 cm
3
) under a nitrogen atmosphere 
and this solution was treated with the catalyst stock solution (1 cm
3
, 10 mol%) then BH3.THF 
(2.50 cm
3
, 2.50 mmol), and allowed to stir at rt for 4 hrs. The reaction was quenched by the 
addition of MeOH (5 cm
3
) and 1M HCl (5 cm
3
), and extracted with CH2Cl2 (3 × 15 cm
3
). The 
combined organic extracts were dried over MgSO4 and filtered. The solvent was removed in 
vacuo to give the crude hydroxy-lactam as a white powder. The crude hydroxy-lactam was 
then dissolved in MeOH (150 cm
3
), treated with p-TsOH.H2O (0.1 equiv. of the crude 
hydroxy-lactam) and heated at reflux until no hydroxy-lactam remained via TLC 
(approximately 17 hrs). The reaction mixture was allowed to cool to room temperature and 
quenched with saturated aqueous NaHCO3 (15 cm
3
). The mixture was then extracted with 
CH2Cl2 (3 × 15 cm
3
), the combined organic extracts dried over MgSO4, filtered and solvent 
removed in vacuo to give a crude brown solid, which was purified via flash column 
chromatography eluting with EtOAc : petroleum ether (40-60) (3:7). 
(3R,3aS,9aR)-2,3,3a,4,9,9a-Hexahydro-3-methoxy-2-(4-methoxyphenyl)-4,9[1',2']-
benzeno-1H-benz[f]isoindol-1-one 107 
 
The title compound was obtained as a white powder from 0.95 g (2.5 mmol) of cycloadduct 
101 using general procedure A (0.60 g, 61% over 2 steps). [α]D
20
  - 86 (c 0.07, CHCl3; > 99% 
ee); Mpt. 102 – 104 oC; vmax (ATR)/cm
-1
 3036, 2954, 2833, 1693, 1608, 1510; 
1
H NMR (400 
MHz; CDCl3) δH 2.73 (1H, ddd, J 9.2, 3.2, 1.2, CH), 3.24 – 3.27 (4H, m, OCH3 + CHCO), 
3.75 (3H, s, ArOCH3), 4.48 (1H, d, J 3.2, CH), 4.63 (1H, app s, NCH), 4.83 (1H, d, J 3.6, 
91 
 
CH), 6.49 [2H, (AX)2, ArCH], 6.73 [2H, (AX)2, ArCH], 7.17 – 7.21 (4H, m, ArCH), 7.33 – 
7.43 (4H, m, ArCH); 
13
C NMR (100 MHz; CDCl3) δC 43.3 (CH), 46.1 (CH), 47.5 (CH), 48.7 
(CH), 52.8 (CH3), 55.4 (CH3), 95.2 (CH), 114.2 (2 × ArCH), 123.8 (ArCH), 124.3 (ArCH), 
124.6 (ArCH), 125.4 (ArCH), 126.4 (ArCH), 126.5 (ArCH), 126.7 (2 × ArCH), 126.8 (2 × 
ArCH), 129.8 (ArC), 139.1 (ArC), 140.6 (ArC), 141.8 (ArC), 142.4 (ArC), 158.5 (ArC), 
173.7 (C=O); m/z (TOF MS ES
+
) 398.1768 (100%, MH
+
 C26H24NO3 requires 398.1756). 
Chiral HPLC, CELLULOSE-1, 10% IPA in hexane @ 1.0 mL min
-1
, tR (major) 20.6 min and 
(minor) 23.7 min. 
(3S,3aS,9aR)-2,3,3a,4,9,9a-Hexahydro-3-hydroxy-2-(4-methoxyphenyl)-4,9[1',2']-
benzeno-1H-benz[f]isoindol-1-one 106 
 
Using general procedure A with imide 101 (0.95 g, 2.5 mmol), but purifying the crude 
hydroxy-lactam before conversion to the methoxy aminal gave the title compound as a white 
powder (0.57 g, 60%). [α]D
20
  -105.7 (c 2.54 CHCl3); Mpt 218 – 220 
o
C; vmax (ATR)/cm
-1
 
3318, 3018, 2938, 2834, 1663, 1609, 1587; 
1
H NMR (400 MHz; CDCl3) δH 2.56 (1H, app d, 
J 11.3, OH), 3.06 (1H, ddd, J 9.9, 7.9, 2.8, CH), 3.27 (1H, dd, J 9.9, 3.7, CHCO), 3.76 (3H, s, 
OCH3), 4.81 (1H, d, J 2.8, CH), 4.91 (1H, d, J 3.7, CH), 5.63 (1H, dd, J 11.3, 7.9, NCH), 
6.72 [2H, (AX)2, ArCH], 6.82 [2H, (AX)2, ArCH], 7.19 – 7.24 (4H, m, ArCH), 7.36 – 7.48 
(4H, m, ArCH); 
13
C NMR (100 MHz; CDCl3) δC 42.1 (CH), 44.3 (CH), 46.1 (CH), 49.7 
(CH), 55.4 (CH), 84.5 (OCH3), 114.3 (2 × ArCH), 123.7 (ArCH), 124.3 (ArCH), 124.4 
(ArCH), 126.2 (ArCH), 126.3 (ArCH), 126.5 (ArCH), 126.6 (2 × ArCH), 126.7 (ArCH), 
127.1 (ArCH), 128.4 (ArC), 140.9 (ArC), 141.8 (ArC), 142.4 (ArC), 143.0 (ArC), 158.3 
(ArC), 171.5 (C=O); m/z (TOF MS ES
+
) 384.1600 (100%, MH
+
 C25H22NO3 requires 
384.1600).  
2-(4-Methoxyphenyl)octahydro-4,9[1',2']-benzeno-1H-benz[f]isoindole 111 
 
Using general procedure A the title compound, a white powder, was obtained as a side 
product from 0.95 g (2.5 mmol) of cycloadduct 101 (0.17 g, 19% over 2 steps). Mpt. 100 – 
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102 
o
C; vmax (ATR)/cm
-1
 2947, 2823, 2495, 2161, 2033, 1978, 1512; 
1
H NMR (400 MHz; 
CDCl3) δH  2.48 – 2.51 (2H, m, 2 × CHH), 2.92 – 2.94 (2H, m, 2 × CHH), 3.49 – 3.53 (2H, 
m, 2 × CH), 3.73 (3H, s, ArOCH3), 4.26 [2H, (AX)2, 2 × CH], 6.44 [2H, (AX)2, ArCH], 6.76 
[2H, (AX)2, ArCH], 7.03 – 7.07 (2H, m, ArCH), 7.10 – 7.14 (2H, m, ArCH), 7.23 – 7.27 (2H, 
m, ArCH), 7.31 – 7.33 (2H, m, ArCH); 13C NMR (100 MHz; CDCl3) δC 44.2 (2 × CH), 47.8 
(2 × CH), 52.1 (2 × CH2), 55.8 (CH3), 114.2 (2 × ArCH), 114.6 (2 × ArCH), 123.7 (2 × 
ArCH), 125.6 (2 × ArCH), 125.9 (2 × ArCH), 126.0 (2 × ArCH), 136.6 (ArC), 141.0 (2 × 
ArC), 143.8 (2 × ArC), 151.5 (ArC); m/z (TOF MS ES
+
) 354.1866 (100%, MH
+
 C25H23NO 
requires 354.1858). 
(3R,3aS,9aR)-2,3,3a,4,9,9a-Hexahydro-3-methoxy-2-benzyl-4,9[1',2']-benzeno-1H-
benz[f]isoindol-1-one 108 
 
Using general procedure A with imide 103 (0.91 g, 2.50 mmol) gave the title compound as a 
white powder (0.71 g, 75%). [α]D
20 - 50.2 (c 0.1, CHCl3; 95% ee). Mpt 159 – 160 
o
C; vmax 
(ATR)/cm
-1
 3030, 2953, 2915, 1692; 
1
H NMR (400 MHz; CDCl3) δH 2.67 (1H, ddd, J 9.9, 
3.5, 1.6, CH), 3.20 (3H, s, OCH3), 3.23 (1H, d, J 3.5, CHCO), 3.66 (1H, d, J 14.8, NCHH), 
4.24 (1H, app s, NCH), 4.31 (1H, d, J 3.5, CH), 4.75 (1H, d, J 14.8, NCHH), 4.79 (1H, d, J 
3.5, CH), 6.34 (2H, app d, J 7.2, ArCH), 7.06 – 7.25 (9H, m, ArCH), 7.37 – 7.42 (2H, m, 
ArCH); 
13
C NMR (100 MHz; CDCl3) δC 43.1 (NCH2), 42.6 (CH), 43.1 (CH), 45.5 (CH), 47.3 
(CH), 50.0 (OCH3), 90.5 (CHN), 123.6 (ArCH), 124.1 (ArCH), 124.8 (ArCH), 125.2 
(ArCH), 126.2 (ArCH), 126.4 (ArCH), 126.7 (ArCH), 126.8 (ArCH), 127.0 (ArCH), 127.8 (2 
× ArCH), 128.4 (2 × ArCH), 134.7 (ArC), 139.2 (ArC), 140.6 (ArC), 142.3 (ArC), 142.9 
(ArC), 173.3 (C=O); m/z (TOF MS ES
+
) 382.1812 (100%, MH
+
 C26H24NO2 requires 
382.1807), 368 (10), 350 (20); Chiral HPLC, KROMASIL 3-CELLUCOAT, 10% IPA in 
hexane @ 1.0 mL min
-1
, tR (major) 8.1 min and (minor) 9.7 min. 
(3R,3aS,9aR)-2,3,3a,4,9,9a-Hexahydro-3-methoxy-2-(4-methoxybenzyl)-4,9[1',2']-
benzeno-1H-benz[f]isoindol-1-one 109 
 
Using general procedure A with imide 104 (0.99 g, 2.50 mmol) gave the title compound as a 
white solid (0.40 g, 39%). [α]D
20  - 63.7 (c 0.2, CHCl3; 97% ee). Mpt 189 – 192 
o
C; vmax 
93 
 
(ATR)/cm
-1
 2956, 2838, 1685, 1608, 1583; 
1
H NMR (400 MHz; CDCl3) δH 2.64 (1H, ddd, J 
9.8, 3.1, 1.5, CH), 3.18 – 3.21 (4H, m, OCH3 and CH), 3.58 (1H, d, J 14.7, NCHH), 3.82 
(3H, s, OCH3), 4.21 (1H, app s, NCH), 4.29 (1H, d, J 3.1, CH), 4.67 (1H, d, J 14.7, NCHH), 
4.78 (1H, d, J 3.1, CH), 6.31 [2H, (AX)2, ArCH], 6.66 [2H, (AX)2, ArCH], 7.07 – 7.41 (8H, 
m, ArCH); 
13
C NMR (100 MHz; CDCl3) δC 42.5 (NCH2), 43.0 (CH), 45.5 (CH), 47.3 (CH), 
49.0 (CH), 51.9 (OCH3), 55.3 (ArOCH3), 90.4 (CHN), 113.8 (2 × ArCH), 123.6 (ArCH), 
124.1 (ArCH), 124.8 (ArCH), 125.2 (ArCH), 126.2 (ArCH), 126.4 (ArCH), 126.6 (ArCH), 
126.7 (ArCH), 126.8 (ArC), 129.2 (2 × ArCH), 139.2 (ArC), 140.6 (ArC), 142.3 (ArC), 142.9 
(ArC), 158.6 (ArC), 173.2 (C=O); m/z (TOF MS ES
+
) 412.1896 (100%, MH
+
 C27H26NO3 
requires 412.1913), 398 (20), 380 (10); Chiral HPLC, KROMASIL 3-CELLUCOAT, 10% 
IPA in hexane @ 1.0 mL min
-1
, tR (major) 8.6 min and (minor) 16.6 min. 
 
6.3 Experimental for the synthesis of pyrrolam A 
(3R,3aS,9aR)-2,3,3a,4,9,9a-Hexahydro-3-allyl-2-(p-methoxyphenyl)-4,9[1',2']-benzeno-
1H-benz[f]isoindol-1-one 161 
 
Methoxylactam 107 (2.30 g, 5.79 mmol) was dissolved in dry CH2Cl2 (30 cm
3
) and cooled to 
-78 
o
C. BF3.OEt2 (1.45 cm
3
, 11.6 mmol) and allyltrimethylsilane (1.84 cm
3
, 11.6 mmol) in 
CH2Cl2 (5 cm
3
) were added drop-wise, the solution was allowed to stir at -78 
o
C for 1 hr then 
allowed to warm to rt and stirred for a further 18 hrs. The reaction was quenched by addition 
of cold saturated NaHCO3 (20 cm
3
), extracted with CH2Cl2 (3 × 15 cm
3
) and organic extracts 
dried over MgSO4. After filtration, the solvent was removed in vacuo to give a brown 
powder, which was purified by flash column chromatography eluting with 50% EtOAc : 
petroleum ether (40 - 60), yielding the title compound as white crystals (1.75 g, 74%); [α]D
20 - 
61.0 (c 0.36, CHCl3); Mpt 184 – 185 
o
C; vmax (ATR)/cm
-1 
2933, 1687, 1511; 
1
H NMR (400 
MHz; CDCl3) δH 2.14 – 2.21 (1H, m, CHH), 2.30 – 2.36 (1H, m, CHH), 2.62 (1H, dt, J 9.8, 
3.0, CH), 3.17 (1H, dd, J 9.8, 3.0, CHCO), 3.43 (1H, dt, J 7.5, 3.0, NCH), 3.75 (3H, s, 
OCH3), 4.29 (1H, d, J 3.0, CH), 4.81 (1H, d, J 3.0, CH), 5.10 – 5.19 (2H, m, =CH2), 5.74 
(1H, ddt, J 17.0, 10.3, 7.0, =CH), 6.44 [2H, (AX)2, ArCH], 6.76 [2H, (AX)2, ArCH], 7.16 – 
7.25 (4H, m, ArCH), 7.34 – 7.40 (4H, m, ArCH); 13C NMR (100 MHz; CDCl3) δC 38.4 
(CH2), 41.5 (CH), 46.0 (CHCO), 48.7 (CH), 49.6 (CH), 55.4 (OCH3), 63.8 (NCH), 114.4 (2 × 
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ArCH), 119.5 (=CH2), 123.7 (ArCH), 124.2 (ArCH), 124.8 (ArCH), 125.4 (ArCH), 126.1 
(ArCH), 126.2 (ArCH), 126.3 (ArCH), 126.8 (ArCH), 127.3 (2 × ArCH), 129.8 (ArC), 132.4 
(=CH), 139.7 (ArC), 141.0 (ArC), 142.2 (ArC), 142.6 (ArC), 158.4 (ArC), 173.0 (C=O); m/z 
(EI) 407.1885 (17%, M
+
 C28H25NO2 requires 407.1903), 366 (7), 229 (6), 202 (4), 188 (100), 
178 (89), 176 (10). 
(3R,3aS,9aR)-2,3,3a,4,9,9a-Hexahydro-3-allyl-4,9[1',2']-benzeno-1H-benz[f]isoindol-1-
one 162 
 
N-PMP amide 161 (1.41 g, 3.50 mmol) was dissolved in acetonitrile (100 cm
3
), and cooled to 
0 
o
C. Cerium (IV) ammonium nitrate (5.69 g, 10.5 mmol) in H2O (100 cm
3
) was added drop-
wise over a 3 min period, and the resulting orange solution stirred vigorously at 0 
o
C for 30 
mins. The acetonitrile was removed under reduced pressure and the aqueous layer extracted 
with EtOAc (3 × 25 cm
3
). The combined organic extracts were washed with saturated 
NaHCO3 (25 cm
3
) and 10% sodium sulfite (20 cm
3
 portions) was then added until the organic 
layer was colourless. The organic layer was washed with brine (20 cm
3
), dried over MgSO4 
and filtered. The solvent was removed in vacuo to give a brown solid, which was purified via 
flash column chromatography on silica gel eluting with 70% EtOAc : petroleum ether (40-
60), affording the title compound as a white powder (0.89 g, 84%). [α]D
20  - 40.0 (c 0.2, 
CHCl3); Mpt 186 – 187 
o
C; vmax (ATR)/cm
-1
 3192, 3071, 2934, 1674, 1511; 
1
H NMR (400 
MHz; CDCl3) δH 2.15 – 2.22 (1H, m, CHH), 2.31 – 2.38 (1H, m, CHH), 2.58 (1H, dt, J 10.1, 
3.2, CH), 3.02 (1H, dd, J 10.1, 3.2, CHCO), 3.08 – 3.12 (1H, m, NCH), 4.27 (1H, d, J 3.2, 
CH), 4.70 (1H, d, J 3.2, CH), 5.10 – 5.16 (2H, m, =CH2 and NH), 5.71 (1H, dddd, J 16.9, 
10.4, 7.8, 6.5, =CH), 7.12 – 7.18 (4H, m, ArCH), 7.30 – 7.39 (4H, m, ArCH); 13C NMR (100 
MHz; CDCl3) δC 41.9 (CH2), 45.2 (CH), 45.4 (CHCO), 48.3 (CH), 48.5 (CH), 56.0 (NCH), 
119.1 (=CH2), 123.7 (ArCH), 124.0 (ArCH), 125.0 (ArCH), 125.1 (ArCH), 126.2 (ArCH), 
126.2 (ArCH), 126.3 (ArCH), 126.6 (ArCH), 133.0 (=CH), 139.6 (ArC), 140.6 (ArC), 142.4 
(ArC), 142.7 (ArC), 175.6 (C=O); m/z (TOF MS ES
+
) 302 (100%, MH
+
 C21H20NO), 324 (10, 
M + Na
+
). 
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(3R,3aS,9aR)-2,3,3a,4,9,9a-Hexahydro-3-(3-hydroxypropyl)-4,9[1',2']-benzeno-1H-
benz[f]isoindol-1-one 163 
 
Alkene 162 (1.41 g, 4.6 mmol) was dissolved in dry THF (10 cm
3
) and cooled to 0 
o
C, before 
BH3.THF (7.0 cm
3
, 7.0 mmol) was added drop-wise. The solution was allowed to warm to rt 
and stirred for a further 1 hr. H2O (2 cm
3
) was added to quench any residual borane, followed 
by addition of 1M NaOH (4 cm
3
) and 30% H2O2 (4 cm
3
) and left to stir vigorously for 1 hr. 
The reaction was quenched by addition of saturated NaHCO3 (5 cm
3
) and the product 
extracted using CH2Cl2 (3 × 10 cm
3
). The organic extracts were washed with brine (10 cm
3
), 
dried over MgSO4 and filtered. The solvent was removed in vacuo to give the crude material 
as a white crystalline solid (1.45 g). Full conversion of starting material was observed in the 
1
H NMR spectrum. However, due to difficulties encountered during using silica gel the crude 
material was taken through to the next synthetic step without further purification. Selected 
data; 
1
H NMR (400 MHz; CDCl3) δH 1.53 – 1.70 (4H, m, 2 × CH2), 2.52 (1H, ddd, J 10.0, 
3.2, 3.1, CH), 2.99 (1H, dd, J 10.0, 3.3, CHCO), 3.04 – 3.11 (1H, m, NCH), 3.65 – 3.68 (2H, 
m, CH2OH), 4.25 (1H, d, J 3.1, CH), 4.67 (1H, d, J 3.3, CH), 5.54 (1H, br s, NH), 7.13 – 7.17 
(4H, m, ArCH), 7.29 – 7.35 (4H, m, ArCH). 
(3R,3aS,9aR)-2,3,3a,4,9,9a-Hexahydro-3-[3-(methylsulfonyloxy)propyl]-4,9[1',2']-
benzeno-1H-benz[f]isoindol-1-one 164 
 
Crude alcohol 163 (1.45 g, ~ 4.55 mmol) in dry CH2Cl2 (15 cm
3
) was cooled to - 10 
o
C. NEt3 
(1.60 cm
3
, 11.38 mmol) and DMAP (0.06 g, ~ 0.5 mmol) were added to the cold solution and 
the reaction left to stir for 10 mins. Methanesulfonyl chloride (0.50 cm
3
, 5.92 mmol) was 
added and the solution was stirred for a further 1 hr at -10 
o
C. The reaction was quenched by 
careful addition of H2O (5 cm
3
) and 1M HCl (5 cm
3
). The product was extracted with CH2Cl2 
(3 × 10 cm
3
), the organic extracts were washed with saturated NaHCO3 (10 cm
3
) and brine 
(10 cm
3
), and dried over MgSO4. After filtration, the solvent was removed in vacuo to give a 
brown powder 1.67 g. Full conversion of the starting material was observed in the 
1
H NMR 
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spectrum but this compound could not be purified on silica gel and it was taken forward to 
the next synthetic step without further purification. Selected data; 
1
H NMR (400 MHz; 
CDCl3) δH 1.41 – 1.50 (1H, m, CHH), 1.63 – 1.81 (3H, m, CHH  + CH2), 2.52 (1H, ddd, J 
10.1, 3.2, 3.1, CH), 2.97–3.12 (5H, m, CHCO + NCH + SO3CH3), 4.22 – 4.27 (3H, m, CHH 
+ CH2SO3Me), 4.68 (1H, d, J 3.5, CHH), 5.43 (1H, br s, NH), 7.12 – 7.16 (4H, m, ArCH), 
7.29 – 7.35 (4H, m, ArCH). 
(3R,3aS,9aR)-2,3,3a,4,9,9a-Octahydro-(4R), 9-[1’, 2’]-benzeno-1H-benz-[f]-isoindolin-
[2,3]-pyrrolidin-1-one 165 
 
Crude mesylate 164 (1.67 g, ~ 4.21 mmol) was dissolved in EtOH (50 cm
3
) and treated with 
DBU (0.80 cm
3
, 5.47 mmol). The mixture was heated at reflux for 24 hrs, cooled to rt, after 
which 1M HCl (10 cm
3
) was added. The mixture was extracted with CH2Cl2 (3 × 15 cm
3
), the 
combined organic extracts dried over MgSO4 and filtered. The solvent was removed in vacuo 
and the product purified by flash column chromatography eluting with 70% EtOAc : 
petroleum ether (40-60). This gave the title compound as a white powder (0.21 g, 20% over 
three steps). [α]D
20 - 67.7 (c 0.16, CHCl3); Mpt 226 – 228 
o
C; vmax (ATR)/cm
-1
 2955, 2868, 
1688; 
1
H NMR (400 MHz; CDCl3) δH 1.14 – 1.25 (1 H, m, NCHH), 1.72 – 1.82 (1H, m, CH), 
1.93 – 2.06 (2H, m, 2 × CHH), 2.65 – 2.71 (2H, m, 2 × CHH), 3.12 – 3.17 (2H, m, 2 × CHH), 
3.45 (1H, dt, J 11.7, 8.3, 1 × NCHH), 4.35 (1H, d, J 3.2, CH), 4.71 (1H, d, J 3.2, CH), 7.11 – 
7.17 (4H, m, ArCH), 7.30 – 7.37 (4H, m, ArCH); 13C NMR (100 MHz; CDCl3) δC 25.0 
(CH2), 31.6 (CH2), 41.4 (NCHH), 42.9 (CH), 45.8 (CH), 48.3 (CH), 53.0 (NCH), 64.5 
(CHCO), 123.7 (ArCH), 123.9 (ArCH), 125.0 (ArCH), 125.1 (ArCH), 126.0 (ArCH), 126.1 
(ArCH), 126.2 (ArCH), 126.6 (ArCH), 140.1 (ArC), 140.7 (ArC), 142.7 (ArCH), 142.8 
(ArC), 174.8 (C=O); m/z (TOF MS ES
+
) 302 (100%, MH
+
 C21H20NO), 324 (10, M + Na
+
). 
(5R)-Azabicyclo[3.3.0]oct-3-en-2-one [(R)-pyrrolam A] 112 
 
Lactam 165 (0.20 g, 0.66 mmol) was subjected to flash vacuum pyrolysis (inlet temperature 
226 
o
C, furnace temperature 490 
o
C, pressure 1 × 10
-2
 mbar) for 30 mins. The crude material 
was collected in the u-tube (0.19 g). Purification by flash column chromatography eluting 
with 70% EtOAc : Petrol (40 - 60 
o
C) on silica gel gave the title compound as a white solid 
which slowly decomposes to yellow oily mixtures when left for 48 hours (0.06 mg, 69% 
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yield). Mpt 59 – 61 oC (Lit.88 59 oC); [α]D
20
  - 23.3 (c 0.9, CHCl3; 94% ee) lit.
88
 -29.3 (c 1.0, 
CHCl3); vmax (ATR) / cm
-1
  3077, 2969, 2951, 2896, 2875, 1669;  
1
H NMR (400 MHz; 
CDCl3) δH 1.14 ‒ 1.23 (1H, m, 1 × CH), 2.08 ‒ 2.15 (1H, m, 1 × CH), 2.23 ‒ 2.41 (2H, m, 
CH2), 3.31 (1H, ddd, J 11.0, 8.8, 2.3, 1 × CHH), 3.50 (1H, dt, J 11.0, 8.9, 1 × CHH), 4.29 
(1H, dd, J 10.4, 6.0, CH), 6.06 (1H, dd, J 5.7, 1.6, =CH), 7.22 (1H, dd, J 5.7, 1.5, =CH) ; 
13
C 
NMR (100 MHz; CDCl3) δC 29.0 (CH2), 29.9 (CH2), 41.9 (CH2N), 67.8 (CHN), 128.5 
(CH=C), 148.8 (C=CH), 175.6 (C=O) . m/z (TOF MS ES
+
) 124 (100%, MH
+
 C7H10NO), 146 
(50 M + Na
+
). Chiral HPLC, Lux 3u CELLULOSE-1, 10% IPA in hexane @ 1.0 mL min
-1
, tR 
(minor) 10.3 min and (major) 11.7 min. All data are in accordance with literature.
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6.4 Experimental for the synthesis of glutarimides 
General Procedure B for the synthesis of 3-(substitutedphenyl)glutaric acids.
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B-1 Synthesis of benzylidenemalonate from 3-(o-Substituted)benzaldehydes 
 
AlCl3 (0.1 equiv.) was slowly added to a mixture of 2-substituted benzaldehyde and 
diethylmalonate (2 equiv.) and stirred at room temperature for 24 h. The mixture was poured 
into an ice-water / conc. HCl solution mixture (25 : 5 cm
3
) and extracted with CH2Cl2 (3 × 15 
cm
3
). The combined organic extracts were dried over MgSO4 and filtered. The solvent was 
removed in vacuo and excess diethylmalonate was removed by vacuum distillation (130 
o
C, 
9.5 × 10
-1
 mbar) to give the crude diethyl 2-substitutedbenzylidenemalonate which was taken 
to next step (B-3) without further purification. 
B-2 Synthesis of benzylidenemalonate from 3-(p-Substituted)benzaldehydes 
 
 
A solution of p-substituted benzaldehyde in toluene (10 cm
3
) was added drop-wise to a 
mixture of AlCl3 (0.1 equiv.) and diethylmalonate (2 equiv.) in toluene (10 cm
3
) and stirred at 
room temperature for 24 h. The mixture was poured into an ice-water / conc. HCl solution 
mixture (25 : 5 cm
3
) and extracted with CH2Cl2 (3 × 25 cm
3
). The combined organic extracts 
were dried over MgSO4 and filtered. The solvent was removed in vacuo and excess 
diethylmalonate was removed by vacuum distillation (130 
o
C, 9.5 × 10
-1
 mbar) to give crude 
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diethyl 4-substitutedbenzylidenemalonate as oily residue which was taken to next step (B-3) 
without further purification. 
B-3 Synthesis of substitutedbenzylidene dimalonate 
 
AlCl3 (0.05 equiv.) was slowly added to a mixture of the crude benzylidenemalonate 
(obtained from procedure B-1 or B-2 above) and diethylmalonate (1 equiv.) and stirred at 60 
o
C for 24 h. Another portion of AlCl3 (0.05 equiv.) was slowly added to the mixture and the 
reaction temperature was raised to 70 
o
C and further stirred for additional 24 h. The mixture 
was allowed to cool to room temperature, poured into an ice / conc. HCl solution mixture (25 
: 5 cm
3
) and extracted with CH2Cl2 (3 × 25 cm
3
). The combined organic extracts were dried 
over MgSO4 and filtered. The solvent was removed in vacuo and excess diethylmalonate was 
removed by vacuum distillation (130 
o
C, 9.5 × 10
-1
 mbar) to give the crude tetraethyl 2-(ortho 
or para substituted phenyl)propane-1,1,3,3-tetracarboxylate as oily residue which was taken 
to the next synthetic step without further purification. 
B-4 Synthesis of 3-(substitutedphenyl) glutaric acids  
 
 The crude benzylidene dimalonate (obtained in B-3 above) in conc. HCl (10 cm
3
) was heated 
at reflux for 24 h. The conc. HCl was evaporated to about 4 cm
3
 and fresh conc. HCl (10 cm
3
) 
was added and further heated at reflux for additional 24 h. The mixture was allowed to cool 
to room temperature, the solid was filtered off and recrystallised from EtOAc / petrol (40 – 
60 
o
C). 
3-(2-Fluorophenyl)pentan-1,5-dioic acid 188 
 
Using general procedure B-1 starting with (8.250 g, 66.47 mmol) of 2-fluorobenzaldehyde 
and diethylmalonate (20.20 cm
3
, 132.9 mmol), the crude diethyl 2-
fluorobenzylidenemalonate (17.00 g) was obtained as a yellow liquid which was not purified. 
Selected data;
 1
H NMR (400 MHz; CDCl3) δH 1.16 ‒ 1.21 (6H, m, 2 × CH3), 4.22 (4H, qd, J 
7.1, 1.2, 4 × CHH), 7.00 ‒ 7.07 (2H, m, ArCH), 7.28 ‒ 7.34 (1H, m, ArCH), 7.38 [1H, (AX)2, 
99 
 
ArCH], 7.83 (1H, s, =CH). This material was subjected to general procedure B-3, the 
tetraethyl 2-(2-fluorophenyl)propane-1,1,3,3-tetracarboxylate (23.29 g) was obtained as a 
yellow liquid.
 1
H NMR (400 MHz; CDCl3) δH 0.90 (6H, t, J 7.1, 2 × CH3), 1.11 (6H, t, J 7.1, 
2 × CH3), 3.82 (4H, q, J 7.1, 2 × CH2), 3.98 – 4.06 [6H, m,  2 × CH2 and 2 × CH(CO)2],  4.36 
(1H, t, J 9.4, CH), 6.83 – 6.88 (1H, m, ArCH), 6.90 – 6.94 (1H, m, ArCH), 7.07 – 7.12 (1H, 
m, ArCH), 7.28 – 7.32 (1H, m, ArCH); 13C NMR (100 MHz; CDCl3) δC  13.7 (2 × CH3), 13.9 
(2 × CH3), 38.3 (CH), 54.4 (2 × CH), 61.4 (2 × CH2), 61.7 (2 × CH2), 115.4 (d, J C-F 22.9, 
ArCH), 123.8 (d, J C-F 3.3, ArCH), 124.8 (d, J C-F 14.6, ArC), 129.5 (d, J C-F 8.6, ArCH), 
131.6 (ArCH), 161.2 (d, J C-F 248, ArC), 167.4 (2 × C=O), 167.8 (2 × C=O). This material 
was subjected to procedure B-4 to give a brown solid that was purified by recrystallisation 
from EtOAc / petrol (40 – 60 oC) giving the title compound as white crystals (7.660 g, 51% 
over 3 steps). Mpt 140 – 142 oC; (Found: C, 58.23; H, 4.96. C12H14O4 requires C, 58.41; H, 
4.90); υmax (ATR)/cm
-1
 2890 (broad), 1693, 1585; 
 1H NMR (400 MHz; DMSO) δH 2.58 (2H, 
dd, J 15.9, 8.5, 2 × CHH), 2.66 (2H, dd, J 15.9, 6.6, 2 × CHH), 3.73 (1H, quintet, J 7.0, CH), 
7.09 – 7.15 (2H, m, ArCH), 7.21 – 7.27 (1H, m, ArCH), 7.37 (1H, td, J 7.7, 1.5, ArCH), 
12.16 (2H, s, 2 × OH); 
13
C NMR (100 MHz; DMSO) δC  31.8 (CH), 39.4 (2 × CH2), 115.8 (d, 
J C-F 22.5, ArCH), 124.7 (d, J C-F 2.9, ArCH), 128.7 (d, J C-F 8.4, ArCH), 129.5 (d, J C-F 4.5, 
ArCH), 130.4 (d, J C-F 14.2, ArC), 160.7 (d, J C-F 244.2, ArC), 173.1 (2 × C=O); m/z (TOF 
MS ES
+
) 227 (70%, MH
+
 C11H12FO4), 209 (100). 
3-(4-Fluorophenyl)pentan-1,5-dioic acid 189 
 
Using general procedure B-2 starting with (10.00 g, 80.57 mmol) of 4-fluorobenzaldehyde 
and diethylmalonate (24.50 cm
3
, 161.1 mmol), the crude diethyl 4-
fluorobenzylidenemalonate (18.22 g) was obtained as a yellow liquid which was not purified. 
Selected data;
 1
H NMR (400 MHz; CDCl3) δH 0.90 (3H, t, J 7.1, CH3), 1.08 (3H, t, J  7.1, 
CH3), 4.16 (2H, q, J  7.1, CH2), 4.21 (2H, q, J 7.1, CH2), 6.82 [2H, (AX)2, ArCH], 7.35 [2H, 
(AX)2, ArCH], 7.56 (1H, s, =CH). This material was subjected to general procedure B-3, and 
the crude tetraethyl 2-(4-fluorophenyl)propane-1,1,3,3-tetracarboxylate (23.29 g) was 
obtained as a yellow liquid which was not purified at this stage. Selected data; 
 1
H NMR (400 
MHz; CDCl3) δH   0.89 (6H, t, J 7.1, 2 × CH3), 1.08 (6H, t, J 7.1, 2 × CH3), 3.82 (4H, q, J 7.1, 
2 × CH2), 3.94 – 4.02 (7H, m, 2 × CH2 and 3 × CH),  6.80 (2H, app t, J 8.7, 2 × ArCH), 7.24 
[2H, (AX)2, ArCH]. This material was subjected to procedure B-4, to give a brown solid that 
100 
 
was purified by recrystallisation from EtOAc / petrol (40 – 60 oC) giving the title compound 
as white crystals (9.881 g, 55% over 3 steps). Mpt 145 – 147 oC (lit.103, 131 146 – 147 oC); 
(Found: 58.36; H, 4.65. C11H11FO4 requires C, 58.41; H, 4.90); υmax (ATR)/cm
-1
 2914 
(broad), 2672, 1708, 1604, 1509; 
 1H NMR (400 MHz; DMSO) δH 2.51 (2H, dd, J 15.8, 8.8,  
2 × CHH), 2.65 (2H, dd, J 15.8, 6.2,  2 × CHH), 3.37 – 3.45 (1H, m, CH), 7.10 (2H, app t, J 
8.8, ArCH), 7.31 [2H, (AX)2, ArCH], 12.11 (2H, bs, 2 × OH); 
13
C NMR (100 MHz; DMSO) 
δC  37.7 (CH), 40.6 (2 × CH2), 115.3 (d, J C-F 21.0, 2 × ArCH), 129.8 (d, J C-F 7.8, 2 × ArCH), 
140.0 (d, J C-F 2.6, ArC), 161.3 (d, J C-F 241.9, ArC), 173.2 (2 × C=O); m/z (TOF MS ES
+
) 
227 (30%, MH
+
 C11H12FO4), 250 (20%, MH
+
 + Na), 209 (100). All data are in accordance 
with literature. 
3-(2-Methylphenyl)pentan-1,5-dioic acid 190 
 
 
Using general procedure B-1 starting with (9.350 g, 77.82 mmol) of 2-methylbenzaldehyde 
and diethylmalonate (23.60 cm
3
, 155.6 mmol), the crude diethyl 2-
methylbenzylidenemalonate (17.00 g) was obtained as a yellow liquid, which was not 
purified. Selected data;
 1
H NMR (400 MHz; CDCl3) δH 1.05 (3H, t, J 7.1, CH3), 1.22 (3H, t, J 
7.1, CH3), 2.24 (3H, s, CH3), 4.10 (2H, q, J 7.1, CH2), 4.20 (2H, q, J 7.1, CH2),  7.02  – 7.09 
(2H, m, ArCH), 7.15 (1H, app td, J 7.5, 1.2, ArCH), 7.26 (1H, d, J 7.5, ArCH), 7.87 (1H, s, 
=CH). This material was subjected to procedure B-3, and the crude tetraethyl 2-(2-
methylphenyl)propane-1,1,3,3-tetracarboxylate (15.90 g) was obtained as a yellow liquid 
which was not purified at this stage. Selected data; 
 1
H NMR (400 MHz; CDCl3) δH 0.89 (6H, 
t, J 7.1, 2 × CH3), 1.17 (6H, t, J 7.1, 2 × CH3), 2.42 (3H, s, CH3), 3.80 (4H, q, J 7.1, 2 × CH2), 
3.96 [2H, d, J 9.5, 2 × CH(CO)2],  4.03 – 4.11 (4H, m, 2 × CH2), 4.51 (1H, t, J 9.5, CH), 7.00 
– 7.06 (3H, m, ArCH), 7.18 (1H, d, J 6.8, ArCH). This material was subjected to general 
procedure B-4 to give a brown solid that was purified by recrystallisation from EtOAc / petrol 
(40 – 60 oC) giving the title compound as white crystals (8.942 g, 52% over 3 steps). Mpt 154 
– 156 oC; (Found: 64.71; H, 6.46. C12H14O4 requires C, 64.85; H, 6.35); υmax (ATR)/cm
-1
 
2971 (broad), 1708; 
 1H NMR (400 MHz; DMSO) δH 2.37 (3H, s, CH3), 2.49 – 2.63 (4H, m, 2 
× CH2), 3.69 – 3.76 (1H, m, CH), 7.04 – 7.16 (3H, m, ArCH), 7.27 (1H, d, J 7.6, ArCH), 
12.60 (2H, s, 2 × OH); 
13C NMR (100 MHz; DMSO) δC  19.7 (CH3), 33.2 (CH), 40.5 (2 × 
101 
 
CH2), 126.2 (ArCH), 126.4 (ArCH), 126.5 (ArCH), 130.5 (ArCH), 136.2 (ArC), 142.3 (ArC), 
173.4 (2 × C=O); m/z (TOF ES
-
) 221 (100%, M-H
-
).  
3-(4-Methylphenyl)pentan-1,5-dioic acid 191 
 
 
Using general procedure B-2 starting with (10.00 g, 83.23 mmol) of 4-methylbenzaldehyde 
and diethylmalonate (25.30 cm
3
, 166.5 mmol), the crude diethyl 4-
methylbenzylidenemalonate (17.23 g) was obtained as a yellow liquid, which was not 
purified. This material was subjected to procedure B-3, and the crude tetraethyl 2-(4-
methylphenyl)propane-1,1,3,3-tetracarboxylate (25.20 g) was obtained as a yellow liquid 
which was not purified at this stage. Selected data; 
 1
H NMR (400 MHz; CDCl3) δH 0.98 (6H, 
t, J 7.1, 2 × CH3), 1.18 (6H, t, J 7.1, 2 × CH3), 2.22 (3H, s, CH3), 3.90 (4H, q, J 7.1, 2 × CH2), 
4.02  – 4.15 (7H, m, 2 × CH2 and 3 × CH), 7.0 (2H, d, J 8.0, 2 × ArCH), 7.17 (2H, d, J 8.0, 2 
× ArCH). This material was subjected to general procedure B-4 to give a brown solid that 
was purified recrystallisation from EtOAc / petrol (40 – 60 oC) giving the title compound as 
white crystals (10.55 g, 57% over 3 steps). Mpt 122 – 124 oC (lit.132 118 ‒ 121 oC); (Found: 
64.85; H, 6.13. C12H14O4 requires C, 64.85; H, 6.35); υmax (ATR)/cm
-1
 2925 (broad), 1704, 
1515; 
 1H NMR (400 MHz; DMSO) δH 2.25 (3H, s, CH3), 2.48 (2H, dd, J 15.7, 8.7, 2 × 
CHH), 2.62 (2H, dd, J 15.7, 6.3, 2 × CHH), 3.34 – 3.41 (1H, m, CH), 7.07 (2H, d, J 8.0, 2 × 
ArCH), 7.14 (2H, d, J 8.0, 2 × ArCH), 12.06 (2H, s, 2 × OH); 
13
C NMR (100 MHz; DMSO) 
δC 21.1 (CH3), 38.0 (CH), 40.7 (2 × CH2), 127.8 (2 × ArCH), 129.2 (2 × ArCH), 135.8 (ArC), 
140.8 (ArC), 173.3 (2 × C=O); m/z (TOF MS ES
+
) 223 (10%, MH
+
), 205 (100, MH
+
 - H2O). 
All data are in accordance with literature. 
3-(1-Naphthyl)pentan-1,5-dioic acid 192 
 
 
Using general procedure B-1 starting with (10.35 g, 66.27 mmol) of 1-naphthaldehyde and 
diethylmalonate 20.12 cm
3
 (132.5 mmol), the crude diethyl 1-naphthylidenemalonate (19.25 
g) was obtained as a pale yellow liquid, which was not purified. Selected data;
 1
H NMR (400 
102 
 
MHz; CDCl3) δH   
1
H NMR (400 MHz; CDCl3) δH 1.06 (3H, t, J 7.1, CH3), 1.38 (3H, t, J 7.1, 
CH3), 4.18 (2H, q, J 7.1, CH2), 4.38 (2H, q, J 7.1, CH2), 7.42 (1H, t, J 7.8, ArCH), 7.49 – 
7.56 (2H, m, ArCH), 7.61 (1H, d, J 7.8, ArCH), 7.83 – 7.87 (2H, m, ArCH), 8.00 (1H, d, J 
7.8, ArCH), 8.50 (1H, s, =CH). This material was subjected to procedure B-3, and the crude 
tetraethyl 2-(1-naphthyl)propane-1,1,3,3-tetracarboxylate (32.56 g) was obtained as dark 
brown liquid which was not purified at this stage. Selected data; 
 1
H NMR (400 MHz; CDCl3) 
δH 0.73 (6H, t, J 7.1, 2 × CH3), 1.17 (6H, t, J 7.1, 2 × CH3), 3.67 – 3.76 (4H, m,  2 × CH2), 
4.06 – 4.14 (4H, m,  2 × CH2),  4.24 [2H, d, J 9.0, 2 × CH(CO)2], 5.25 (1H, t, J 9.0, CH), 
7.37 (1H, t, J 7.7, ArCH), 7.43 (1H, t, J 7.7, ArCH), 7.51 – 7.56 (2H, m, ArCH), 7.70 (1H, d, 
J 8.1, ArCH), 7.76 (1H, d, J 8.1, ArCH), 8.41 (1H, d, J 8.1, ArCH). This material was 
subjected to general procedure B-4 to give a brown solid that was purified recrystallisation 
from EtOAc / petrol (40 – 60 oC) giving the title compound as white crystals (10.20 g, 60% 
over 3 steps). Mpt 185 – 187 oC (lit.133 181.5 oC); (Found: C, 69.64; H, 5.39. C15H14O4 
requires C, 69.76; H, 5.46); υmax (ATR)/cm
-1
 2904 (broad), 1707, 1599, 1511;
 1
H NMR (400 
MHz; DMSO) 2.76 (4H, d, J 7.2, 2 × CH2), 3.39 (1H, quintet, J 7.2, CH), 7.46 – 7.62 (4H, m, 
ArCH), 7.80 (1H, d, J 7.8, ArCH), 7.93 (1H, d, J 8.1, ArCH), 8.21 (1H, d, J 8.6, ArCH), 
12.17 (2H, s, 2 × OH); 
13C NMR (100 MHz; DMSO) δC 38.0 (CH), 40.3 (2 × CH2), 123.5 
(ArCH), 123.7 (ArCH), 125.9 (ArCH), 126.0 (ArCH), 126.6 (ArCH), 127.3 (ArCH), 129.2 
(ArCH), 131.5 (ArC), 134.0 (ArC), 140.0 (ArC), 173.4 (2 × C=O); m/z (TOF MS ES
‒
) 257 
(100%, M-H
-
 C15H13O4). 
3-Isopropylpentan-1,5-dioic acid 194 
 
 
Piperidine (1.180 g, 13.86 mmol) was added to a mixture of isobutyraldehyde (10.00 g, 138.7 
mmol) and diethylmalonate (22.21 g, 138.7 mmol) dissolved in pyridine (25 cm
3
) and stirred 
at 70 
o
C for 48 h. The mixture was cooled to room temperature and ethyl acetate (150 cm
3
) 
was added, washed with 1M HCl (4 × 20 cm
3
), then brine (20 cm
3
), dried over MgSO4 and 
filtered. The solvent was removed in vacuo to give crude diethyl isopropylidenemalonate 
(21.53 g) as a yellow oily residue which was not purified. This material was subjected to 
procedure B-3, and the crude tetraethyl 2-isopropylpropane-1,1,3,3-tetracarboxylate (25.56 g) 
was obtained as an oily residue which was not purified at this stage. This material was 
subjected to general procedure B-4 but the final acidic mixture, after allowing to cool to room 
temperature, was poured in to ice / water mixture (50 cm
3
) and extracted with ether (4 × 30 
103 
 
cm
3
). The combined ethereal portions were washed with water, dried over MgSO4, filtered 
and solvent evaporated in vacuo to obtain a dark brown liquid which upon standing in fridge 
turned to brown solid. Purification by recrystallisation from EtOAc / petrol (40 – 60 oC) gave 
the title compound as white crystals (8.211 g, 34% over 3 steps). Mpt 94 – 96 oC (lit.134 100 – 
101 
o
C); (Found: 55.14; H, 8.16. C8H14O4 requires C, 55.16; H, 8.10); υmax (ATR)/cm
-1
 2966 
(broad), 2160, 1692; 
1H NMR (400 MHz; DMSO) δH 0.82 (6H, d, J 6.9,  2 × CH3), 1.70 (1H, 
pent d, J 6.9, 3.4, CH), 2.10 – 2.15 (3H, m, 2× CHH and CH), 2.19 – 2.26 (2H, m, 2 × CHH), 
12.10 (2H, bs, 2 × OH); 
13
C NMR (100 MHz; DMSO) δC 19.2 (2 × CH3), 29.9 (CH), 35.9 (2 
× CH2), 37.5 (CH), 174.5 (2 × C=O); m/z (TOF MS ES
+
) 198 (40%, M + Na
+
), 175 (30, MH
+
 
C8H15O4), 157 (100). Only melting point and 
1
H NMR were given in literature. 
3-tert-Butylpentan-1,5-dioic acid 195 
 
A mixture of trimethylacetaldehyde (10.00 g, 116.3 mmol), ethylcyanoacetate (13.14 g, 116.3 
mmol) and piperidine (0.100 cm
3
, 1.163 mmol) in toluene (40 cm
3
) was heated at reflux for 4 
hours and allowed to cool to room temperature. The solvent was removed in vacuo and the 
residue was dissolved in CH2Cl2 (30.00 cm
3
), dried over MgSO4 and filtered. The solvent 
was evaporated in vacuo to give an orange oily residue (20.70 g) which was added to a 
solution of dimethylsodiomalonate [made from dimethylmalonate (15.35 g, 116.3 mmol) and 
sodium (0.268 g, 11.63 mmol) in dry MeOH (20 cm
3
)]. The mixture was heated at reflux for 
17 hours, allowed to cool to room temperature and acidified with 1M HCl (15 cm
3
). The 
mixture was then extracted with ether (5 × 60 cm
3
) and the combined ethereal fractions were 
washed with water (60 cm
3
), dried over MgSO4 and filtered. The ether was evaporated under 
reduced pressure to give the crude cyanotricarboxylate as orange oil (29.60 g). The crude 
cyanotricarboxylate (29.60 g, ~ 94.57 mmol) in conc. HCl (10 cm
3
) was heated at reflux for 
24 h. The conc. HCl was evaporated to about 4 cm
3
 and fresh conc. HCl (10 cm
3
) was added. 
The reaction mixture was again heated at reflux for additional 24 h. The mixture was allowed 
to cool to room temperature, poured in to ice / water mixture (50 cm
3
) and extracted with 
ether (5 × 30 cm
3
). The combined ethereal portions were washed with water, dried over 
MgSO4, filtered and solvent evaporated in vacuo to obtain a dark brown liquid as crude 
which upon standing in fridge turned to brown solid. Purification by recrystallisation from 
EtOAc / hexane gave the title compound as white crystals (12.76 g, 58% over 3 steps). Mpt 
146 – 148 oC (lit.52 144.5 – 145.5 oC); υmax (ATR)/cm
-1
 2966 (broad), 2671, 1704; 
1
H NMR 
(400 MHz; CDCl3) δH 0.96 (9H, s, 3 × CH3), 2.15 – 2.22 (2H, m, 2 × CHH), 2.32 (1H, tt, J 
104 
 
9.7, 1.8, CH), 2.66 (2H, dd, J 14.2, 1.8, 2 × CHH), 12.36 (2H, bs, 2 × OH); 
13
C NMR (100 
MHz; CDCl3) δC  27.3 (3 × CH3), 33.1 (C), 36.1 (2 × CH2), 42.4 (CH), 180.9 (2 × C=O); m/z 
(TOF MS ES
+
) 189.1130 (100%, MH
+
 C9H17O4 requires 189.1127). Only melting point and 
IR were provided in the literature.
52,
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General Procedure C for the synthesis of glutaric anhydrides.
67
  
A mixture of glutaric acid in acetyl chloride (30 cm
3
) was heated at reflux for 48 h. The 
mixture was cooled to room temperature and the acetyl chloride was removed in vacuo to 
give brown liquid which was purified by recrystallisation. 
4-Phenyldihydropyran-2,6-dione 172 
 
 
Using general procedure C starting with commercially available 3-phenylglutaric acid (4.10 
g, 0.02 mol), the title compound was obtained as white crystals by recrystallisation from 
EtOAc / hexane (3.22 g, 84%). Mpt 104 – 106 oC (lit.52, 136 104 – 105 oC); υmax (ATR)/cm
-1
 
1812, 1752; 
 1
H NMR (400 MHz; CDCl3) δH 2.90 (2H, dd, J 17.5, 11.5, 2 × CHH), 3.11 (2H, 
dd, J 17.5, 4.3, 2 × CHH), 3.42 (1H, tt, J 11.5, 4.3 CH), 7.21 – 7.24 (2H, m, ArCH), 7.34 – 
7.45 (3H, m, ArCH); 
13
C NMR (100 MHz; CDCl3) δC 34.1 (CH), 37.2 (2 × CH2), 126.2 (2 × 
ArCH), 128.2 (ArCH), 129.4 (2 × ArCH), 139.1 (ArC), 165.8 (C=O); m/z (TOF MS ES
+
) 191 
(100%, MH
+
 C11H11O3). All data are in accordance with the literature.
52,
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4-(2-Fluorophenyl)dihydropyran-2,6-dione 201 
 
 
Using general procedure C starting with glutaric acid 188 (3.00 g, 13.3 mmol), the title 
compound was obtained as white crystals by recrystallisation from EtOAc / petrol (40 – 60 
o
C) (2.00 g, 73%). Mpt 84 – 86 oC; υmax (ATR)/cm
-1
 2914, 1812, 1754, 1710, 1586; 
 1
H NMR 
(400 MHz; CDCl3) δH 2.99 (2H, dd, J 17.2, 11.2, 2 × CHH), 3.13 (2H, dd, J 17.2, 4.2, 2 × 
CHH), 3.66 ‒ 3.73 (1H, m, CH), 7.11 – 7.21 (3H, m, ArCH), 7.33 – 7.38 (1H, m, ArCH); 13C 
105 
 
NMR (100 MHz; CDCl3); δC 28.9 (CH), 35.5 (2 × CH2), 116.3 (d, J C-F 21.8, ArCH), 125.0 
(d, J C-F 3.4, ArCH), 126.0 (d, J C-F 13.3, ArC), 127.2 (d, J C-F 3.8, ArCH), 129.9 (d, J C-F 8.5, 
ArCH), 160.7 (d, J C-F 246.6, ArC), 165.7 (2 × C=O); m/z (EI
+
)  208.0544 (30%, M
+
 
C11H9FO3 requires 208.0536), 123 (25), 122 (100), 96 (20). 
4-(4-Fluorophenyl)dihydropyran-2,6-dione 202 
 
Using general procedure C starting with glutaric acid 189 (2.50 g, 11.1 mmol), the title 
compound was obtained as white crystals by recrystallisation from EtOAc / petrol (40 – 
60
o
C) (1.96 g, 85%). Mpt 84 – 86 oC (lit.103 98.5 – 99 oC); (Found: C, 63.22; H, 4.08. 
C11H9FO3 requires C, 63.46; H, 4.36); υmax (ATR)/cm
-1
 1806, 1755, 1717, 1606, 1512; 
 1
H 
NMR (400 MHz; CDCl3) δH 2.86 (2H, dd, J 17.4, 11.4, 2 × CHH), 3.13 (2H, dd, J 17.4, 4.4, 2 
× CHH), 3.45 (1H, tt, J 11.4, 4.4, CH), 7.09 – 7.14 (2H, m, ArCH), 7.18 – 7.23 (2H, m, 
ArCH); 
13
C NMR (100 MHz; CDCl3); δC 33.5 (CH), 37.3 (2 × CH2), 116.4 (d, J C-F 21.6, 2 × 
ArCH), 127.9 (d, J C-F 8.1, 2 × ArCH), 134.8 (d, J C-F 3.2, ArC), 162.3 (d, J C-F 248.5, ArC), 
165.6 (2 × C=O); m/z (EI
+
) 208 (40%, M
+
 C11H9FO3), 123 (30), 122 (100). All data are in 
accordance with literature.
103,
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4-(2-Methylphenyl)dihydropyran-2,6-dione 203 
 
 
Using general procedure C starting with glutaric acid 190 (3.00 g, 13.5 mmol), the title 
compound was obtained as white crystals by recrystallisation from EtOAc / hexane (2.07 g, 
75%). Mpt 103 – 105 oC (lit.137 106 – 109 oC); υmax (ATR)/cm
-1
 1808, 1749, 1712; 
 1
H NMR 
(400 MHz; CDCl3) δH 2.39 (3H, s, CH3), 2.86 (2H, dd, J 17.4, 11.6, 2 × CHH), 3.08 (2H, dd, 
J 17.4, 4.4, 2 × CHH), 3.65 (1H, tt, J 11.6, 4.4, CH), 7.13 (1H, d, J 6.9, ArCH), 7.24 – 7.31 
(3H, m, ArCH); 
13
C NMR (100 MHz; CDCl3) δC 19.3 (CH3), 30.1 (CH), 36.6 (2 × CH2), 
124.1 (ArCH), 127.1 (ArCH), 127.9 (ArCH), 131.4 (ArCH), 135.6 (ArC), 137.2 (ArC), 166.1 
106 
 
(2 × C=O). m/z (EI
+
) 204.0792 (40%, MH
+
 C12H13O3 requires 204.0786), 144 (60), 118 
(100), 117 (75). All data are in accordance with literature. 
4-(4-Methylphenyl)dihydropyran-2,6-dione 204 
 
 
Using general procedure C starting with glutaric acid 191 (7.00 g, 31.5 mmol), the title 
compound was obtained as white crystals by recrystallisation from EtOAc / petrol (40 – 
60
o
C) (6.0 g, 93%). Mpt 136 – 138 oC; υmax (ATR)/cm
-1 
1806, 1753, 1518; 
 1
H NMR (400 
MHz; CDCl3) δH 2.37 (3H, s, CH3), 2.87 (2H, dd, J 17.4, 11.4, 2 × CHH), 3.12 (2H, dd, J 
17.4, 4.5, 2 × CHH), 3.41 (1H, tt, J 11.4, 4.5, CH), 7.11 (2H, d, J 8.0, ArCH), 7.22 (2H, d, J 
8.0, ArCH); 
13
C NMR (100 MHz; CDCl3); δC 21.0 (CH3), 33.7 (CH), 37.3 (2 × CH2), 126.1 
(2 × ArCH), 130.0 (2 × ArCH), 136.1 (ArC), 138.0 (ArC), 165.9 (2 × C=O); m/z (EI
+
) 
204.079550 (40%, M
+
 C12H12O3 requires 204.078644), 118 (100), 117 (40), 91 (20). No 
analytical data was given for the compound in the literature.
138
 
4-(1-Naphthyl)dihydropyran-2,6-dione 205 
 
 
Using general procedure C starting with glutaric acid 192 (3.00 g, 0.01 mol), the title 
compound was obtained as white crystals by recrystallisation from EtOAc / petrol (40 – 
60
o
C) (2.24 g, 80%). Mpt 148 – 150 oC; (Found: C, 74.64; H, 4.68. C15H12O3 requires C, 
74.99; H, 5.03); υmax (ATR)/cm
-1
 1808, 1753, 1599, 1508; 
 1
H NMR (400 MHz; CDCl3) δH 
3.05 (2H, dd, J 17.3, 10.5, 2 × CHH), 3.31 (2H, dd, J 17.3, 4.5, 2 × CHH), 4.28 (1H, tt, J 
10.5, 4.5, CH), 7.31 (1H, d, J 7.2, ArCH), 7.49 ‒ 7.53 (1H, m, ArCH), 7.57 – 7.66 (2H, m, 
ArCH), 7.87 (1H, d, J 8.2, ArCH), 7.94 ‒ 7.98 (2H, m, ArCH); 13C NMR (100 MHz; CDCl3) 
δC 29.5 (CH), 36.8 (2 × CH2), 121.8 (ArCH), 122.0 (ArCH), 125.5 (ArCH), 126.3 (ArCH), 
127.1 (ArCH), 128.9 (ArCH), 129.5 (ArCH), 130.6 (ArC), 134.1 (ArC), 134.8 (ArC), 166.0 
(2 × C=O); m/z (TOF MS ES
+
) 241 (100%, MH
+
 C15H13O3). 
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4-Methyldihydropyran-2,6-dione 206 
 
Using general procedure C starting with commercially available 3-methylglutaric acid (10.0 
g, 63.5 mmol), the title compound was obtained as white crystals by recrystallisation from 
EtOAc / petrol (40 – 60oC) (6.89 g, 79%). Mpt 44 – 46 oC, (Found: C, 56.27; H, 6.31. 
C6H8O3 requires C, 56.24; H, 6.29); υmax (ATR)/cm
-1
 2977, 1806, 1757, 1744; 
 1
H NMR (400 
MHz; CDCl3) δH 1.16 (3H, d, J 6.4, CH3), 2.29 – 2.37 (1H, m, CH), 2.39 – 2.46 (2H, m, 2 × 
CHH), 2.88 (2H, dd, J 17.1, 4.2, 2 × CHH); 
13
C NMR (100 MHz; CDCl3) δC 20.0 (CH3), 24.0 
(CH), 37.7 (2 × CH2), 166.4 (2 × C=O); m/z (TOF MS ES
+
) 129 (100%, MH
+
 C6H9O3). 
4-Isopropyldihydropyran-2,6-dione 207 
 
 
Using general procedure C starting with glutaric acid 194 (5.74 g, 33.0 mmol), a brown 
liquid was obtained. This was vacuum distilled (temp. 110 
o
C, 85 × 10
-2
 mbar); bp lit.
52
 138 
o
C (0.5 Torr), to give a colourless liquid which solidified upon standing. The solid was 
recrystallised from hexane to give the title compound as white crystals (3.93 g, 76%). Mpt 25 
– 26 oC (lit.52 25.5 – 26.5 oC); υmax (ATR)/cm
-1
 2967, 2878, 1798, 1757, 1702; 
1
H NMR (400 
MHz; CDCl3) δH 0.97 (6H, d, J 6.8,  2 × CH3), 1.62 (1H, octet, J 6.8, CH), 1.94 (1H, dtt, J 
11.5, 6.8, 4.4, CH), 2.43 (2H, dd, J 17.3, 11.5, 2 × CHH), 2.88 (2H, dd, J 17.3, 4.4, 2 × 
CHH); 
13
C NMR (100 MHz; CDCl3) δC 18.9 (2 × CH3), 31.3 (CH), 34.0 (2 × CH2), 35.0 
(CH), 166.9 (2 × C=O); m/z (TOF MS ES
+
) 157.0870 (100%, MH
+
 C6H8O3 requires 
157.0865). All data are in accordance with literature. 
4-tert-Butyldihydropyran-2,6-dione 208 
 
Using general procedure C starting with glutaric acid 195 (5.00 g, 26.6 mmol), a brown 
liquid was obtained. This was vacuum distilled (temp. 120 
o
C, 16 × 10
-2
 mbar); bp lit.
52
 146 – 
148 
o
C (0.55 Torr), to give a colourless liquid which solidified upon standing to give the title 
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compound as a white solid (3.15 g, 70%). Mpt. 62 – 64 oC (lit.52 63.5 – 64.5 oC); υmax 
(ATR)/cm
-1
 2967, 1808, 1748; 
 1
H NMR (400 MHz; CDCl3) δH 0.96 (9H, s, 3 × CH3), 1.94 
(1H, tt, J 12.9, 4.1, CH), 2.35 ‒ 2.43 (2H, m, 2 × CHH), 2.90 (2H, dd, J 17.2, 4.1, 2 × CHH); 
13
C NMR (100 MHz; CDCl3) δC 26.4 (3 × CH3), 32.0 (C), 32.3 (2 × CH2), 38.7 (CH), 167.2 
(C=O); m/z (TOF MS ES
+
) 171.1024 (100%, MH
+
 C9H15O3 requires 171.1021). All data are 
in accordance with literature. 
General Procedure D for the synthesis of glutarimides.
67
 
The corresponding amine (1.0 equiv.) was slowly added to a solution of the glutaric 
anhydride (1.0 equiv.) and triethylamine (1.0 equiv.) in dry THF (30 cm
3
). The mixture was 
heated at reflux for 48 h, cooled to room temperature and concentrated under reduced 
pressure. Dichloromethane (15 cm
3
) was added and the resulting solution was washed with 
1M HCl (5 cm
3
) and brine (5 cm
3
), dried over MgSO4 and filtered. The solvent was removed 
in vacuo and the residue was dissolved in acetyl chloride (30 cm
3
), heated at 60 
o
C for 48 h 
and cooled to room temperature. The solvent was removed in vacuo to give a brown solid 
which was purified by recrystallisation. 
N-(4-Methoxyphenyl)-4-phenylpiperidin-2,6-dione
 
173 
 
 
Using general procedure D starting with 3-phenylglutaric anhydride 172 (1.00 g, 5.26 mmol), 
p-anisidine (0.65 g, 5.26 mmol) and triethylamine (0.70 cm
3
, 5.26 mmol), the title compound 
was obtained as white crystals by recrystallisation from EtOAc (1.23 g, 80%). Mpt 248 – 250 
o
C; (Found: C, 73.00; H, 5.52; N, 4.66. C18H17NO3 requires C, 73.20; H, 5.80; N, 4.74); υmax 
(ATR)/cm
-1
 1731, 1672, 1610, 1511; 
1
H NMR (400 MHz; CDCl3) δH 3.02 (2H, dd, J 17.2, 
11.4, 2 × CHH), 3.18 (2H, dd, J 17.2, 4.4, 2 × CHH), 3.58 (1H, tt, J 11.4, 4.4, CH), 3.85 (3H, 
s, OCH3), 6.99 – 7.06 (4H, m, ArCH), 7.28 – 7.45 (5H, m, ArCH); 
13
C NMR (100 MHz; 
CDCl3) δC 34.7 (CH), 40.1 (2 × CH2), 55.4 (CH3), 114.7 (2 × ArCH), 126.4 (2 × ArCH), 
127.3 (ArC), 127.7 (ArCH), 129.2 (2 × ArCH), 129.3 (2 × ArCH), 140.5 (ArC) 159.5 (ArC), 
172.0 (C=O); m/z (TOF MS ES
+
) 296 (100%, MH
+
 C18H18NO3), 270 (10), 249 (40), 241 (8). 
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1-(Phenylmethyl)-4-phenylpiperidin-2,6-dione 174 
 
Using general procedure D starting with 3-phenylglutaric anhydride 172 (1.50 g, 7.89 mmol), 
benzylamine (0.85 g, 7.89 mmol) and triethylamine (1.10 cm
3
, 7.89 mmol), the title 
compound was obtained as white crystals by recrystallisation from EtOAc : petrol (40 – 60) 
(1.87 g, 85%). Mpt 100 – 102 oC (lit.139 94 – 96 oC) ; υmax (ATR)/cm
-1
 3031, 1726, 1668, 
1605; 
1
H NMR (400 MHz; CDCl3) δH 2.85 (2H, dd, J 17.2, 11.8, 2 × CHH), 3.05 (2H, dd, J 
17.2, 4.3, 2 × CHH), 3.38 (1H, tt, J 11.8, 4.3, CH), 5.02 (2H, s, NCH2), 7.21 [2H, (AX)2, 
ArCH], 7.28 – 7.42 (8H, m, ArCH); 13C NMR (100 MHz; CDCl3) δC 34.6 (CH), 39.9 (2 × 
CH2), 42.9 (CH2), 126.3 (2 × ArCH), 127.5 (ArCH), 127.6 (ArCH), 128.4 (2 × ArCH), 128.9 
(2 × ArCH), 129.1 (2 × ArCH), 137.1 (ArC) 140.6 (ArC), 171.6 (2 × C=O). m/z (TOF MS 
ES
+
) 280 (100%, MH
+
). Only melting point and 
1
H NMR were cited in the literature.
139,
 
124,
 
140
  
1-(2-Methylphenylmethyl)-4-phenylpiperidin-2,6-dione 175 
 
Using general procedure D starting with 3-phenylglutaric anhydride 172 (1.70 g, 8.95 mmol), 
2-methylbenzylamine (1.09 g, 8.95 mmol) and triethylamine (1.25 cm
3
, 8.95 mmol), the title 
compound was obtained as white crystals by recrystallisation from EtOAc : petrol (40 – 60) 
(1.87 g, 71%). Mpt 123 – 125 oC; (Found: C, 77.53, H, 6.51, N, 4.76. C19H19NO2 requires C, 
77.79; H, 6.53; N, 4.77); υmax (ATR)/cm
-1
 2973, 1727, 1667; 
1
H NMR (250 MHz; CDCl3) δH 
2.44 (3H, s, CH3), 2.91 (2H, dd, J 17.0, 11.5, 2 × CHH), 3.10 (2H, dd, J 17.0, 4.4, 2 × CHH), 
3.46 (1H, tt, J 11.5, 4.4, CH), 5.01 (2H, s, NCH2), 6.96 [1H, (AX)2, ArCH], 7.08 – 7.18 (3H, 
m, ArCH), 7.23 – 7.27 (2H, m, ArCH), 7.32 – 7.44 (3H, m, ArCH); 13C NMR (100 MHz; 
CDCl3) δC 19.4 (CH3), 34.6 (CH), 39.9 (2 × CH2), 40.4 (CH2), 126.0 (ArCH), 126.0 (ArCH), 
126.4 (2 × ArCH), 127.1 (ArCH), 127.7 (ArCH), 129.1 (2 × ArCH), 130.3 (ArCH), 134.7 
(ArC), 135.8 (ArC), 140.5 (ArC), 171.7 (2 × C=O); m/z (TOF MS ES
+
) 294  (100%, MH
+
 
C19H20NO2). 
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1-(2-Methoxyphenylmethyl)-4-phenylpiperidin-2,6-dione 176 
 
 
Using general procedure D starting with 3-phenylglutaric anhydride 172 (2.00 g, 10.5 mmol), 
2-methoxybenzylamine (1.37 cm
3
, 10.5 mmol) and triethylamine (1.47 cm
3
, 10.5 mmol), the 
title compound was obtained as white crystals by recrystallisation from EtOAc : petrol (40 – 
60) (1.97 g, 60%). Mpt 98 – 100 oC; (Found: C, 73.50, H, 6.06, N, 4.44. C19H19NO3 requires 
C, 73.77; H, 6.19; N, 4.5); υmax (ATR)/cm
-1
 2960, 1728, 1671, 1603; 
1
H NMR (400 MHz; 
CDCl3) δH 2.91 (2H, dd, J 17.1, 11.5, 2 × CHH), 3.08 (2H, dd, J 17.1, 4.3, 2 × CHH), 3.44 
(1H, tt, J 11.5, 4.3, CH), 3.86 (3H, s, OCH3), 5.08 (2H, s, NCH2), 6.88 – 6.96 (3H, m, ArCH), 
7.22 – 7.28 (3H, m, ArCH), 7.31 – 7.35 (1H, m, ArCH), 7.38 – 7.40 (2H, m, ArCH); 13C 
NMR (100 MHz; CDCl3) δC 34.6 (CH), 38.5 (2 × CH2), 39.9 (CH2), 55.4 (CH3), 110.4 
(ArCH), 120.3 (2 × ArCH), 124.8 (ArC), 126.5 (2 × ArCH), 127.0 (ArCH), 127.6 (ArCH), 
128.2 (ArCH), 129.1 (ArCH), 140.7 (ArC) 157.1 (ArC), 171.5 (2 × C=O); m/z (TOF MS 
ES
+
) 310.1451 (100%, MH
+
 C19H20NO3 requires 310.1443). 
1-(Phenylmethyl)-4-(2-fluorophenyl)piperidin-2,6-dione 209 
 
Using general procedure D starting with glutaric anhydride 201 (2.00 g, 9.62 mmol), 
benzylamine (1.10 cm
3
, 9.62 mmol) and triethylamine (1.34 cm
3
, 9.62 mmol), the title 
compound was obtained as white powder by recrystallisation from EtOAc : petrol (40 – 60) 
(1.7 g, 60%). Mpt 76 – 78 oC; (Found: C, 72.38; H, 5.26; N, 4.57. C18H16FNO2 requires C, 
72.71; H, 5.42; N, 4.71); υmax (ATR)/cm
-1
 3068, 2895, 1728, 1672, 1582; 
1
H NMR (400 
MHz; CDCl3) δH 2.91 (2H, dd, J 16.9, 11.4, 2 × CHH), 3.04 (2H, dd, J 16.9, 4.0, 2 × CHH), 
3.61 ‒ 3.68 (1H, m, CH), 5.02 (2H, s, NCH2), 7.07 – 7.13 (3H, m, ArCH), 7.27 – 7.34 (4H, 
m, ArCH), 7.42 (2H, d, J 7.0, ArCH); 
13
C NMR (100 MHz; CDCl3) δC 29.1 (CH), 38.3 (2 × 
CH2), 43.0 (CH2), 116.1 (d, J C-F 22.1, ArCH), 124.7 (d, J C-F 3.3, ArCH), 127.2 (d, J C-F 4.0, 
ArCH), 127.4 (ArC), 127.6 (ArCH), 128.5 (2 × ArCH), 129.0 (2 × ArCH), 129.3 (d, J C-F 8.5, 
ArCH), 137.1 (ArC), 160.8 (d, J C-F 246.6, ArC), 171.4 (2 × C=O); m/z (TOF MS ES
+
) 298 
(100%, MH
+
 C18H17FNO2). 
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1-(Phenylmethyl)-4-(4-fluorophenyl)piperidin-2,6-dione 210 
 
 
Using general procedure D starting with glutaric anhydride 202 (4.00 g, 19.20 mmol), 
benzylamine (2.10 cm
3
, 19.2 mmol) and triethylamine (2.60 cm
3
, 19.2 mmol), the title 
compound was obtained as white powder by recrystallisation from EtOAc : petrol (40 – 60) 
(1.20 g, 67%). Mpt 120 – 122 oC; (Found: C, 72.47; H, 5.31; N, 4.77. C18H16FNO2 requires 
C, 72.71; H, 5.42; N, 4.71); υmax (ATR)/cm
-1
 3060, 2955, 1718, 1672, 1604, 1512; 
1
H NMR 
(400 MHz; CDCl3) δH 2.81 (2H, dd, J 17.1, 11.5, 2 × CHH), 3.00 (2H, dd, J 17.1, 4.3, 2 × 
CHH), 3.37 (1H, tt, J 11.5, 4.3, CH), 5.01 (2H, s, NCH2), 7.02 ‒ 7.07 (2H, m, ArCH), 7.13 ‒ 
7.17 (2H, m, ArCH), 7.28 – 7.32 (3H, m, ArCH), 7.38 ‒ 7.41 (2H, m, ArCH); 13C NMR (100 
MHz; CDCl3)  δC  33.9 (CH), 40.0 (2 × CH2), 42.9 (CH2), 115.9 (ArCH), 116.1 (ArCH), 127.6 
(ArCH), 127.9 (ArCH), 128.0 (ArCH), 128.4 (2 × ArCH), 128.9 (2× ArCH), 136.3 (d, J C-F 
3.0, ArC), 137.0 (ArC), 162.0 (d, J C-F 246.6, ArC), 171.3 (2 × C=O); m/z (TOF MS ES
+
) 
298.1233 (100%, MH
+
 C18H17FNO2 requires 298.1243). Only 
1
H NMR was cited in 
literature.
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1-(Phenylmethyl)-4-(2-methylphenyl)piperidin-2,6-dione 211 
 
Using general procedure D starting with glutaric anhydride 203 (1.50 g, 7.35 mmol), 
benzylamine (0.81 cm
3
, 7.35 mmol) and triethylamine (1.02 cm
3
, 7.35 mmol), the title 
compound was obtained as white powder by recrystallisation from EtOAc : petrol (40 – 60) 
(1.88 g, 87%). Mpt 138 – 140 oC; υmax (ATR)/cm
-1
 3017, 2953, 1728, 1670, 1605; 
1
H NMR 
(400 MHz; CDCl3) δH 2.37 (3H, s, CH3), 2.81 (2H, dd, J 17.2, 11.8, 2 × CHH), 2.98 (2H, dd, 
J 17.2, 4.3, 2 × CHH), 3.58 (1H, tt, J 11.8, 4.3, CH), 5.04 (2H, s, NCH2), 7.09 – 7.12 (1H, m, 
ArCH), 7.20 ‒ 7.23 (3H, m, ArCH), 7.27 – 7.37 (3H, m, ArCH), 7.43 ‒ 7.46 (2H, m, ArCH); 
13
C NMR (100 MHz; CDCl3) δC 19.3 (CH3), 30.7 (CH), 39.3 (2 x CH2), 43.0 (CH2), 124.5 
(ArCH), 126.8 (ArCH), 127.4 (ArCH), 127.6 (ArCH), 128.5 (2 × ArCH), 129.1 (2 × ArCH), 
131.1 (ArCH), 135.6 (ArC), 137.1 (ArC), 138.7 (ArC), 171.9 (2 × C=O); m/z (TOF MS ES
+
) 
294.1485 (100%, MH
+
 C19H20NO2 requires 294.1494).  
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1-(Phenylmethyl)-4-(4-methylphenyl)piperidin-2,6-dione 212 
 
Using general procedure D starting with glutaric anhydride 204 (5.00 g, 24.5 mmol), 
benzylamine (2.67 cm
3
, 24.5 mmol) and triethylamine (3.40 cm
3
, 24.5 mmol), the title 
compound was obtained as white powder by recrystallisation from EtOAc : petrol (40 – 60) 
(5.10 g, 71%). Mpt 106 – 108 oC; υmax (ATR)/cm
-1
 2955, 2910, 1727, 1669, 1516; 
1
H NMR 
(400 MHz; CDCl3) δH 2.36 (3H, s, CH3), 2.82 (2H, dd, J 17.1, 11.8, 2 × CHH), 3.03 (2H, dd, 
J 17.1, 4.2, 2 × CHH), 3.34 (1H, tt, J 11.8, 4.2, CH), 5.02 (2H, s, NCH2), 7.09 (2H, d, J 8.0, 
ArCH), 7.18 (2H, d, J 8.0, ArCH), 7.26 – 7.35 (3H, m, ArCH), 7.39 ‒ 7.52 (2H, m, ArCH); 
13
C NMR (100 MHz; CDCl3) δC  21.0 (CH3), 34.2 (CH), 40.1 (2 × CH2), 42.9 (CH2), 126.2 (2 
× ArCH), 127.5 (ArCH), 128.4 (2 × ArCH), 128.9 (2 × ArCH), 129.7 (2 × ArCH), 137.1 
(ArC), 137.3 (ArC), 138.6 (ArC), 171.7 (2 × C=O); m/z (TOF MS ES
+
) 294.1504 (100%, 
MH
+
 C19H20NO2 requires 294.1494).  
1-(Phenylmethyl)-4-(1-naphthyl)piperidin-2,6-dione 213 
 
Using general procedure D starting with glutaric anhydride 205 (2.00 g, 8.33 mmol), 
benzylamine (0.90 cm
3
, 8.33 mmol) and triethylamine (1.16 cm
3
, 8.33 mmol), the title 
compound was obtained as white powder by recrystallisation from EtOAc : petrol (40 – 60) 
(1.42 g, 52%). Mpt 116 – 118 oC; υmax (ATR)/cm
-1
 3052, 2964, 1723, 1672, 1598, 1509; 
1
H 
NMR (400 MHz; CDCl3) δH 2.98 (2H, dd, J 16.9, 10.8, 2 × CHH), 3.21 (2H, dd, J 16.9, 3.8, 2 
× CHH), 4.15 – 4.22 (1H, m, CH), 5.08 (2H, s, NCH2), 7.23 – 7.38 (4H, m, ArCH), 7.40 – 
7.48 (3H, m, ArCH), 7.53 – 7.61 (2H, m, ArCH), 7.82 (1H, d, J 8.2,  ArCH), 7.92 (1H, d, J 
7.6,  ArCH), 8.0 (1H, d, J 8.2,  ArCH); 
13
C NMR (100 MHz; CDCl3) δC 30.0 (CH), 39.5 (2 × 
CH2), 43.1 (CH2), 122.2 (ArCH), 122.3 (ArCH), 125.5 (ArCH), 126.1 (ArCH), 126.8 
(ArCH), 127.6 (ArCH), 128.3 (ArCH), 128.5 (2 × ArCH), 129.1 (2 × ArCH), 129.3 (ArCH), 
130.8 (ArC), 134.1 (ArC), 136.3 (ArC), 137.1 (ArC), 171.8 (2 × C=O); m/z (TOF MS ES
+
) 
330.1504 (100%, MH
+
 C22H20NO2 requires 330.1494). 
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1-(Phenylmethyl)-4-methylpiperidin-2,6-dione 214 
 
Using general procedure D starting with glutaric anhydride 206 (3.50 g, 27.3 mmol), 
benzylamine (2.93 g, 27.3 mmol) and triethylamine (3.82 cm
3
, 27.3 mmol), the title 
compound was obtained as white powder by recrystallisation from 50% EtOAc : hexane 
(4.13 g, 70%). Mpt 68 – 70 oC; (Found: C, 71.74; H, 6.87; N, 6.46. C13H15NO2 requires C, 
71.87; H, 6.96; N, 6.45); υmax (ATR)/cm
-1
 2961, 1721, 1665; 
1
H NMR (400 MHz; CDCl3) δH  
1.08 (3H, d, J 6.4, CH3), 2.17 – 2.29 (1H, m, CH), 2.31 – 2.37 (2H, m, 2 × CHH), 2.80 (2H, 
dd, J 16.7, 3.8, 2 × CHH), 4.97 (2H, s, NCH2), 7.24 – 7.32 (3H, m, ArCH), 7.39 [2H, (AX)2, 
ArCH]; 
13
C NMR (100 MHz; CDCl3) δC 20.3 (CH3), 24.5 (CH), 40.7 (2 × CH2), 42.7 (CH2), 
127.4 (ArCH), 128.4 (2 × ArCH), 128.8 (2 × ArCH), 137.3 (ArC), 172.1 (2 × C=O); m/z 
(TOF MS ES
+
) 218 (100%, MH
+
 C13H16NO2). Only 
1
H NMR was cited in literature.
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1-(Phenylmethyl)-4-isopropylpiperidin-2,6-dione 215 
 
Using general procedure D starting with glutaric anhydride 207 (2.00 g, 12.8 mmol), 
benzylamine (1.37 g, 12.8 mmol) and triethylamine (1.80 cm
3
, 12.8 mmol), a yellowish liquid 
was obtained that turned to a yellowish solid upon standing. The solid was purified via flash 
column chromatography eluting with EtOAc : petroleum ether (40-60) (3:7) to afford the title 
compound as colourless liquid which turned to a white solid upon standing (2.10 g, 67%). 
Mpt 45 – 46 oC; (Found: C, 73.24; H, 7.75; N, 5.53. C15H19NO2 requires C, 73.44; H, 7.81; N, 
5.71); υmax (ATR)/cm
-1
 3031, 2960, 2900, 2874, 1724, 1668; 
1
H NMR (400 MHz; CDCl3) δH  
0.95 (6H, d, J 6.7,  2 × CH3), 1.57 (1H, octet, J 6.7, CH), 1.81 ‒ 1.91 (1H, m, CH), 2.35 (2H, 
dd, J 17.1, 12.3, 2 × CHH), 2.82 (2H, dd, J 17.1, 4.0, 2 × CHH), 4.96 (2H, s, NCH2), 7.23 – 
7.32 (3H, m, ArCH), 7.39 [2H, (AX)2, ArCH]; 
13
C NMR (100 MHz; CDCl3) δC 19.2 (2 × 
CH3), 31.4 (CH), 35.5 (CH), 36.9 (2 × CH2), 42.8 (CH2), 127.4 (ArCH), 128.4 (2 × ArCH), 
128.8 (2 × ArCH), 137.2 (ArC), 172.6 (2 × C=O); m/z (TOF MS ES
+
) 246.1504 (100%, MH
+
 
C15H19NO2 requires 246.1494).  
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1-(Phenylmethyl)-4-tert-butylpiperidin-2,6-dione 216 
 
Using general procedure D starting with glutaric anhydride 208 (1.30 g, 7.65 mmol), 
benzylamine (0.89 g, 7.65 mmol) and triethylamine (1.10 cm
3
, 7.65 mmol), a yellowish solid 
was obtained. The solid was purified via flash column chromatography eluting with EtOAc : 
petroleum ether (40-60) (3:7) to afford the title compound as colourless liquid which turned 
to a white solid upon standing (1.12 g, 57%). Mpt 44 – 46 oC; υmax (ATR)/cm
-1
 2951, 2874, 
1719, 1666; 
1
H NMR (400 MHz; CDCl3) δH 0.93 (9H, s, 3 × CH3), 1.86 (1H, tt, J 13.5, 3.8, 
CH), 2.30 ‒ 2.37 (2H, m, 2 × CHH), 2.83 (2H, dd, J 17.0, 3.8, 2 × CHH), 4.96 (2H, s, NCH2), 
7.24 – 7.33 (3H, m, ArCH), 7.39 [2H, (AX)2, ArCH]; 
13
C NMR (100 MHz; CDCl3) δC 26.5 (3 
× CH3), 31.8 (C), 35.0 (2 × CH2), 39.2 (CH), 42.8 (CH2), 127.5 (ArCH), 128.4 (2 × ArCH), 
128.8 (2 × ArCH), 137.2 (ArC), 172.9 (2 × C=O); m/z (TOF MS ES
+
) 260.1650 (100%, MH
+
 
C16H22NO2 requires 260.1651).  
6.5 Experimental for the enantioselective desymmetrisation of glutarimides 
Background reaction of N-(4-Methoxyphenyl)-4-phenylpiperidin-2,6-dione 173 with 
BH3.THF 
 
 
N-(4-Methoxyphenyl)-4-phenylpiperidin-2,6-dione 173 (0.15 g, 0.51 mmol) was dissolved in 
THF (4 cm
3
) and treated with BH3.THF (0.50 cm
3
, 0.50 mmol). The mixture was allowed to 
stir at rt for 18 hrs. The reaction was quenched by addition of 1M HCl (1 cm
3
) and H2O (1 
cm
3
) and the product was extracted with CH2Cl2 (3 × 5 cm
3
). The organic extracts were dried 
over MgSO4 and filtered. The solvent was removed in vacuo to give a white powder. 
1
H 
NMR analysis showed no conversion to the corresponding hydroxy-lactam. 
Background reaction of 1-(phenylmethyl)-4-phenylpiperidin-2,6-dione 174 with 
BH3.THF 
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1-(Phenylmethyl)-4-phenylpiperidin-2,6-dione 174 (0.14 g, 0.50 mmol) was dissolved in 
THF (4 cm
3
), treated with BH3.THF (0.50 cm
3
, 0.50 mmol) and allowed to stir at rt for 24 
hrs. The reaction was quenched by addition of 1M HCl (1 cm
3
) and H2O (1 cm
3
), the product 
was extracted with CH2Cl2 (3 × 5 cm
3
) and the organic extracts dried over MgSO4 and 
filtered. The solvent was removed in vacuo to give a white powder. 
1
H NMR analysis showed 
no conversion to the corresponding hydroxy-lactam. 
General Procedure E for the asymmetric reduction of glutarimides using B-Me catalyst 
76 followed by conversion to the corresponding lactam 
 
A suspension of (1R, 2S)-cis-amino-2-indanol (0.15 g, 1.00 mmol) in dry toluene (3 cm
3
) was 
treated with trimethylboroxine (0.05 cm
3
, 0.33 mmol) and allowed to stir under nitrogen for 
30 mins. Dry toluene (5 cm
3
) was added and the reaction distilled until approximately 2 cm
3 
of solvent remained. This procedure was repeated twice after which the final volume of 
toluene was removed under pressure to give a yellow solid. Dry dichloromethane (5 cm
3
) was 
added to give a stock solution of the B-Me catalyst 76. The catalyst (0.5 cm
3
, 10 mol %) was 
added to the solution of the glutarimide substrate (1.00 mmol) in dry dichloromethane (30 
cm
3
) followed by a drop-wise addition of BH3.THF (1 cm
3
, 1.00 mmol). The solution was 
then allowed to stir at room temperature for 3 hours (for N-PMP glutarimide) or 24 hours (for 
N-Bn glutarimides). The reaction was finally quenched by addition of MeOH (2 cm
3
) and 1M 
HCl (2 cm
3
), extracted with CH2Cl2 (3 × 15 cm
3
), dried over MgSO4 and filtered. The solvent 
was evaporated in vacuo to give the crude hydroxy-lactam as a white powder which was 
immediately re-dissolved in CH2Cl2 (30 cm
3
) and treated with TFA (1 cm
3
) and triethylsilane 
(1 cm
3
) in CH2Cl2 (5 cm
3
). This mixture was allowed to stir at rt for 1 h, after which the 
solution was added to an ice-water mixture (15 cm
3
) followed by extraction with CH2Cl2 (3 × 
15 cm
3
). The combined organic extracts were washed with saturated NaHCO3 (3 × 15 cm
3
), 
dried over MgSO4 and filtered. The solvent was removed in vacuo to give a crude white 
solid, which was purified via flash column chromatography eluting with EtOAc : petroleum 
ether (40-60) (7:3). 
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General Procedure F for the asymmetric reduction of 4-phenylglutarimides using B-
OMe catalyst 77 followed by conversion to the corresponding lactam 
 
A solution of (1R, 2S)-cis-1-aminoindan-2-ol (0.15 g, 1.00 mmol) in THF (3 cm
3
) was treated 
with trimethylborate (0.10 cm
3
, 1.00 mmol) and allowed to stir for 45 mins. The solution was 
then diluted to 5 cm
3
 by further addition of THF, to give the catalyst 77 as a stock solution. 
The glutarimide (1.00 mmol) was dissolved in dry DCM (30 cm
3
) under a nitrogen 
atmosphere and this solution was treated with the catalyst stock solution (0.50 cm
3
, 10 mol%) 
then a drop-wise addition of BH3.THF (1.00 cm
3
, 1.00 mmol), and allowed to stir at rt for 3 
hours (for N-PMP glutarimide) or 24 hours (for N-Bn glutarimide). The reaction was 
quenched by the addition of MeOH (5 cm
3
) and 1M HCl (5 cm
3
), and extracted with CH2Cl2 
(3 × 15 cm
3
). The combined organic extracts were dried over MgSO4 and filtered. The solvent 
was removed in vacuo to give the crude hydroxy-lactam as a white powder which was 
immediately re-dissolved in CH2Cl2 (25 cm
3
) and treated with TFA (1 cm
3
) and triethylsilane 
(1 cm
3
) in CH2Cl2 (5 cm
3
). This mixture was allowed to stir at rt for 1 h, after which the 
solution was added to an ice-water mixture (15 cm
3
) followed by extraction with CH2Cl2 (3 × 
15 cm
3
). The combined organic extracts were washed with saturated NaHCO3 (15 cm
3
), dried 
over MgSO4 and filtered. The solvent was removed in vacuo to give a white solid, which was 
purified via flash column chromatography. 
Procedure for the asymmetric reduction of N-(benzyl)-4-phenylpiperidin-2,6-dione 174 
using CBS catalyst 22 followed by conversion to the corresponding lactam 
 
A suspension of (S)-(–)-α,α-diphenyl-2-pyrrolidinemethanol 20 (0.25 g, 1.00 mmol) in dry 
toluene (3 cm
3
) was treated with trimethylboroxine (0.05 cm
3
, 0.33 mmol) and allowed to stir 
under nitrogen for 30 mins. Dry toluene (5 cm
3
) was added and the reaction distilled until 
approximately 2 cm
3 
of solvent remained. This procedure was repeated twice after which the 
final volume of toluene was removed under pressure to give a yellow solid. Dry 
dichloromethane (5 cm
3
) was added to give a stock solution of the B-Me CBS catalyst. The 
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catalyst (0.50 cm
3
, 10 mol %) was added to the solution of the glutarimide substrate 174 
(0.28 g, 1.00 mmol) in dry dichloromethane (30 cm
3
) followed by a drop-wise addition of 
BH3.THF (1 cm
3
, 1.00 mmol). The solution was then allowed to stir at room temperature for 
24 hours. The reaction was finally quenched by addition of MeOH (2 cm
3
) and 1M HCl (2 
cm
3
), extracted with CH2Cl2 (3 × 15 cm
3
), dried over MgSO4 and filtered. The solvent was 
evaporated in vacuo to give the crude hydroxy-lactam as a white powder which was 
immediately re-dissolved in CH2Cl2 (30 cm
3
) and treated with TFA (1 cm
3
) and triethylsilane 
(1 cm
3
) in CH2Cl2 (5 cm
3
). This mixture was allowed to stir at rt for 1 h, after which the 
solution was added to an ice-water mixture (15 cm
3
) followed by extraction with CH2Cl2 (3 × 
15 cm
3
). The combined organic extracts were washed with saturated NaHCO3 (15 cm
3
), dried 
over MgSO4 and filtered. The solvent was removed in vacuo to give a crude white solid, 
which was purified via flash column chromatography eluting with EtOAc : petroleum ether 
(40-60) (7:3) to afford the corresponding lactam as white solid (0.03 g, 13% over 2 steps). 
14% ee. Chiral HPLC, Lux 3u Cellulose-2, 20% IPA in hexane, tR (minor) 21.1 min and 
(major) 23.1 min. All data correspond to those reported for compound 180. 
(S)-(–)-N-Ethoxycarbonylproline methyl ester 260141 
 
Potassium carbonate (6.80 g, 49.0 mmol) was added to a solution of L-proline (6.00 g, 52.0 
mmol) in MeOH (100 cm
3
). The solution was cooled to 0 °C and ethyl chloroformate (11.5 
cm
3
, 120 mmol) was added drop-wise. The mixture was allowed to warm to rt and was stirred 
overnight. MeOH was evaporated under reduced pressure and the residual oil was dissolved 
in water (15 cm
3
). This solution was extracted with CHCl3 (3 × 30 cm
3
), the combined 
organic phases washed with brine (50 cm
3
), dried over MgSO4 and filtered. Subsequent 
concentration under reduced pressure and drying on Schlenk line yielded the product as thick, 
colourless oil (10.30 g, 98%). [α]D
20 -58.0 (c 1.05 CHCl3), Lit.
141
 - 60.3 (c 1.26 CHCl3) 
1
H 
NMR (400 MHz, CDCl3, mixture of rotamers) δH 0.99 (2H, t, J 7.1 Hz, CH2, rotamer A), 
1.06 (2H, t, J 7.1 Hz, CH2, rotamer B), 1.69 – 1.80 (4H, t, 2 × CH2), 1.96 – 2.07 (1H, m, 
CHN), 3.23 ‒ 3.39 (2H, m, CH2N), 3.51 (1.5H, s, OCH3, rotamer A), 3.52 (1.5H, s, OCH3, 
rotamer B), 3.94 – 3.99 (2H, m, CH2), 4.10 (0.5H, t, J 8.8, 4.0 Hz, CHN, rotamer A), 4.15 
(0.5H, t, J 8.8, 4.0 Hz, CHN, rotamer B). All data are in accordance with the literature. 
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(S)-(–)-α,α-Diphenyl-2-pyrrolidinemethanol 2036 
 
Magnesium turnings (9.66 g, 0.40 mol) and THF (100 cm
3
) were introduced into a 250 cm
3
 
two-necked flask fitted with a dropping funnel. Bromobenzene (21.0 cm
3
, 0.20 mol) and THF 
(75 cm
3
) were introduced into the dropping funnel and added drop-wise over 1 h. The 
mixture was stirred for 1 h afterwards. (S)-N-Ethoxycarbonylproline methyl ester 260 (10.0 g, 
0.05 mol) was introduced into a 500 cm
3
 3-necked round bottomed flask fitted with a 
dropping funnel, followed by THF (100 cm
3
). The mixture was cooled to 0 °C and the 
solution of phenylmagnesium bromide was transferred via a dropping funnel, then added 
drop-wise over 30 min. After addition was complete, the reaction mixture was warmed to rt 
and stirred overnight. The reaction was quenched with saturated aqueous ammonium chloride 
solution (20 cm
3
). The mixture was extracted with CH2Cl2 (2 × 200 cm
3
), the combined 
organic phases washed with brine (100 cm
3
) and concentrated under reduced pressure. The 
crude material was dissolved in MeOH (100 cm
3
) into a round-bottom flask fitted with a 
condenser. Potassium hydroxide (28.0 g, 0.50 mol) was added and the mixture was heated at 
reflux for 24 h. After cooling to ambient temperature, methanol was removed under reduced 
pressure and the residue was treated with water (150 cm
3
). This was extracted with 
dichloromethane (3 × 120 cm
3
), the combined organic phases were washed with brine (100 
cm
3
), dried over magnesium sulfate and filtered. The crude product was recrystallised in 
hexane to yield (S)-α,α-diphenyl-2-pyrrolidinemethanol as pale brown crystals (7.85 g, 62%). 
Mpt 78 – 79 ºC (lit.36 79.0 – 79.5 ºC); [α]D
20 - 57.0 (c 0.21, MeOH) [lit.
36
 - 57.2 (c 0.26, 
MeOH)]; (Found: C, 80.48; H, 7.59; N, 5.44; C17H19NO requires C, 80.60; H, 7.56; N, 5.53); 
υmax (ATR)/cm
-1
 3086, 2972, 2944, 2834, 1598; 
1
H NMR (400 MHz, CDCl3) δH 1.58 – 1.79 
(4H, m, 2 × CH2), 2.98 (1H, dd, J 16.7, 7.3 Hz, CHHN), 3.03 – 3.08 (1H, m, CHHN), 4.29 
(1H, t, J 7.5 Hz, CHN), 7.18 – 7.23 (2H, m, ArCH), 7.28 – 7.35 (4H, m, ArCH), 7.54 (2H, d, 
J 8.1, 7.3 Hz, ArCH), 7.61 (2H, d, J 8.1, 7.3 Hz, ArCH); 
13
C NMR (100 MHz, CDCl3) δC 
25.5 (CH2), 26.3 (CH2), 46.8 (CH2N), 64.5 (CHN), 125.6 (2 × ArCH), 125.9 (2 × ArCH), 
126.4 (ArCH), 126.5 (ArCH), 128.0 (2 × ArCH), 128.3 (2 × ArCH), 145.4 (ArC), 148.2 
(ArC); m/z (TOF MS ES
+
) 254.1550 (100%, MH
+
 C17H20NO requires 254.1545). All data are 
in accordance with the literature. 
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4(R)-1-(4-Methoxyphenyl)-4-phenylpiperidin-2-one 179 
 
Using glutarimide 173 (0.30 g, 1.00 mmol) the title compound was obtained as a white solid 
using general procedure E (0.07 g, 34% over 2 steps). Mpt 204 – 206 oC; [α]D
20
  + 6.0 (c 1.3, 
CHCl3; 95% ee); vmax (ATR) / cm
-1
  1640, 1506; 
1
H NMR (400 MHz; CDCl3) δH 2.11 – 2.21 
(1H, m, CHH), 2.23 – 2.30 (1H, m, CHH), 2.73 (1H, dd, J 17.5, 10.8, CHH), 2.92 (1H, ddd, J 
17.5, 5.3, 1.9, CHH), 3.29 (1H, tdd, J 10.8, 5.3, 3.4, CHPh), 3.65 (1H, ddd, J 10.8, 5.3, 3.4, 
CHH), 3.74 ‒ 3.81 (1H, m, CHH), 3.84 (3H, s, OCH3), 6.96 [2H, (AX)2, ArCH], 7.22 [2H, 
(AX)2, ArCH],  7.28 – 7.32 (3H, m, ArCH), 7.38 – 7.42 (2H, m, ArCH); 
13
C NMR (100 
MHz; CDCl3) δC 30.7 (CH2), 38.8 (CH), 39.8 (CH2), 51.0 (CH2), 55.5 (CH3), 114.6 (2 × 
ArCH), 126.6 (2 × ArCH), 126.9 (ArCH), 127.4 (2 × ArCH), 128.8 (2 × ArCH), 135.9 (ArC), 
143.4 (ArC), 158.3 (ArC), 169.6 (C=O); m/z (TOF MS ES
+
) 282.1493 (100%, MH
+
 
C18H20NO2 requires 282.1494). Chiral HPLC, CELLULOSE-1, 20% IPA in hexane @ 1.0 
mL min
-1
, tR (minor) 27.3 min and (major) 29.9 min. Optical rotation is comparable with 
literature for 4(R)-1-(4-methoxyphenyl)-4-(4-fluorophenyl)piperidin-2-one [+8.0 (c 1.3 
CHCl3).
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4(R)-5-Hydroxy-1-(4-methoxyphenyl)-4-phenylpiperidin-2-one 177 
 
Using general procedure E with glutarimide 173 (0.30 g, 1.00 mmol) but purifying the crude 
hydroxy-lactam before conversion to the N-PMP lactam gave the title compound as a white 
powder in a 2:1 diastereomeric ratio (0.06 g, 20%). Mpt 156 – 158 oC; [α]D
20
  + 18.2 (c 1.7, 
CHCl3); vmax (ATR) / cm
-1
  3188, 3030, 2936, 2836, 2543, 2160, 2035, 1979, 1644, 1620, 
1602, 1507; 
1
H NMR (400 MHz; CDCl3) major diastereomer δH 2.60 – 2.74 (2H, m, 2 × 
CHH), 2.86 – 2.96 (2H, m, 2 × CHH), 3.21 – 3.31 (2H, m, 2 × CH), 3.84 (3H, s, OCH3), 5.30 
– 5.34 (1H, m, OH), 6.96 – 6.98 (3H, m, ArCH), 7.28 – 7.30 (6H, m, ArCH); 13C NMR (100 
MHz; CDCl3) major diastereomer δC 30.7 (CH2), 33.1 (CH), 51.0 (CH2), 55.5 (CH3), 81.9 
(CH), 114.8 (2 × ArCH), 126.7 (2 × ArCH), 127.4 (ArCH), 128.8 (2 × ArCH), 129.2 (2 × 
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ArCH), 133.4 (ArC), 143.1 (ArC), 158.9 (ArC), 170.0 (C=O); m/z (TOF MS ES
+
) 298.1446 
(100%, MH
+
 C18H20NO2 requires 298.1443). 
4(R)-1-(Phenylmethyl)-4-phenylpiperidin-2-one 180 
 
Using glutarimide 174 (0.30 g, 1.00 mmol) the title compound was obtained as a white solid 
using general procedure E (0.16 g, 60% over 2 steps) Mpt 80 – 82 oC (lit.115 88 ‒ 90 oC); 
[α]D
20
  + 33.0 (c 1.1, CHCl3; 90% ee), lit.
100
 [α]D
20
  + 35.0 (c 1.1, CHCl3); vmax (ATR) / cm
-1
  
1619, 1494; 
1
H NMR (400 MHz; CDCl3) δH 1.97 (1H, dtd, J 13.2, 10.8, 6.0, CHH), 2.07 – 
2.14 (1H, m, CHH), 2.63 (1H, dd, J 17.5, 11.0, CHH), 2.83 (1H, ddd, J 17.5, 5.2, 2.0, CHH), 
3.13 (1H, tdd, J 11.0, 5.2, 3.1, CHPh), 3.26 – 3.37 (2H, m, 2 × CHH), 4.59 (1H, d, J 14.5, 
NCHH), 4.77 (1H, d, J 14.5, NCHH), 7.21 – 7.39 (10H, m, ArCH); 13C NMR (100 MHz; 
CDCl3) δC 30.3 (CH2), 38.7 (CH), 39.5 (CH2), 46.4 (CH2), 50.0 (CH2), 126.5 (2 × ArCH), 
126.8 (ArCH), 127.5 (ArCH), 128.2 (2 × ArCH), 128.6 (2 × ArCH), 128.8 (2 × ArCH), 137.1 
(ArC), 143.4 (ArC), 169.3 (C=O); m/z (EI
+
) 265 (100%, M
+
 C18H19NO), 174 (12), 131 (32), 
104 (230), 131 (32), 91 (70). Chiral HPLC, Lux 3u CELLULOSE-2, 20% IPA in hexane @ 
1.0 mL min
-1
, tR (major) 23.5 min and (minor) 26.1 min. All data are in accordance with 
literature.
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4(R)-1-(2-Methylbenzyl)-4-phenylpiperidin-2-one 182 
 
Using glutarimide 175 (0.30 g, 1.00 mmol) the title compound was obtained as a white solid 
using general procedure E (0.07 g, 25% over 2 steps) Mpt 72 – 74 oC; [α]D
20
  + 26.58 (c 0.8, 
CHCl3; 88% ee); (Found: C, 81.81; H, 7.82; N, 4.85. C19H21NO requires C, 81.68; H, 7.58; N, 
5.01); vmax (ATR) / cm
-1
  3024, 2915, 1737, 1627, 1605; 
1
H NMR (400 MHz; CDCl3) δH 1.93 
– 2.03 (1H, m, CHH), 2.09 – 2.15 (1H, m, CHH), 2.34 (3H, s, CH3), 2.64 (1H, dd, J 17.5, 
11.1, CHH), 2.88 (1H, ddd, J 17.5, 5.2, 2.1, CHH), 3.15 (1H, tdd, J 11.1, 5.2, 3.1, CHPh), 
3.22 – 3.31 (2H, m, 2 × CHH), 4.63 (1H, d, J 15.1, NCHH), 4.81 (1H, d, J 15.1, NCHH), 
7.17 – 7.29 (7H, m, ArCH), 7.35 – 7.39 (2H, m, ArCH); 13C NMR (100 MHz; CDCl3) δC 
19.25 (CH3), 30.3 (CH2), 38.7 (CH), 39.5 (CH2), 46.3 (CH2), 47.7 (CH2), 126.1 (ArCH), 
126.5 (2 × ArCH), 126.8 (ArCH), 127.5 (ArCH), 128.1 (ArCH), 128.8 (2 × ArCH), 130.5 
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(ArCH), 134.5 (ArC), 136.6 (ArC), 143.4 (ArC), 169.2 (C=O); m/z (TOF MS ES
+
) 280.1713 
(100%, MH
+
 C22H22NO requires 280.1701). Chiral HPLC, Lux 3u CELLULOSE-2, 20% IPA 
in hexane @ 1.0 mL min
-1
, tR (major) 20.6 min and (minor) 22.3 min.  
4(R)-1-(2-Methoxybenzyl)-4-phenylpiperidin-2-one 183 
 
Using glutarimide 176 (0.30 g, 1.00 mmol) the title compound was obtained as a white solid 
using general procedure E (0.06 g, 21% over 2 steps) Mpt. 80 – 82 oC; [α]D
20
  + 21.72 (c 1.0, 
CHCl3; 90% ee); vmax (ATR) / cm
-1
  2940, 2159, 1738, 1636; 
1
H NMR (400 MHz; CDCl3) δH 
1.95 – 2.03 (1H, m, CHH), 2.09 – 2.13 (1H, m, CHH), 2.62 (1H, dd, J 17.5, 11.1, CHH), 2.84 
(1H, ddd, J 17.5, 5.3, 2.0, CHH), 3.15 (1H, tdd, J 11.1, 5.3, 3.2, CH), 3.31 – 3.37 (2H, m, 
CH2), 3.86 (3H, s, CH3),  4.65 (1H, d, J 15.1, NCHH), 4.77 (1H, d, J 15.1, NCHH), 6.90 (1H, 
d, J 8.0, ArCH), 6.97 (1H, td, J 7.5, 0.9, ArCH),  7.23 – 7.30 (5H, m, ArCH), 7.34 – 7.38 
(2H, m, ArCH); 
13
C NMR (100 MHz; CDCl3) δC 30.4 (CH2), 38.7 (CH), 39.5 (CH2), 44.5 
(CH2), 46.8 (CH2), 55.4 (CH3), 110.3 (ArCH), 120.7 (ArCH), 125.1 (ArC), 126.6 (2 × 
ArCH), 126.8 (ArCH), 128.5 (ArCH), 128.7 (2 × ArCH), 129.1 (ArCH), 143.6 (ArC), 
157.6(ArC), 169.4 (C=O); m/z (ES
+
) 296.1563 (100%, M
+
 C19H21NO2 requires 295.1572), 
264 (50), 176 (27), 149 (35), 121 (60), 91 (85). Chiral HPLC, Lux 3u CELLULOSE-2, 20% 
IPA in hexane @ 1.0 mL min
-1
, tR (major) 21.3 min and (minor) 23.6 min.  
4(R)-1-(Phenylmethyl)-4-(2-fluorophenyl)piperidin-2-one 217 
 
Using glutarimide 209 (0.30 g, 1.00 mmol) the title compound was obtained as a white solid 
using general procedure E (0.14 g, 51% over 2 steps) Mpt 60 – 62 oC; [α]D
20 + 20.1 (c 2.1, 
CHCl3; 82% ee); vmax (ATR) / cm
-1
  2925, 1616, 1587; 
1
H NMR (400 MHz; CDCl3) δH 1.98 – 
2.10 (2H, m, 2 × CHH), 2.64 (1H, dd, J 17.4, 10.8, CHH), 2.85 (1H, ddd, J 17.4, 5.3, 1.9, 
CHH), 3.25 – 3.38 (2H, m, 2 × CHH), 3.45 (1H, td, J 10.8, 5.3, 3.9, CH), 4.58 (1H, d, J 14.6, 
NCHH), 4.76 (1H, d, J 14.6, NCHH), 7.03 – 7.36 (9H, m, ArCH); 13C NMR (100 MHz; 
CDCl3) δC 28.9 (CH2), 32.2 (d, J 1.5, CH), 38.0 (CH2), 46.3 (CH2), 50.1 (CH2), 115.6 (d, J C-F 
22.4, ArCH), 124.4 (d, J C-F 3.5, ArCH), 127.3 (d, J C-F 4.6, ArCH), 127.5 (ArCH), 128.2 (2 × 
ArCH), 128.3 (d, J C-F 8.4, ArCH), 128.7 (2 × ArCH), 130.1 (d, J C-F 14.2, Ar-F), 137.0 
122 
 
(ArC), 160.6 (d, J C-F 245.8, ArC), 169.1 (C=O); m/z (EI
+
) 283.1382 (100%, M
+
 C18H18FNO 
requires 283.1372), 149 (50), 109 (25), 103 (58) 105 (93), 91 (95), 77 (98). Chiral HPLC, 
Lux 3u CELLULOSE-2, 20% IPA in hexane @ 1.0 mL min
-1
, tR (major) 16.4 min and 
(minor) 18.2 min.  
4(R)-1-(Phenylmethyl)-4-(4-fluorophenyl)piperidin-2-one 218 
 
Using glutarimide 210 (0.30 g, 1.00 mmol) the title compound was obtained as a white solid 
using general procedure E (0.15 g, 54% over 2 steps) Mpt 114 – 116 oC; [α]D
20 + 30.0 (c 1.1, 
CHCl3; 92% ee), lit.
100
 [α]D
20 + 33.0 (c 1.07, CHCl3); vmax (ATR) / cm
-1
  3071, 2927, 1625, 
1601, 1510; 
1
H NMR (400 MHz; CDCl3) δH 1.87 – 1.97 (1H, m, CHH), 2.07 – 2.10 (1H, m, 
CHH), 2.57 (1H, dd, J 17.4, 11.0, CHH), 2.83 (1H, dd, J 17.4, 3.4, CHH), 3.09 ‒ 3.14 (1H, 
m, CH), 3.25 – 3.36 (2H, m, 2 × CHH), 4.57 (1H, d, J 14.5, NCHH), 4.77 (1H, d, J 14.5, 
NCHH), 7.03 [2H, (AX)2, ArCH], 7.18 [2H, (AX)2, ArCH], 7.28 – 7.38 (5H, m, ArCH); 
13
C 
NMR (100 MHz; CDCl3) δC 30.3 (CH2), 38.0 (CH), 39.6 (CH2), 46.2 (CH2), 50.0 (CH2), 
115.5 (d, J C-F 21.2, 2 × ArCH), 127.5 (ArCH), 128.0 (d, J C-F 7.8, 2 × ArCH), 128.2 (2 × 
ArCH), 128.7 (2× ArCH), 137.1 (ArC), 139.1 (d, J C-F 3.0, ArC), 161.7 (d, J C-F 245.0, ArC), 
169.1 (C=O); m/z (TOF MS ES
+
) 284.1437 (100%, MH
+
 C18H19FNO requires 284.1451). 
Chiral HPLC, CHIRAL PAK IA, 7% IPA in hexane @ 1.0 mL min
-1
, tR (minor) 38.2 min and 
(major) 40.0 min. All data are in accordance with literature.
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4(R)-1-(Phenylmethyl)-4-(2-methylphenyl)piperidin-2-one 219 
 
Using glutarimide 211 (0.30 g, 1.00 mmol) the title compound was obtained as a white solid 
using general procedure E (0.17 g, 61% over 2 steps) Mpt 68 – 70 oC; [α]D
20 + 39.4 (c 0.3, 
CHCl3; 86% ee); vmax (ATR) / cm
-1
  2925, 1626, 1587; 
1
H NMR (400 MHz; CDCl3) δH 2.01 – 
2.04 (2H, m, 2 × CHH), 2.37 (3H, s, CH3), 2.56 (1H, dd, J 17.5, 11.0, CHH), 2.81 (1H, ddd, J 
17.5, 5.2, 1.9, CHH), 3.28 – 3.37 (3H, m, 2 × CHH and CH), 4.55 (1H, d, J 14.5, NCHH), 
4.85 (1H, d, J 14.5, NCHH), 7.16 – 7.22 (4H, m, ArCH), 7.33 – 7.40 (5H, m, ArCH); 13C 
NMR (100 MHz; CDCl3) δC 19.3 (CH3), 29.3 (CH2), 34.6 (CH), 39.0 (CH2), 46.5 (CH2), 50.1 
123 
 
(CH2), 125.0 (ArCH), 126.5 (ArCH), 126.6 (ArCH), 127.5 (ArCH), 128.3 (2 × ArCH), 128.7 
(2 × ArCH), 130.7 (ArCH), 135.3 (ArC), 137.2 (ArC), 141.5 (ArC) 169.6 (C=O); m/z (TOF 
MS ES
+
) 280.1710 (100%, MH
+
 C19H22NO requires 280.1701). Chiral HPLC, Lux 3u 
CELLULOSE-2, 20% IPA in hexane @ 1.0 mL min
-1
, tR (minor) 15.3 min and (major) 18.3 
min.  
4(R)-1-(Phenylmethyl)-4-(4-methylphenyl)piperidin-2-one 220 
 
Using glutarimide 212 (0.30 g, 1.00 mmol) the title compound was obtained as a white solid 
using general procedure E (0.14 g, 51% over 2 steps) Mpt 105 – 106 oC; [α]D
20 + 33.6 (c 1.1, 
CHCl3; 88% ee); (Found: C, 81.58; H, 7.54; N, 4.90. C19H21NO requires C, 81.68; H, 7.58; N, 
5.01); vmax (ATR) / cm
-1
  2924, 1625, 1516; 
1
H NMR (400 MHz; CDCl3) δH 1.89 – 1.99 (1H, 
m, CHH), 2.05 – 2.12 (1H, m, CHH), 2.36 (3H, s, CH3), 2.60 (1H, dd, J 17.5, 11.1, CHH), 
2.83 (1H, ddd, J 17.5, 5.2, 2.0, CHH), 3.10 (1H, tdd, J 11.1, 5.2, 3.1, CH), 3.25 – 3.36 (2H, 
m, 2 × CHH), 4.59 (1H, d, J 14.6, NCHH), 4.76 (1H, d, J 14.6, NCHH), 7.13 [2H, (AX)2, 
ArCH], 7.17 [2H, (AX)2, ArCH], 7.28 – 7.39 (5H, m, ArCH); 
13
C NMR (100 MHz; CDCl3) 
δC 21.0 (CH3), 30.4 (CH2), 38.3 (CH), 39.6 (CH2), 46.4 (CH2), 50.0 (CH2), 126.4 (2 × ArCH), 
127.4 (ArCH), 128.2 (2 × ArCH), 128.6 (2 × ArCH), 129.4 (2 × ArCH), 136.4 (ArC), 137.2 
(ArC), 140.5 (ArC) 169.4 (C=O); m/z (TOF MS ES
+
) 280.1692 (100%, MH
+
 C19H22NO 
requires 280.1701). Chiral HPLC, CHIRAL PAK IA, 7% IPA in hexane @ 1.0 mL min
-1
, tR 
(minor) 31.3 min and (major) 32.9 min.  
4(R)-1-(Phenylmethyl)-4-(1-naphthyl)piperidin-2-one 221 
 
Using glutarimide 213 (0.33 g, 1.00 mmol) the title compound was obtained as a white solid 
using general procedure E solid (0.06 g, 20% over 2 steps) Mpt 122 – 124 oC; [α]D
20 -13.3 (c 
0.5, CHCl3; 54% ee); vmax (ATR) / cm
-1
  3196, 2950, 1707, 1636, 1624; 
1
H NMR (400 MHz; 
CDCl3) δH 2.10 – 2.20 (1H, m, CHH), 2.25 – 2.28 (1H, m, CHH), 2.74 (1H, dd, J 17.5, 10.1, 
CHH), 3.05 (1H, dd, J 17.5, 3.6, CHH), 3.10 (1H, dt, J 10.1, 4.7, CH), 3.38 – 3.45 (1H, m, 
CHH), 3.95 – 3.99 (1H, m, CHH), 4.61 (1H, d, J 14.5, CHH), 4.84 (1H, d, J 14.5, CHH), 
7.31 ‒ 7.41 (6H, m, ArCH), 7.44 – 7.57 (3H, m, ArCH), 7.78 (1H, d, J 8.2, ArCH), 7.90 (1H, 
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dd, J 7.7, 1.5, ArCH), 8.06 (1H, d, J 8.2, ArCH); 
13
C NMR (100 MHz; CDCl3) δC 29.6 (CH2), 
33.8 (CH), 39.3 (CH2), 46.2 (CH2), 50.2 (CH2), 122.4 (ArCH), 122.7 (ArCH), 125.6 (ArCH), 
125.7 (ArCH), 126.3 (ArCH), 127.4 (ArCH), 127.5 (ArCH), 128.3 (2 × ArCH), 128.7 (2 × 
ArCH),  129.1 (ArCH), 131.0 (ArC), 134.0 (ArC), 137.1 (ArC), 138.9 (ArC), 169.5 (C=O); 
m/z (TOF MS ES
+
) 316.1689 (100%, MH
+
 C22H22NO requires 316.1701). Chiral HPLC, 
CHIRAL PAK IA, 7% IPA in hexane @ 1.0 mL min
-1
, tR (major) 41.3 min and (minor) 44.9 
min.  
4(R)-1-(Phenylmethyl)-4-methylpiperidin-2-one 222 
 
Using general procedure E and glutarimide 214 (0.22 g, 1.00 mmol) a crude oily solid was 
obtained which was purified via flash column chromatography eluting with EtOAc : 
petroleum ether (40-60) : Et3N (2:8:0.05) to afford the title compound as pale yellow oil (0.09 
g, 46% over 2 steps) [α]D
20 + 46.6 (c 3.3, CHCl3; 90% ee); vmax (ATR) / cm
-1
  3469, 2953, 
2927, 2871, 2030, 1634, 1452; 
1
H NMR (400 MHz; CDCl3) δH 1.01 (3H, d, J 6.5, CH3), 1.39 
– 1.47 (1H, m, CHH), 1.78 ‒ 1.85 (1H, m, CHH), 1.90 ‒ 2.00 (1H, m, CH), 2.07 (1H, dd, J 
17.2, 10.7, CHH), 2.58 (1H, ddd, J 17.2, 4.9, 2.1, CHH), 3.18 ‒ 3.22 (2H, m, 2 × CHH), 4.48 
(1H, d, J 14.7, NCHH), 4.72 (1H, d, J 14.7, NCHH), 7.24 – 7.34 (5H, m, ArCH); 13C NMR 
(100 MHz; CDCl3) δC 21.0 (CH3), 28.0 (CH), 30.9 (CH2), 40.5 (CH2), 46.3 (CH2), 50.0 
(CH2), 127.3 (ArCH), 128.0 (2 × ArCH), 128.6 (2 × ArCH), 137.3 (ArC), 169.7 (C=O); m/z 
(TOF MS ES
+
) 217 (100), 204.1394 (70%, MH
+
 C13H18NO requires 204.1388),. Chiral 
HPLC, Lux 3u CELLULOSE-2, 20% IPA in hexane @ 1.0 mL min
-1
, tR (minor) 13.2 min 
and (major) 14.1 min.  
4(R)-1-(Phenylmethyl)-4-isopropylpiperidin-2-one 223 
 
Using general procedure E and glutarimide 215 (0.22 g, 1.00 mmol) a crude oily solid was 
obtained which was purified via flash column chromatography eluting with EtOAc : DCM : 
petroleum ether (40-60) (3:1:6) to afford the title compound as yellow oil (0.09 g, 41% over 2 
steps) [α]D
20 + 44.3 (c 1.9, CHCl3; 86% ee); vmax (ATR) / cm
-1
  3168, 2957, 2871, 2173, 1676, 
1638; 
1
H NMR (400 MHz; CDCl3) δH 0.93 (6H, dd, J 6.6, 2.2, 2 × CH3), 1.40 – 1.60 (3H, m, 
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2 × CHH and CH), 1.85 ‒ 1.90 (1H, m, CH), 2.17 (1H, dd, J 17.5, 11.6, CHH), 2.61 (1H, 
ddd, J 17.5, 4.9, 2.3, CHH), 3.15 ‒ 3.27 (2H, m, 2 × CHH), 4.53 (1H, d, J 14.6, NCHH), 4.71 
(1H, d, J 14.6, NCHH), 7.25 – 7.36 (5H, m, ArCH); 13C NMR (100 MHz; CDCl3) δC 19.3 
(CH3), 19.6 (CH3), 26.6 (CH2), 31.9 (CH), 36.3 (CH2), 39.4 (CH), 46.8 (CH2), 49.9 (CH2), 
127.3 (ArCH), 128.0 (2 × ArCH), 128.6 (2 × ArCH), 137.2 (ArC), 170.3 (C=O); m/z (TOF 
MS ES
+
) 254 (30, M + Na
+
), 232.1709 (100%, MH
+
 C15H22NO requires 232.1701). Chiral 
HPLC, Lux 3u CELLULOSE-2, 5% IPA in hexane @ 1.0 mL min
-1
, tR (minor) 47.1 min and 
(major) 49.0 min. 
4(R)-1-(Phenylmethyl)-4-tert-butylpiperidin-2-one 224 
 
Using general procedure E and glutarimide 216 (0.26 g, 1.00 mmol) a crude oily solid was 
obtained which was purified via flash column chromatography eluting with EtOAc : DCM : 
petroleum ether (40-60) (3:1:6) to afford the title compound as yellow oil (0.11 g, 46% over 2 
steps). [α]D
20 + 36.8 (c 1.4, CHCl3; 87% ee); vmax (ATR) / cm
-1
 2957, 2867, 2173, 1636; 
1
H 
NMR (400 MHz; CDCl3) δH 0.90 (9H, s, 3 × CH3), 1.40 (1H, qd, J 12.5, 5.5, CHH), 1.57 
(1H, tdd, J 12.5, 4.8, 2.3, t-BuCH), 1.86 ‒ 1.90 (1H, m, CHH), 2.21 (1H, dd, J 17.3, 12.5, 
COCHH), 2.59 (1H, ddd, J 17.3, 4.8, 2.3, COCHH), 3.17 (1H, td, J 12.6, 4.8, CHHN), 3.26 
(1H, ddd, J 12.6, 5.5, 2.3, CHHN), 4.53 (1H, d, J 14.6, PhCHHN),  4.71 (1H, d, J 14.6, 
PhCHHN), 7.26 – 7.36 (5H, m, ArCH); 13C NMR (100 MHz; CDCl3) δC 24.6 (CH2), 26.8 (3 
× CH3), 32.0 (C), 34.3 (CH2), 43.2 (CH), 47.1 (CH2), 49.9 (CH2), 127.3 (ArCH), 128.1 (2 × 
ArCH), 128.6 (2 × ArCH), 137.2 (ArC), 170.5 (C=O); m/z (TOF MS ES
+
) 246.1861 (100%, 
MH
+
 C16H24NO requires 246.1858). Chiral HPLC, Lux 3u CELLULOSE-1, 5% IPA in 
hexane @ 1.0 mL min
-1
, tR (minor) 11.3 min and (major) 12.4 min.   
1-(4-Methoxyphenyl)-4-phenylpiperidine 178 
 
Using general procedure E and glutarimide 173 (0.30 g, 1.00 mmol) the title compound was 
obtained as an undesired product as white crystals (0.08 g, 30% over 2 steps); Mpt 150 – 152 
o
C; (Found: C, 80.74; H, 7.91; N, 5.12. C18H22NO requires C, 80.86; H, 7.92; N, 5.24); vmax 
(ATR) / cm
-1
  2953, 2938, 2917, 2840, 2810, 2744, 1508; 
1
H NMR (250 MHz; CDCl3) δH 
1.95 – 1.96 (4H, m, 4 × CHH), 2.61 – 2.69 (1H, m, CH), 2.75 – 2.82 (2H, m, 2 × CHH), 3.65 
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– 3.69 (2H, m, 2 × CHH), 3.81 (2H, s, OCH3), 6.90 [2H, (AX)2, ArCH], 7.00 [2H, (AX)2, 
ArCH], 7.24 – 7.38 (5H, m, ArCH); 13C NMR (100 MHz; CDCl3) δC 33.6 (2 × CH2), 42.4 
(CH), 52.2 (2 × CH2), 55.6 (CH3), 114.4 (2 × ArCH), 118.9 (2 × ArCH), 126.3 (ArCH), 126.9 
(2 × ArCH), 128.5 (2 × ArCH), 146.2 (ArC), 146.4 (ArC), 153.8 (ArC); m/z (TOF MS ES
+
) 
268.1693 (100%, MH
+
 C18H22NO requires 268.1701). Only 
1
H NMR and mass spectrometry 
were provided in the literature.
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1-(Phenylmethyl)-4-phenylpiperidine 181
 
 
Using general procedure E and glutarimide 174 (0.30 g, 1.00 mmol) the title compound was 
obtained as an undesired product as yellow oil (0.03 g, 12% over 2 steps vmax (ATR) / cm
-1
  
3061, 3026, 2933, 2798, 2754, 1602; 
1
H NMR (250 MHz; CDCl3) δH 1.75 – 1.95 (4H, m, 4 × 
CHH), 2.05 – 2.21 (2H, m, 2 × CHH), 2.48 – 2.60 (1H, m, CH), 3.03 – 3.10 (2H, m, 2 × 
CHH), 3.60 (2H, s, NCH2), 7.20 – 7.40 (10H, m, ArCH); 
13
C NMR (50 MHz; CDCl3) δC 33.6 
(2 × CH2), 42.8 (CH), 54.3 (2 × CH2), 63.5 (CH2), 126.1 (ArCH), 126.9 (2 × ArCH), 127.0 
(ArCH), 128.2 (2 × ArCH), 128.4 (2 × ArCH), 129.2 (2 × ArCH), 138.6 (ArC), 146.6 (ArC); 
m/z (TOF MS ES
+
) 252.1764 (100%, MH
+
 C18H22N requires 252.1752). All data are in 
accordance with literature.
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5.6 Experimental for the synthesis of α-substituted lactams 
General Procedure G for the synthesis of 3-substituted N-Bn-4-phenylpiperidin-2-
ones
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Diisopropylamine (1.10 cm
3
, 7.50 mmol) was added to a flask containing dry THF (5.10 cm
3
) 
under N2 atmosphere at - 78 
o
C and stirred gently. n-BuLi (3.80 cm
3
, 7.50 mmol, 2.0 M in 
hexane) was added drop-wise and the mixture stirred at - 78 
o
C for 10 mins to give the LDA 
stock solution (7.50 mmol / 10 cm
3
 solution). The LDA (2.00 cm
3
, 1.50 mmol) from the stock 
solution was added drop-wise to a solution of the N-benzyl substrate 180 (0.27 g, 1.00 mmol) 
in dry THF (5.00 cm
3
) under N2 atmosphere. The solution was allowed to stir at - 78 
o
C for 
20 mins. Then the electrophile (1.00 equiv.) was slowly added and the mixture stirred at - 78 
o
C for 2 h, allowed to warm to room temperature slowly and further stirred for 18 h. The 
reaction was quenched by slow addition of saturated NaHCO3 (10 cm
3
), concentrated in 
vacuo and extracted with CH2Cl2 (3 × 20 cm
3
). The combined organic extracts were dried 
over MgSO4, filtered and the solvent removed under reduced pressure to give a crude yellow 
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oily solid, which was purified via flash column chromatography eluting with EtOAc : 
petroleum ether (40-60) (3:7). 
(3S, 4R)-1-(Phenylmethyl)-3-methyl-4-phenylpiperidin-2-one 245 
 
Using general procedure G and methyl iodide (0.06 cm
3
, 1.00 mmol) as the electrophile, the 
title compound was obtained as a yellow solid as a single diastereomer (0.17 g, 61%) Mpt 70 
‒ 72 oC; (Found: C, 81.38; H, 7.85; N, 5.28. C19H21NO requires C, 81.68; H, 7.58; N, 5.01); 
[α]D
20
  + 26.1 (c 0.7, CHCl3); vmax (ATR) / cm
-1
  3062, 3031, 2967, 2872, 2174, 1618; 
1
H 
NMR (400 MHz; CDCl3) δH 2.20 (3H, d, J 6.9, CH3), 1.98 – 2.04 (2H, m, 2 × CHH), 2.64 
(1H, dq, J 10.4, 6.9, CH), 2.70 ‒ 2.76 (1H, m, CH), 3.26 ‒ 3.40 (2H, m, 2 × CHH), 4.53 (1H, 
d, J 14.5, NCHH), 4.82 (1H, d, J 14.5, NCHH), 7.20 [2H, (AX)2, ArCH], 7.25 – 7.40 (8H, m, 
ArCH); 
13
C NMR (100 MHz; CDCl3) δC 16.1 (CH3), 30.6 (CH2), 43.1 (CH), 46.5 (CH2), 47.0 
(CH), 50.5 (CH2), 126.8 (ArCH), 127.1 (2 × ArCH), 127.4 (ArCH), 128.1 (2 × ArCH), 128.6 
(2 × ArCH), 128.7 (2 × ArCH), 137.4 (ArC), 143.8 (ArC), 172.7 (C=O); m/z (TOF MS ES
+
) 
280.1700 (100%, MH
+
 C19H22NO requires 280.1701).  
(3S, 4R)-1-(Phenylmethyl)-3-allyl-4-phenylpiperidin-2-one 246 
 
Using general procedure G and allyl bromide (0.10 cm
3
, 1.00 mmol) as the electrophile, the 
title compound was obtained as a yellow solid as a single diastereomer (0.19 g, 62% ) Mpt 62 
– 64 oC; [α]D
20
  + 37.2 (c 1.2, CHCl3); vmax (ATR) / cm
-1
  3029, 2977, 2920, 2959, 1633, 1585; 
1
H NMR (400 MHz; CDCl3) δH 1.96 – 2.01 (2H, m, 2 × CHH), 2.13 (1H, ddd, J 13.6, 7.5, 
3.9, CH), 2.76 ‒ 2.88 (2H, m, 2 × CHH), 3.00 (1H, dt, J 9.9, 7.5, CH), 3.23 (1H, dt, J 12.1, 
3.9, CHH), 3.33 (1H, ddd, J 12.1, 8.7, 7.5, CHH), 4.66 (1H, d, J 14.5, NCHH), 4.73 (1H, d, J 
14.5, NCHH), 4.64 – 4.75 (2H, m, 2 × =CHH), 5.74 – 5.84 (1H, m, =CH), 7.20 [2H, (AX)2, 
ArCH], 7.25 – 7.39 (8H, m, ArCH); 13C NMR (100 MHz; CDCl3) δC 30.4 (CH2), 33.6 (CH2), 
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42.4 (CH), 46.4 (CH2), 47.4 (CH), 50.6 (CH2), 117.7 (=CH2), 126.8 (ArCH), 127.3 (2 × 
ArCH), 127.4 (ArCH), 128.2 (2 × ArCH), 128.6 (2 × ArCH), 128.8 (2 × ArCH), 135.4 
(=CH), 137.3 (ArC), 143.5 (ArC), 171.3 (C=O); m/z (TOF MS ES
+
) 328.1682 (80%, M + 
Na
+
, C21H23NONa requires 328.1677), 340 (100).  
(3S, 4R)-1,3-di(Phenylmethyl)-4-phenylpiperidin-2-one 247 
 
Using general procedure G and benzyl bromide (0.10 cm
3
, 1.00 mmol) as the electrophile, a 
yellow oily solid was obtained which was purified via flash column chromatography eluting 
with EtOAc : petroleum ether (40-60) (2:8) to afford the title compound as yellow solid as a 
single diastereomer (0.17 g, 57%) Mpt 66 – 68 oC; [α]D
20
  - 4.6 (c 4.0, CHCl3); vmax (ATR) / 
cm
-1
  3027, 2927, 2161, 1631, 1583; 
1
H NMR (400 MHz; CDCl3) δH 1.88 – 1.94 (2H, m, 2 × 
CHH), 2.74 (1H, dd, J 13.7, 5.0, CHH), 2.84 (1H, td, J 9.7, 6.2, CHPh), 3.07 ‒ 3.15 (3H, m, 2 
× CHH and CH), 3.48 (1H, dd, J 13.7, 5.0, CHH), 4.50 (1H, d, J 14.5, NCHH), 4.90 (1H, d, J 
14.5, NCHH), 7.17 – 7.36 (15H, m, ArCH); 13C NMR (100 MHz; CDCl3) δC 30.8 (CH2), 
35.0 (CH2), 41.9 (CH), 46.3 (CH2), 48.5 (CH), 50.8 (CH2), 126.2 (ArCH), 126.8 (ArCH), 
127.4 (ArCH), 127.4 (2 × ArCH), 128.2 (2 × ArCH), 128.2 (2 × ArCH), 128.6 (2 × ArCH), 
128.8 (2 × ArCH), 130.1 (2 × ArCH), 132.0 (ArC), 139.2 (ArC), 143.5 (ArC), 171.4 (C=O); 
m/z (TOF MS ES
+
) 356.2024 (100%, MH
+
 C25H26NO requires 356.2014). All data are in 
accordance with literature.
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(3S, 4R)-1-Benzyl-2-oxo-4-phenylpiperidine-3-ethyl carboxylate 248 
 
Using general procedure G and ethyl chloroformate (0.10 cm
3
, 1.00 mmol) as the 
electrophile, a yellow oily solid was obtained which was purified via flash column 
chromatography eluting with EtOAc : DCM : petroleum ether (2:1:7) to afford the title 
compound as yellow solid in 10:1 diastereomeric ratio (0.24 g, 71%) Mpt 140 – 142 oC; [α]D
20
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+ 3.0 (c 0.1, CHCl3); vmax (ATR) / cm
-1
  3029, 2929, 2927, 1733, 1635; 
1
H NMR (400 MHz; 
CDCl3) Major diastereomer δH 1.12 (3H, t, J 7.1, CH3), 2.00 ‒ 2.11 (2H, m, 2 × CHH), 3.30 
(1H, ddd, J 11.0, 5.3, 3.2, CHPh), 3.39 ‒ 3.50 (2H, m, 2 × CHH), 3.66 (1H, d, J 11.0, 
CHCO), 4.12 (2H, q, J 7.1, CH2), 4.56 (1H, d, J 14.5, NCHH), 4.79 (1H, d, J 14.5, NCHH), 
7.22 [2H, (AX)2, ArCH], 7.29 – 7.39 (8H, m, ArCH); 
13
C NMR (100 MHz; CDCl3) δC 14.0 
(CH3), 29.3 (CH2), 42.6 (CH), 46.2 (CH2), 50.3 (CH2), 56.5 (CH), 61.2 (CH2), 126.9 (2 × 
ArCH), 127.3 (ArCH), 127.6 (ArCH), 128.2 (2 × ArCH), 128.7 (2 × ArCH), 128.2 (2 × 
ArCH), 128.8 (2 × ArCH), 136.7 (ArC), 141.4 (ArC), 166.0 (OC=O), 170.1 (NC=O); m/z 
(TOF MS ES
+
) 338.1758 (100%, MH
+
 C21H24NO3 requires 338.1756). 
(3S, 4R)-1-Benzyl-2-oxo-4-(4-fluorophenyl)piperidine-3-ethyl carboxylate 257 
 
Using general procedure G, starting with the 4-(p-fluorophenyl) lactam 218 (0.36 g, 1.00 
mmol) and ethyl chloroformate (0.10 cm
3
, 1.00 mmol) as the electrophile, a yellow oily solid 
was obtained which was purified via flash column chromatography eluting with EtOAc : 
DCM : petroleum ether (40-60) (2:1:7) to afford the title compound as yellow solid in 10:1 
diastereomeric ratio (0.22 g, 62% ) Mpt 148 – 150 oC; [α]D
20
  + 3.5 (c 0.1, CHCl3); vmax (ATR) 
/ cm
-1
  2933, 1734, 1640, 1605; 
1
H NMR (400 MHz; CDCl3) Major diastereomer δH 1.14 
(3H, t, J 7.1, CH3), 1.98 ‒ 2.09 (2H, m, 2 × CHH), 3.30 (1H, ddd, J 11.0, 5.4, 2.9, CHPh), 
3.39 ‒ 3.49 (2H, m, 2 × CHH), 3.59 (1H, d, J 11.0, CHCO), 4.13 (2H, q, J 7.1, CH2), 4.53 
(1H, d, J 14.5, NCHH), 4.81 (1H, d, J 14.5, NCHH), 7.02 [2H, (AX)2, ArCH], 7.18 [2H, 
(AX)2, ArCH], 7.28 – 7.39 (5H, m, ArCH); 
13
C NMR (100 MHz; CDCl3) δC 14.0 (CH3), 29.4 
(CH2), 41.9 (CH), 46.2 (CH2), 50.3 (CH2), 56.7 (CH), 61.3 (CH2), 115.7 (d, J C-F 21.4, 2 × 
ArCH), 127.6 (ArCH), 128.2 (2 × ArCH), 128.4 (d, J C-F 8.0, 2 × ArCH), 128.7 (2 × ArCH), 
136.6 (ArC), 137.1 (ArC), 161.9 (d, J C-F 245.5, ArC), 165.8 (OC=O), 170.0 (NC=O); m/z 
(TOF MS ES
+
) 356.1645 (100%, MH
+
 C21H23FNO3 requires 356.1662). 
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(3S, 4R)-1-Benzyl-3-[1(R)-hydroxyphenylmethyl]-4-phenylpiperidin-2-one 253 
 
Using general procedure G and benzaldehyde (0.10 cm
3
, 1.00 mmol) as the electrophile, a 
yellow oily solid was obtained which was purified via flash column chromatography eluting 
with EtOAc : petroleum ether (40-60) : Et3N (1:9:0.05) to afford the title compound as a 
yellow solid as a single diastereomer (0.23 g, 62% ) Mpt 66 – 68 oC; [α]D
20
  -13.4 (c 0.97, 
CHCl3); vmax (ATR) / cm
-1
  3337 (broad), 3061, 3028, 2921, 1608, 1583; 
1
H NMR (400 MHz; 
CDCl3) δH 1.80 ‒ 1.98 (2H, m, 2 × CHH), 2.66 (1H, td, J 11.7, 4.4, CHPh), 3.02 ‒ 3.15 (2H, 
m, 2 × CHH), 3.44 (1H, dd, J 11.7. 4.4, CH), 4.61 (1H, d, J 4.4, OCHPh), 4.75 (1H, d, J 14.7, 
NCHH), 4.96 (1H, d, J 14.7, NCHH), 6.77 (1H, bs, OH), 7.16 [2H, (AX)2, ArCH], 7.27 – 
7.34 (11H, m, ArCH), 7.41 [2H, (AX)2, ArCH]; 
13
C NMR (100 MHz; CDCl3) δC 31.7 (CH), 
41.9 (CH2), 46.8 (CH), 50.4 (CH), 52.0 (CH2), 74.1 (CH2), 127.3 (2 × ArCH), 127.3 (ArCH), 
127.6 (ArCH), 127.7 (ArCH), 127.8 (2 × ArCH), 128.0 (2 × ArCH), 128.2 (2 × ArCH), 128.7 
(2 × ArCH), 129.1 (2 × ArCH), 136.1 (ArC), 141.6 (ArC), 142.4 (ArC), 172.2 (C=O); m/z 
(TOF MS ES
+
) 372.1967 (100%, MH
+
 C25H26NO2 requires 372.1964).  
General Procedure H for the reduction of 3-substituted N-Bn-4-phenylpiperidin-2-ones 
to the corresponding piperidines using LiAlH4.
121
 
LiAlH4 (3 equiv.) was added to a solution of the piperidin-2-one in dry THF. The mixture 
was heated at reflux for 24 h and cooled to room temperature. Saturated Na2SO4 (2 cm
3
) was 
added and the resultant solution was filtered. The filtrate was concentrated in vacuo and 
extracted with CH2Cl2 (3 × 20 cm
3
).  The combined organic extracts were dried over MgSO4, 
filtered and the solvent removed under reduced pressure to give a yellow oil which was 
purified via flash column chromatography eluting with acetone : hexane  : Et3N (1:9:0.05). 
General Procedure I for the reduction of 3-substituted N-Bn-4-phenylpiperidin-2-ones 
to the corresponding piperidines using BH3.THF.
112
 
BH3.THF (3 equiv.) was added to a solution of the piperidin-2-one in dry THF. The mixture 
was heated at reflux for 5 h and cooled to room temperature. Distilled H2O (2 cm
3
) was 
slowly added and the resultant solution was extracted with CH2Cl2 (3 × 20 cm
3
).  The 
131 
 
combined organic extracts were dried over MgSO4, filtered and the solvent removed under 
reduced pressure to give the crude material which was purified via flash column 
chromatography. 
(3S, 4R)-1-(Phenylmethyl)-3-methyl-4-phenylpiperidine 249 
 
Using general procedure I and compound 245 (0.08 g, 0.29 mmol) the title compound was 
obtained as a white solid in a 10:1 dr (0.05 g, 65%) Mpt 138 – 140 oC; [α]D
20
  - 24.5 (c 1.8, 
CHCl3); vmax (ATR) / cm
-1
  3026, 2957, 2927, 2870, 2333, 2275, 1652, 1600; 
1
H NMR (400 
MHz; CDCl3) Major diastereomer δH 0.62 (3H, d, J 6.6, CH3), 1.64 – 1.69 (1H, m, CH), 
1.90 (1H, td, J 11.4, 3.8, CHH), 2.29 (1H, app t, J 11.4, PhCH), 2.68 (2H, d, J 9.8, 2 × CHH), 
2.79 ‒ 2.87 (1H, m, CHH), 3.00 (1H, ddd, J 11.4, 3.8, 2.3, CHH), 3.04 (1H, dt, J 7.3, 2.3, 
CHH), 4.14 (2H, s, NCH2), 7.21 – 7.24 (4H, m, ArCH), 7.39 – 7.46 (6H, m, ArCH); 
13
C 
NMR (100 MHz; CDCl3) δC 17.5 (CH3), 29.8 (CH2), 31.8 (CH), 49.4 (CH), 56.5 (CH2), 63.2 
(CH2), 70.4 (CH2), 126.6 (ArCH), 127.6 (2 × ArCH), 128.3 (2 × ArCH), 128.5 (2 × ArCH), 
129.1 (ArCH), 130.3 (ArC), 133.2 (2 × ArCH), 143.9 (ArC); m/z (TOF MS ES
+
) 266.1917 
(100%, MH
+
 C19H24N requires 266.1909).  
(3S, 4R)-1-(Phenylmethyl)-3-allyl-4-phenylpiperidine 250 
 
Using general procedure H and compound 246 (0.10 g, 0.33 mmol) the title compound was 
obtained as a yellow oil (0.05 g, 52% ) [α]D
20
  - 15.0 (c 0.4, CHCl3); vmax (ATR) / cm
-1
  3061, 
3027, 2915, 2798, 2755, 1639, 1602; 
1
H NMR (400 MHz; CDCl3) δH 1.63 ‒ 1.71 (1H, m, 
CHH), 1.76 – 1.84 (3H, m, 2 × CHH and CH), 1.94 – 2.03 (3H, m, 2 × CHH and CH), 2.20 
(1H, td, J 11.0, 4.7, CHPh), 2.97 (1H, dd, J 11.0, 8.1, CHH), 3.12 (1H, ddd, J 11.0, 3.3, 1.7, 
CHH), 3.49 (1H, d, J 13.1, CHH), 3.68 (1H, d, J 13.1, CHH), 4.85 ‒ 4.92 (2H, m, 2 × 
=CHH), 5.59 ‒ 5.69 (1H, m, =CH), 7.21 – 7.23 (3H, m, ArCH), 7.30 – 7.37 (7H, m, ArCH); 
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13
C NMR (100 MHz; CDCl3) δC 34.9 (CH2), 36.3 (CH2), 40.8 (CH), 48.7 (CH), 53.9 (CH2), 
59.6 (CH2), 63.5 (CH2), 116.0 (=CH2), 126.2 (ArCH), 127.0 (ArCH), 127.8 (2 × ArCH), 
128.2 (2 × ArCH), 128.4 (2 × ArCH), 129.2 (2 × ArCH), 136.5 (=CH), 138.3 (ArC), 145.0 
(ArC); m/z (TOF MS ES
+
) 292.2061 (100%, MH
+
 C21H26N requires 292.2065).  
(3S, 4R)-1-(Phenylmethyl)-3-benzyl-4-phenylpiperidine 251 
 
Using general procedure H and compound 247 (0.17 g, 0.48 mmol) the title compound was 
obtained as a colourless oil (0.10 g, 61%) [α]D
20
  - 16.6 (c 2.9, CHCl3); vmax (ATR) / cm
-1
  
3082, 3060, 3025, 2913, 2796, 2752, 1601; 
1
H NMR (400 MHz; CDCl3) δH 1.79 – 1.90 (3H, 
m, 2 × CHH and CH), 1.98 (1H, dd, J 14.9, 10.9, CHH), 2.11 (1H, dd, J 14.9, 10.9, CHH), 
2.21 ‒ 2.32 (2H, m, 2 × CHH), 2.63 (1H, app d, J 12.9, CHH), 2.92 ‒ 3.02 (2H, m, CHH and 
CH), 3.34 (1H, d, J 13.1, CHH), 3.69 (1H, d, J 13.1, CHH), 7.04 (1H, d, J 7.1, ArCH), 7.15 – 
7.36 (13H, m, ArCH); 
13
C NMR (100 MHz; CDCl3) δC 35.1 (CH2), 38.4 (CH2), 43.1 (CH), 
49.4 (CH), 53.4 (CH2), 59.8 (CH2), 63.4 (CH2), 125.7 (ArCH), 126.3 (ArCH), 126.9 (ArCH), 
127.8 (2 × ArCH), 128.1 (2 × ArCH), 128.2 (2 × ArCH), 128.6 (2 × ArCH), 129.0 (2 × 
ArCH), 129.2 (2 × ArCH), 138.2 (ArC), 140.5 (ArC), 145.2 (ArC); m/z (TOF MS ES
+
) 
342.2217 (100%, MH
+
 C25H28N requires 342.2222). All data are in accordance with 
literature.
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(3S, 4R)-1-(Phenylmethyl)-3-(hydroxymethyl)-4-phenylpiperidine 252 
 
Using general procedure I and compound 248 (0.22 g, 0.65 mmol) the title compound was 
obtained as a white solid as a single diastereomer (0.10 g, 55% ) Mpt 106 – 108 oC; [α]D
20
  - 
22.2 (c 2.0, CHCl3); vmax (ATR) / cm
-1
  3063 (broad), 3030, 2926, 2867, 2353, 2277, 1646, 
1602; 
1
H NMR (400 MHz; CDCl3) δH 1.68 – 1.73 (2H, m, 2 × CHH), 2.30 (1H, td, J 11.9, 
4.3, PhCH), 2.62 ‒ 2.80 (3H, m, 2 × CHH and CH), 2.39 ‒ 2.98 (1H, m, CHH), 3.03 ‒ 3.06 
133 
 
(1H, m, CHH), 3.17 ‒ 3.24 (2H, m, 2 × CHH), 3.40 (1H, app dd, J 11.0, 3.0, OH), 4.17 (2H, 
s, NCH2), 7.24 – 7.44 (10H, m, ArCH); 
13
C NMR (100 MHz; CDCl3) δC 29.4 (CH2), 39.3 
(CH), 43.2 (CH), 56.4 (CH2), 59.3 (CH2), 63.2 (CH2), 70.6 (CH2), 126.9 (ArCH), 127.5 (2 × 
ArCH), 128.3 (2 × ArCH), 128.8 (2 × ArCH), 129.1 (ArCH), 130.3 (ArC), 133.2 (2 × ArCH), 
143.2 (ArC); m/z (TOF MS ES
+
) 282 (100%, MH
+ 
C19H24NO). All data are in accordance 
with literature.
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